**10/2020**

 **CURRICULUM VITAE**

**NAME**: **Steven H. Abman**

**BIRTHPLACE:** Chicago, Illinois

**CURRENT POSITION**: Professor with Tenure, Pediatric Pulmonary Medicine

 Director, Pediatric Heart-Lung Center

 Co-Director, Pulmonary Hypertension Program

 Founder and former Director, Ventilator Care Program

 Director, Pediatric Pulmonary Hypertension

 Network (PPHNet)

 Founder and Executive Board Member, BPD Collaborative

 President, American Pediatric Society (APS)

 Faculty, Clinical Sciences Graduate Program,

 Department of Pediatrics,

 University of Colorado Denver School of Medicine, and Children's Hospital Colorado, Aurora, Colorado.

**PAST ACADEMIC APPOINTMENTS:** Associate Professor, Department of Pediatrics,

 University of Colorado School of Medicine, 1990-6;

 Assistant Professor, Department of Pediatrics,

 University of Colorado School of Medicine, 1986-90.

**CURRENT ADDRESS:** 1717 E. Arizona Street

 Denver, Colorado 80210

**HOME PHONE:** Cell phone: 303-881-9765

**MARITAL STATUS:** Married to Carolyn Frank Abman, MD

 Four children: Ryan (12/11/83), Lauren

 (1/17/86), and Megan and Mark (9/8/91)

**LICENSURE:**  State of Colorado, #24116

**BOARD CERTIFICATION:** Diplomat, American Board of Pediatrics, 1986;

 (#33226)

 Pediatric Pulmonology, 1989; #159

 Pediatric Critical Care Medicine, 1996; #568

**UNDERGRADUATE EDUCATION:** B.A., Carleton College, Northfield, MN, (9/71-6/75)

 **Honors:** Graduated cum laude with honors

 Honors thesis: *Rhythmic Behavior of the*

 *Bermudan Littoral Crab, P. Transversus*

 Elected member, Sigma Xi, research society

 **Awards:** Recipient, National Science Foundation, Student

 Research grant, Dept of Biochemistry, Carleton

 College, 1972;

**MEDICAL EDUCATION:** M.D., Northwestern University Medical School,

 Chicago, IL, (9/75 - 6/79)

 **Awards:** Recipient, *American Diabetes Association Research*

 *Award,* Mentor: Dr. Norbert Freinkel, Dept of Medicine,

 Northwestern University Medical School, 1976;

**INTERNSHIP AND RESIDENCY:** Pediatrics, University of Colorado Health Sciences Center (UCHSC), Denver, Colorado

 **Internship:** June 1979 - June 1980

 **Residency:** July 1980 - June 1982

 **Honors:** Recipient, *Bruce M. Garber Memorial Award* as *"Outstanding Resident,"* Dept. of Pediatrics,

 UCHSC, 1982;

**POST-RESIDENCY:** *Chief Resident* and Clinical Instructor, Department of Pediatrics, University of Colorado Health Sciences

 Center, Denver, Colorado, 1982-1983;

 Fellow, Pediatric Pulmonary and Critical Care

 Medicine, Dept. of Pediatrics, UCHSC, 1983-86;

 Assistant Professor, Department of Pediatrics,

 UCHSC, 1986-90;

 Associate Professor, Department of Pediatrics,

 UCHSC, 1990-6;

 Professor with tenure, Department of Pediatrics,

 University of Colorado School of Medicine,

 1996 – current;

 Founder and Director, ***Pediatric Heart Lung Center***,

 Department of Pediatrics and The Children’s Hospital,

 UCHSC, 1994 - current.

 Founder and Co-Director, ***Pulmonary Hypertension***

 ***Program*,** The Children’s Hospital, 1994 – current.

 Founder and Director, ***Ventilator Care Program***, The

 Children’s Hospital, 2006 - 2012.

 Founder and Director, ***Pediatric Pulmonary***

 ***Hypertension Network (PPHNet****),* 2008 – current

 Co-Founder and Executive Committee Member,

 ***Bronchopulmonary Dysplasia Collaborative****,* 2012-

 current.

 Co-Chair, Pediatric and Congenital Heart Diease Task Force,

***Pulmonary Vascular Research Institute***, 2016- current.

 **Awards/Honors:** Recipient, Cystic Fibrosis Foundation Fellowship

 Award, 1983-1985

 Recipient, American Lung Association Fellowship

 Award, 1983 (declined);

 Recipient, American Lung Association Fellowship

 Award, 1985-1986.

 Recipient, ***David W. Smith Research Award***,

 for "Outstanding Research," from the

 Western Society for Pediatric Research, 1986

 Recipient, ***National Award for Excellence in Pediatric***

 ***Research, American Academy of Pediatrics***, 1998

 Recipient, ***E. Mead Johnson Award* for Pediatric**

 **Research,** Society for Pediatric Research, 1999

  Listed in *"Best Doctors in America",* 1994 - current;

 Advisor to Health Council of the Netherlands, *Extra-*

 *corporeal membrane oxygenation utilization in*

 *the Netherlands,* 1997.

 *Associate Editor*, American Journal of Respiratory

 and Critical Care Medicine, *1999- 2005*, *2006 –*

 *2010*, *2015 – current*.

 ***Robert J. Haslam Lecture***, Department of Pediatrics,

 Hospital for Sick Children, Toronto, Canada, 1999.

 ***Jerry Elliot Memorial Lectureship***, Greater New York

 Conference on Perinatal Research, State University

 of NY-Stoneybrook, Mineola, NY, 2001.

 Nominee for Howard Hughes Clinical Investigator

 Award, University of Colorado School of

 Medicine, 2002.

 ***Drew Wiltsie Memorial Lecture***, University of Pittsburgh School of Medicine, 2002.

 ***James B. Strain Award*** *for physician best exemplifying the values of the American Academy of Pediatrics, The Children’s Hospital Medical Staff, 2003.*

 ***Barry Smith Memorial Lecture****,* Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto Canada, 2003.

***Dunlevie Family Lecture, Dedication of Wall Center,***

Department of Pediatrics, Stanford University

 School of Medicine, Palo Alto, CA, 2004.

***Seizo Iwai Memorial Lecture***, 10th Annual Meeting of

the Japanese Society of Pediatric Anesthesiology,

 Tsu City, Mie Prefecture, Japan, 2004.

***Jerry Elliot Memorial Lecture****,* 27th Annual Western Conference on Perinatal Research, Rancho Mirage, CA, 2006.

 ***Nils W. Svenningsen Memorial Lecture****,* 22nd International Workshop on Surfactant Replacement, Ancona Italy, 2007.

 International Fellow, *Pulmonary Vascular Research*

 *Institute*, 2007 - current.

 International Task Force on Development and

 Pathology, *4th World Symposium on Pulmonary*

 *Hypertension,* Dana Point, CA*,* 2007.

***David Schiff Memorial Lectureship***, Department of Pediatrics, University of Alberta, Edmonton, Canada, 2008.

***Sprague Family Lecture***, Department of Pediatrics, Children’s Hospital of Philadelphia, University of Pennsylvania, 2008.

***Gilbert Forbes Scholar Lectureship****,* Department of Pediatrics, University of Rochester School of Medicine, Rochester NY, 2009.

***Fyler Lectureship****,* Department of Cardiology, Boston Children’s Hospital, Boston, MA, 2009.

 *Keynote speaker*, “Pediatric Pulmonary Hypertension:

 Historical Perspectives,” Pediatric Cardiac

 Intensive Care Society, Miami FL, 2008.

 *Guest speaker* for Research Day, Department of

 Pediatrics, Mount Sinai School of Medicine,

 New York, NY, 2009.

 *Guest speaker and program reviewer*, 7th Annual Retreat of the International Graduate Program on Molecular Biology and Medicine of the Lung, International Max Planck Research School for Heart and Lung Research, Giessen Germany, 2009.

 ***First Annual Maddie Morgan – Butterflies for Maddie Pulmonology Lectureship****,* University of Louisville, KY, 2010.

 *Member, Scientifc Board,* Ludwig-Boltzmann Institute of Lung Vascular Dise ase, Graz, Austria, 2010 – current.

 ***William H. Tooley Professor Lectureship****,* Division of Neonatology and Cardiovascular Research Institute, University of California San Francisco, CA, 2010.

***Frank Sterner Lectureship****,* Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, 2010.

 ***Dharmapuri Vidyasagar Lecturer*** *and Visiting*

 *Professor*, Department of Pediatrics, University of

 Illinois at Chicago, Chicago IL, 2011.

 ***Phil George Lectureship***, Le Bonheur Children’s

 Hospital and University of Tennessee Health

 Sciences Center, Memphis TN, 2011.

***33rd Annual Gregory Tauber Memorial Lectureship***,

National Children’s Hospital and George

Washington University Medical School,

Washington, DC, 2011.

***Career Teaching Scholar Award****,* Department of

 Pediatrics, University of Colorado School of

 Medicine, Aurora CO, 2012.

***5th Annual Visiting Professor of Pulmonary Hypertension***, Department of Pediatrics, Baylor University Medical School, Houston TX, 2013

***First Robyn Barst Memorial Lectureship***, American Heart Association, Grover Conference, Deckers, CO. 2013

 ***Thomas Hazinski Memorial Lectureship****,* Department of Pediatrics,Vanderbilt University School of Medicine, Nashville TN, 2014.

 ***Maureen Andrew Mentorship Award*** f*or outstanding mentorship from the Society for Pediatric Research,* presented at thePediatric Academics Societies Meeting, San Diego CA, 2015.

***Distinguished Achievement Award of the American***

 ***Thoracic Society*** for outstanding contributions

 to fighting respiratory disease through research,

 education, patient care and advocacy, presented

 at the ATS meeting, Denver, CO 2015.

***Mary Ellen Avery Award*** from the American Pediatric

 Society and Society for Pediaric Research “*to*

 *recognize the lifetime achievement of a pediatric*

 *investigator who has made important*

 *contributions to neonatal health through basic*

 *or translational research,”* presented at the

 Pediatric Academic Societies Meeting,

 Baltimore, MD, Spring, 2016.

 ***Bengt Robertson Award*** ***Lectureship*** *for research*

 *concerning the neonatal lung* from the European

 Society for Pediatric Research and the European

 Academy of Paediatric Societies, Geneva,

 Switzerland, 2016.

 ***International Arvo Yllpo Medal Award*** is given once

 every 5 years in recognition of outstanding

 research of newborn and premature infants, from

 the chairs of the Departments of Pediatrics at the 5

 Finnish medical schools, the Finnish Foundation

 for Pediatric Research, the Finnish Pediatric

 Association and the Mannerheim League for

 Child Welfare, Helsinki Finland, 2017.

 ***Thomas H. Pauley MD Lectureship***, Department of

 Pediatrics, University of Kentucky Medical

 School, Lexington, KY, 2017.

 ***Robert DeLemos Memorial Lectureship***, “Management

 of Pulmonary Hypertension in Infants and

 Children,” 35th Annual Advances in Respiratory

 Care Snowbird Conference, 2018.

 ***Robin Barst Keynote Lecture***: “Perinatal Origins of

 Pulmonary Vascular Disease,” 11th Annual

 Neonatal and Pediatric Pulmonary Vascular

 Disease,” San Francisco, CA, 2018.

 ***Moritz Ziegler Lecture:*** “Pulmonary vascular disease in the

 newborn: diverse phenotypes and therapies,”

 Department of Pediactric Surgery, Children’s

 Hospital Colorado, Aurora CO, 2019.

 ***Keynote Lecture***: “Pulmonary Vascular Endothelial

 Control of Cardio-Pulmonary Diseases: Molecular

 Opportunities for Novel Treatments,” Experimental

 Biology, San Diego, CA, 2020. (Postponed and re-

 scheduled due to the COVID pandemic).

 ***David Schiff Memorial Lectureship***, Department of

 Pediatrics, University of Alberta, Edmonton,

 Canada, 2020 (Postponed and rescheduled due to the

 COVID pandemic).

  ***Invited Professorhsip, Neonatology Day 2020****,* University

 of Iowa School of Medicine, Iowa City Iowa.

 ***13th Annual Bengt Robertson Award*** ***Lectureship,***  *SPIN*

 *2021 Conference, Vilnius.*

# MEMBERSHIP IN PROFESSIONAL SOCIETIES

 American Heart Association

 American Pediatric Society

 American Physiologic Society

 American Thoracic Society

 BPD Collaborative

 European Respiratory Society

 Pediatric Pulmonary Hypertension Network

 Perinatal Research Society

 Pulmonary Vascular Research Institute

 Sigma Xi, Honorary Research Society

 Society for Critical Care Medicine

 Society for Experimental Biology and Medicine

 Society for Pediatric Research

# REVIEW WORK FOR JOURNALS (partial listing):

 American Journal of Physiology

 American Journal of Respiratory and Critical

 Care Medicine

 Anesthesia

 Archives Diseases of Childhood

 Biology of the Neonate

 British Journal of Obstetrics and Gynecology

 Chest

 Circulation

 Circulation Research

 Critical Care Medicine

 Development

 European Respiratory Journal

 FASEB Journal

 Gene Therapy

 Intensive Care Medicine

 Journal of the American College of Cardiology

 Journal of the American Medical Association

 Journal of Applied Physiology

 Journal of Clinical Endocrinology and Metabolism

 Journal of Clinical Investigation

 Journal of Heart and Lung Transplantation

 Journal of Pediatrics

 Journal of Perinatology

 Lancet

 Neonatology

 Key Opinions

 Pediatric Research

 Pediatric Pulmonology

 Pediatrics

 Plos One

 Respiratory Research

 Stem Cells and Development

 Thorax

# EDITORIAL WORK FOR MEDICAL JOURNALS

 Thorax (Editorial Board, 1995-1999)

 “Up to Date in Pulmonary and Critical Care

 Medicine” (Co-Editor, Pediatric Section)

 *Pediatric Pulmonology (Editorial Board, 1996 - current)*

 American Journal of Respiratory and Critical Care

 Medicine (Associate Editor; 1999 – 2010);

 Journal of Pediatrics (Editorial Board, 2004- 2017)

 Journal of Pediatrics (Associate Editor, 2010 - 2011)

 *Pulmonary Circulation (Editorial Board; 2011-current)*

 *American Journal of Physiology Lung, Molecular and Cell*

 *(Editorial Board, 2011 – current)*

 *Neonatology, Editorial Board (current)*

 *American Journal of Respiratory and Critical Care*

 *Medicine (Associate Editor; 2016 - current);*

 *Pediatric Research (Corresponding editor; 2020 - current)*

# REVIEW WORK FOR NATIONAL/INTERNATIONAL RESEARCH GRANTS

1989 March of Dimes Clinical Research Advisory Committee (Ad Hoc)

1992 NIH Heart, Lung, Blood Institutes, Site Visit, Sickle Cell

 Comprehensive Center

1992-1996: American Lung Association Grant Review Committee

 Manitoba Health Research Council, Canada

1995 March of Dimes Scientific Advisory Committee

1997 NIH HLBI Lung Biology and Pathology Study Section (ad hoc)

1997-1999 American Heart Association, Colorado-Wyoming (local affiliate)

1997-2002 American Lung Association National Research Grants Award Committee

1996-2002 March of Dimes Basic Research Grant Review Committee (National)

1999-present The Wellcome Fund, UK

2000,2001 NIH Medical Biochemistry Study Section (ad hoc)

2001 National Science Foundation, Switzerland

2001 NIH/HLBI Lung Biology and Pathology Study Section (ad hoc)

2002 Internal Grants, Hospital for Sick Children, Toronto Canada

2003 NIH/HLBI Special Emphasis Panel, “Coordination of angiogenesis and lung

 growth”

#  NIH/HLBI Special Emphasis Panel, “Collaborative Program in BPD”

2003 Canadian Institutes for Health Research, Canada.

2004 Medical Research Council, Australia

2004 NIH/HLBI Special Emphasis Panel, “Pulmonary Complications of Sickle

 Cell Disease”

2004 - 2008 Regular Member, NIH Study Section, Respiratory Integrative Biology and

 Translational Research. (RIBT).

2006 Ad hoc Reviewer, NIH Special Emphasis Panel.

2006 Ad hoc reviewer, NIH Study Section, Institutional Fellowship Training

 Programs (T32)

2009 Chair, NHLBI Special Emphasis Panel for RFA, “"Developmental Origins of

 Altered Lung Physiology and Immune Function."

2009 Reviewer, Raine Medical Research Foundation, University of Western

 Australia

2010 Reviewer, NICHD/Food and Drug Administration Best Pharmaceuticals for

 Children Act, Bethesda MD.

2010 Reviewer, Thrasher Foundation.

2010 Reviewer, NHLBI Special Emphasis Panel, “Developmental Pharmacology”

2011 Reviewer, NHLBI PO1 “Programs in Translational Research in Lung Disease”

2012 Reviewer, NHLBI UO1 Program, “Consortium of Lung Repair and

 Regeneration: Building the Foundation”

2013 Ad hoc reviewer, NHLBI U01 Program, “Phase II Clinical Trials of Novel

 Therapies for Lung Diseases”

2013 - 2017 Grant review committee, *Parker B. Francis Family Foundation*, Kansas City MO.

2014 Ad hoc reviewer, NHLBI *Respiratory Integrative Biology and Translational*

 *Research (RIBTR)* Study Section;

2014 Reviewer, NHLBI *Special Emphasis Panel*, ZRG1 CVRS-G (02), “Pulmonary

 Disease,” Bethesda, MD.

2014 Reviewer, NHLBI Special Emphasis Panel, *T32 Training Grants*.

2015 Reviewer, National Center for Advancing Translational Sciences (NCATS),

 *“Collaborative Innovation Awards,”* Bethesda MD.

2016- 2020 Standing Member, *NHLBI Study Section on Clinical Trials (CLTR),* Bethesda,

 MD.

2017 Reviewer, *Physician Scientist Development Program (PSDP)* of the American

 Medical School Pediatric Department Chairs, APS, San Francisco CA

# ADMINISTRATION (local)

1989-1993 Director, *Special Care Unit*, The Children's Hospital

1989-1993 Director, *Pediatric Pulmonary Fellowship Training Program*, UCHSC

1991-1993 Dean's Seminar Committee, UCHSC

1991-1994 Director, *Nitric Oxide Study Group*

1994-1996 Course Director, Aspen Conference on the Fetus and Newborn

1996-1999 Board Member, American Heart Association of Colorado/Wyoming

1997 Search Committee, Chairman of Pathology, The Children's Hospital

1997-1998 Research Committee, *Vision 2020 Planning Committee*, UCHSC;

1. Consultant, Institutional Review of the Department of Medicine, National

 Jewish Research and Medical Center, Denver, CO.

1994-present: Director, *Pediatric Heart-Lung Center,* Department of Pediatrics,

 The Children’s Hospital and UCHSC;

1994- present Founder and Co-Director, *Pediatric Pulmonary Hypertension Program*, TCH,

 Denver CO.

1. Consultant, Pediatric Pulmonary Program, Department of Pediatrics and Mercy

 Children’s Hospital, KC, MO.

2003 - 2010 Member, The Children’s Hospital Research Institute Board, Denver, CO.

2003 - 2004 Co-head, Task Force on Collaboration, Department of Pediatrics, UCHSC

2004 - 2007 Member, Clinical-Translational Research Advisory Committee for the Dean,

 University of Colorado School of Medicine, UCHSC.

2007 – 2011 Founder and Director, *Ventilator Care Program*, The Children’s Hospital.

2008 Interviewer, Medical Scientist Training Program Applicants, University of

 Colorado School of Medicine.

2008 - present Member, Medical Student Research Program, University of Colorado School of

 Medicine.

2008 – 2010 Member, Research Strategy Task Force, Department of Pediatrics, The

 Children’s Hospital

2006- 2010 Advisory Committee on Research, Department of Pediatrics

2010- present MD-PhD applicant interviews for Pediatric Residency Program

2010- present Member, Medical Student Research Track Committee, UCD School of Medicine

2011- 2016 Member, NIH K12 Child Health Research Program, Dept. of Pediatrics, UCHSC

2011 Mentorship Planning Committee, Department of Pediatrics, UCHSC

2011- 2016 Member, Executive Committee for Child Health Research, Children’s Hospital

 Colorado.

2011- 2012 Planning Committee, March of Dimes Center for Prematurity, Departments of

 Pediatrics and Obstetrics-Gynecology, University of Colorardo School of

 Medicine, Aurora CO.

2011- 2017 Committee Member, Summer Research Program, Department of Pediatrics,

 University of Colorado School of Medicine

2013-2016 Review Committee, Boettcher Foundation Webb-Waring Biomedical Research

 Awards Program, University of Colorado Denver School of Medicine.

2013-present Mentor, NIH K12 program “*Building Interdisciplinary Research Careers in*

 *Women’s Health,”* University of Colorado School of Medicine.

2013-2016 Member, Grant Review Committee, Children’s Hospital Colorado Research

 Institute

2014 - 2016 Reviewer, Children’s Research Career Development Awards (K12), Dept. of

 Pediatrics, University of Colorado

2014-2016 Reviewer, *Early Career Scholars Program*, Department of Medicine, University

 of Colorado

2015-present Member, *Dean’s Research Advisory Committee*, University of Colorado School

 of Medicine

2020 Reviewer, Pews Scholar Grant Nomination, UCSOM

#### COMMITTEE AND ADMINISTRATIVE WORK FOR NATIONAL/INTERNATIONAL ORGANIZATIONS

1992 Program Planning Committee Secretary, Pediatric Assembly,

 American Thoracic Society (ATS).

1993 Chairman-elect, Program Planning Committee, Pediatrics Assembly, ATS.

1994 Chairman, Program Planning Committee, Pediatric Assembly, ATS

1993- current Abstract Reviewer, Society for Pediatric Research - Pediatric Academic

 Societies National Meetings.

1997 - 1998 American Lung Association/ATS Publications Committee

1996 – 2002 March of Dimes Basic Science Research Committee

1997 – 1998 American Heart Association Research Committee (Affiliate)

1997 – 2001 American Lung Association/ATS Research Grant Committee (National)

2000 NIH/HLBI Workshop on Chronic Lung Disease of Infancy, Bethesda, MD

2001 American Thoracic Society Sub-committee, “Guidelines for the Use of

 Inhaled NO Therapy”

2002-3 Health and Science Policy Committee of the American College of Chest

 Physicians, “Evidence Based Guidelines on the Diagnosis and

 Treatment of Pulmonary Hypertension.”

2002 NIH/HLBI Workshop on “Strategies to Augment Alveolization,” Bethesda,

 MD

2002-2005 E. Mead Johnson Award Selection Committee, Society for Pediatric

 Research.

2004 NICHD/FDA Newborn Drug Development Initiative.Workship, Baltimore,

 MD.

2004- 2007 Pediatric Academic Societies Program Planning Committee (National)

2007 Development and Pathology Working Group, International Task Force on

 Pulmonary Arterial Hypertension

2007- current Member, Pulmonary Vascular Research Institute (International Society).

2008 Planning Group and Organizer, NIH HLBI Workshop on Pediatric Pulmonary

 Diseases, Task Force Leader on Pulmonary Vascular Disease, Bethesda

 MD.

2008 Member, Child Health Research Committee, Federation of Pediatric

 Organizations (FOPO)

2009 Member, NHLBI Workshop on Academic Training in Pediatric and Adult

 Medicine, Bethesda MD

2008 - current Founder and Director, *Pediatric Pulmonary Hypertension Network (PPHNet)*

2010 Speaker and Discussant, NIH Consensus Development Conference, “Inhaled

 NO Therapy for Premature Infants,” Bethesda MD.

2010 Member, NHLBI Working Group, “Improving Transitional Care in Chronic

 Heart, Lung and Blood Diseases,” Bethesda, MD.

2010 Abstracts reviewer, Pediatric Academic Societies International Conference,

 Denver CO

2010 Member, “Reviving Pediatric Pulmonary Medicine,” Pediatric Assembly

 Committee, American Thoracic Society.

2010- 2014 Chairman, American Heart Association and American Thoracic Society Joint

 Guidelines on Pediatric Pulmonary Hypertension.

2011-current External Advisor, NIH T32 Training Program, ““Pulmonary and Critical Care

 Post-Doctoral Research Training Program,” University of Illinois Chicago.

2011- 2013 Co-chair, NHBLI T32 Directors Working Group on Career Development

2011- 2013 Co-Chair, Federation of Pediatric Organizations (FOPO) Child Health Research

 Committee on “Crafting Successful Clinician-Scientists”

2011 Ad Hoc Reviewer, NHLBI Translational Program Grants, Bethesda MD.

2011 Reviewer, NHLBI Special Emphasis Panel, “Consortium of lung repair and regeneration: building the foundation (U01)” and “Lung repair and regeneration consortium administrative coordinating center (U01)”

2011 Co-Chair, NHLBI Division of Lung Disesase Workshop, “Improving outcomes for pulmonary vascular disease,” Bethesda MD.

2011 Invited Participant, NHLBI Division of Lung Disease Workshop, “Lung Development,” Bethesda, MD.

2011- current Member, NICHD Better Pharmaceuticals for Children Act (BPCA), Pulmonary Therapeutic Area Working Group.

2012 External Reviewer, Pediatric Pulmonary Medicine Section, Cincinnati Children’s Hospital Medical Center, Cincinnati OH.

2012-13 Pediatric Task Force Member, 5th World Congress on Pulmonary Hypertension, Nice France.

2012- 2013 Group Leader, Transdisciplinary Program for the Prevention of Prematurity,

 March of Dimes Initiative, University of Colorado School of Medicine.

2012- current Co-founder and Executive Committee member, the National *Bronchopulmonary*

 *Dysplasia (BPD) Collaborative.*

2012- 2013 Peru Community Health Projects Committee, Global Health Institute,

 Adventists Hospital.

2012 Reviewer, Abstract Selection Committee, Pediatric Academic Societies

 Conference 2013

2013 Chair, Pulmonary Hypertension Subcommittee Group, NHLBI Workshop on

 “Primary Prevention of Lung Diseases Research Strategy,” Bethesda, Md.

2013 Member, BPD Subcommitte Group, NHLBI Workshop on “Primary Prevention

 of Lung Diseases Research Strategy,” Bethesda, Md.

2013 Member, *Federation of Pediatric Organizations (FOPO)* Child Health

 Research Committee Workshop, Washington DC.

2013 Member, Data Safety and Monitoring Board, “Role of CC10 Therapy for the

 Prevention of BPD,” *Tufts University*, Boston MA

2013- 2017 Reviewer, *Parker B. Francis Family Foundation Grant Program*.

2014- current Co-Leader, Pediatric Task Force, *Pulmonary Vascular Resistance Institute*

 *(PVRI)*

2014 Co-Chair, *Neonatal Cardio-Pulmonary Biology Young Investigators’ Forum*,

 Chicago, IL

2014 Reviewer, Workshop Conference Selection Committee, Pediatric Academic

 Society International Conference

2014 Ad Hoc Reviewer, NHLBI Special Emphasis Panel, “T32 training programs in

 pulmonary medicine,” Bethesda, MD.

2014 Ad hoc reviewer, NHLBI NHLBI Special Emphasis Panel, Bethesda MD.

2015 – current Member, Committee on BPD, International Neonatology Consortium, Critical

 Path Institute, Tucson Arizona.

2015 Chairman, Data Safety and Monitoring Board, “Intravenous Remodulin

 therapy for Persistent Pulmonary Hypertension of the Newborn.”

2015 Co-Chair, *Neonatal Cardio-Pulmonary Biology Young Investigators’ Forum*,

 Chicago, IL

2016-current Chairman, Data Safety and Monitoring Board, “Riociguat therapy for pediatric

 pulmonary hypertension” (BAYER)

2016-current Member, *Mary Ellen Avery Award* Selection Committee, PAS/SPR,

2016 Invited participant, NHLBI workshop on “Enhancing treatments for pulmonary

 vascular diseases through precision medicine,” Chicago IL.

2016- current Standing Member, NHLBI Study Section on Clinical Trials (CLTR), Bethesda,

 MD.

2016- Co-Chair, *“3rd Annual Neonatal Cardiopulmonary Biology Young Investigators*

 *Forum,*” Chicago IL.

2016 Invited participant, “Bronchopulmonary Dysplasia,” NICHD / FDA workshop,

 Bethesda, MD.

2016- current Advisory Board, PHAware Patient Advocacy Group

2017- current Member, Airway Outcomes Working Group, NIH Environmental Influences on

 Child Health Outcomes (ECHO) Program

2017 Selection Committee, Physician Scientist Development Program, SPR/PAS.

2017- current Member, *Scientific Leadership Council*, Pulmonary Hypertension Association.

2017 Co-Chair, “*4th Annual Neonatal Cardiopulmonary Biology Young Investigators*

 *Forum*,” Chicago IL.

2017 Chair, *Maureen Andrews Award Selection Committee*, PAS/SPR.

2018 Member, Pediatric Task Force, 6th World Symposium on Pulmonary

 Hypertension, Nice France.

2018 Co-Chair, “*5th Annual Neonatal Cardiopulmonary Biology Young Investigators*

 *Forum*,” Chicago IL.

2018 Participant, “Advancing Endpoint Development for Preterm Neonates with

 Pulmonary Morbidities,” Duke Margolis Center for Health Policy,

 Washington DC.

2010- current *Member, Scientifc Board,* Ludwig-Boltzmann Institute of Lung Vascular Disease,

 Graz, Austria.

2018– current Head, Data Safety Monitoring Board, “Riociguat Therapy for Pediatric Pulmonary

 Hypertension,” Bayer Pharmaceuticals.

2018-2019 Organizer, Co-Chair and Moderator, “*The Pulmonary Vasculature in Development,*

 *Homeostasis, Injury and Repair,”* ATS Robert Grover Conference on the

 Pulmonary Circulation, Lost Valley Ranch, Deckers CO.

2018- current Member, Executive Committee, Pulmonary Circulation Assembly, ATS

2019- current Organizing Committee, Chronic Lung Disease Symposium, Philadelphia PA.

2019- current Pediatric Academic Society (PAS) Planning Committee

2019 *President-elect,* American Pediatric Society (APS)

2020 – current *President,* American Pediatric Society (APS)

2020 - current Member, Data Safety Monitoring Board, NHLBI *“Clinical Study of the*

 *Safety of Sildenafil in Premature Infants with Severe BPD”*

2020- current Standing Member, NIH R38 StARR Study Section

2020 Moderator and Speaker, NIH Workshop, “*Clinical Trials in Down Syndrome for*

 *Co-Occurring Conditions Across the Lifespan”*

2020- current Member, Pulmonary Hypertension Association Scientific Leadership Council

 Research Committee.

2020- current Organizer and Moderator, *American Pediatric Society and Society for Pediatric*

 *Research Virtual Chats on the Challenges of Academic Pediatric Medicine*

 *Series*.

2020- current Member, *Tackling Racism as Leaders of Academic Societies* Working Group.

2020-current Member, *Council of Pediatric Subspecialties.*

**INVITED NATIONAL AND INTERNATIONAL PRESENTATIONS**

1987 - American Thoracic Society (ATS) "Long Term Management of Infants with Severe BPD" (Symposium)

1991 - 3rd International Conference on Pulmonary Rehabilitation and Home Ventilation - "Pediatric Home Ventilation"

1991- American Thoracic Society (ATS) Conference- "Role of Endothelial-Derived Products in Perinatal Pulmonary Vasoregulation"

1992 - Society for Pediatric Research (SPR) Conference - "Endothelin in Perinatal Biology" - Poster Symposium Summary.

1992 - American Heart Association (AHA) National Meeting: Postgraduate Series -"Endothelin and the Fetal and Neonatal Pulmonary Circulation".

1992- University of Miami School of Medicine, Neonatal Symposium on New Developments in Neonatal Respiratory Care: ("New Concepts in Pathophysiology and Treatment of PPHN," "Pulmonary Hypertension and Cardiovascular Sequelae of BPD," "Pathogenesis of PPHN: Experimental Aspects").

1992- Hot Topics in Neonatology, 1992, (Ross Laboratories; Washington D.C.): "Clinical Role of Inhaled Nitric Oxide in PPHN Therapy".

1993- ATS Symposium: Abnormal Cardiopulmonary Interactions in Pediatrics (Chairman) and Presentation - "Cardiopulmonary Interactions in Chronic Lung Disease"

1993- SPR Symposium: "Clinical and Cellular Aspects of Nitric Oxide", (moderator).

1993- ATS Symposium: "Clinical Pediatric Cases", (moderator).

1993- NIH Heart Lung Blood Institute Workshop: "Nitric Oxide and the Lung", Presentation: "NO and the Perinatal Pulmonary Circulation".

1993- Hot Topics in Neonatology (Ross Laboratories, Washington D.C.): "Inhaled NO Therapy for PPHN" (Symposium Moderator); Lecture: “NO and the Perinatal Lung."

1993- American Academy of Pediatrics National Meeting: "Role of NO in the Pathophysiology and Treatment of PPHN".

1993- 5th Annual High Frequency Ventilation Conference, Phoenix, Az. "Inhaled NO/PPHN."

1994- Management of the Tiny Baby Conference, Orlando, FL: 1) "NO in the Nursery;” 2) “Long-Term Sequelae of BPD."

1994- Newborn Medicine Update, Marina Del Rey, CA. "Strategies to Prevent Neonatal Lung Injury."

1994- Aspen Conference on the Fetus and Newborn, Aspen, CO. "Steriod Therapy for BPD" and "Inhaled NO Treatment of PPHN."

1994- American Thoracic Society (Boston, MA), Invited Speaker, Joint Symposium of the European Respiratory Society and ATS, Symposium on the Biology of Nitric Oxide: Lecture: "Clinical Uses of Inhaled NO."

1994- International Conference on the Biochemistry and Molecular Biology of Nitric Oxide - Invited Speaker, "Inhalational NO Therapy."

1994- Joint European and American Study Group on NO, Paris, France. "Acute Respiratory Failure."

1994- American Association for Clinical Chemistry, "NO: Its Physiologic Role.”

1994- Hot Topics in Neonatology, (Ross Laboratories Washington, D.C.): "Inhaled NO in Premature Neonates," Invited Speaker.

1994- Grover Conference on the Pulmonary Circulation. Symposium moderator, "Nitric Oxide - Clinical Applications."

1994- 45th Perinatal and Developmental Medicine Symposium: "Regulation of Fetal Development and Postnatal Function," Invited Speaker.

1994- Israeli Neonatology Association, Herzlyi, Israel: "Inhaled NO Therapy."

1995- 29th Aspen Conference of the Fetus and Newborn: "Novel Therapies for Neonatal Respiratory Failure," Conference moderator: Presentation: "Pathophysiologic Mechanisms of PPHN."

1995- Neonatal Pharmacology (Steamboat Springs, CO): "Inhaled NO and PPHN" and "Efficacy of Steroids in BPD."

1995- 9th International Hypoxia Symposium, Alberta, Canada: "Inhaled NO Treatment of Pulmonary Hypertension," Invited Speaker.

1995- 4th International Congress of Pediatric Intensive Care: Padua, Italy, Invited Speaker.

1995- Scandinavian Society of Anesthesiologists, 23rd Congress: Reykjavik, Iceland, Invited Speaker.

1995- SPR Symposium: "Experimental Biology of Pulmonary Hypertension", Moderator. San Diego, CA.

1995- ATS Course, "Lung Growth and Development: Basic Science and Clinical Correlates", Moderator. Seattle, WA.

1995- Society for Critical Care Medicine. Board Review Course, La Jolla, CA. "Pulmonary Hypertension;" "Lung Growth and Development; and Chronic Lung Disease".

1995- American Academy of Pediatrics - NeoPrep "Boards Review Course": "Pulmonary Vascular Development," "Pulmonary Hypertension: Management," San Diego, CA.

1995- 7th European Congress of Paediatric, Surgical and Neonatal Intensive Care, Invited Speaker. Cambridge, UK.

1995- Abbott Round Table Meeting on Neonatology, "Bronchopulmonary dysplasia;" "Pathogenesis of PPHN;" "Inhaled NO Therapy." Drakensberg, South Africa.

1995- 20th Annual Symposium on Clinical Aspects of Perinatal Medicine and Neonatal Ventilation: Invited Speaker, Chicago, IL.

1995- 11th Annual Symposium on Problems and Controversies in Newborn Medicine; Invited Speaker, Norwalk, Connecticut.

1995- Special Ross Conference: Hot Topics in Neonatology, "Phosphodiesterase Inhibitors and PPHN," Invited Speaker, Washington, D.C.

1996- Society for Critical Care Medicine, Current Concepts in Pediatric Critical Care, "Therapeutic Use of Nitric Oxide in Pediatric Lung Disease", Invited Speaker.

1996- 12th Annual CNMC Symposium on ECMO and Advanced Therapies for Respiratory Failure, "Mechanisms of Abnormal Pulmonary Vasoreactivity in PPHN," Invited Speaker.

1996- European Society Pediatric Intensive Care and European Society for Pediatric Research, Joint Plenary Meeting, "Perinatal Pulmonary Vasoreactivity," Invited Speaker, Lyon, France.

1996- American Thoracic Society International Conference. Postgraduate course on Pulmonary Hypertension, "NO in the Pathogenesis and Treatment of Neonatal Pulmonary Hypertension," Invited Speaker.

1996- 2nd World Congress on Pediatric Intensive Care. "Nitric Oxide in Neonatal and Pediatric Patients," Invited Speaker, Rotterdam, The Netherlands.

1996- Society for Pediatric Research Lung Club Lecture, "NO and the Perinatal Pulmonary Circulation," Washington, D.C.

1996- Society for Pediatric Research, "Mechanisms of Lung Development" (Moderator), Washington, D.C.

1996- Midwestern Society for Pediatric Research, "State of the Art Lecture: NO and PPHN". Invited Speaker, Chicago, IL.

1996- District V/VI Section on Perinatal Pediatrics, "Controversies in the Management of PPHN," Invited Speaker, Chicago, IL.

1996- AAP, "NeoPrep" Board Review Course: "Pulmonary Vascular Development" and "Use of Inhaled NO in PPHN", St. Petersburg, Florida.

1996- NIH Workshop, Acute Chest Study Group, "New Understanding and Treatment of ARDS: How does it relate to acute chest syndrome." Washington, DC.

1997- Federation American Society Experimental Biology (FASEB) Symposium, "The NO Signal Transduction System in the Lung: From Molecular Biology to Bedside Therapy," Invited Speaker, New Orleans, LA.

1997 - American Thoracic Society National Meeting, "Combined Therapies for the Treatment of Severe Respiratory Failure in Neonates."

1997 - American Thoracic Society Postgraduate Course: "Novel Technologies in Pediatric Respiratory Failure." San Francisco, CA.

1997 - 3rd European Postgraduate Course in Neonatal and Pediatric Intensive Care, "Adaptation to Extrauterine Life" and "Use and Misuse of NO". Invited Speaker, Berne, Switzerland.

1997 - 2nd International Congress on NO in Cardiovascular Regulation and Intensive Care, "Inhaled NO in Neonatal care," Stockholm, Sweden.

1997- American Academy of Pediatrics, NeoPrep Board Review Course: "Development of the Pulmonary Circulation and the Transition," Phoenix, AZ.

1997 - Clinical Respiratory Physiology Forum 1997: Inhaled NO, Shanghai, China.

1998 - Society for Pediatrics Research: "Pulmonary Vascular Biology." Moderator.

1998- Issues in Neonatology 1998: "Update on the role of NO in the Pathophysiology and Treatment of PPHN." Invited Speaker, Mineola, NY.

1998 - Food and Drug Administration Advisory Meeting, Cardio-Renal Section: "NO Toxicity"; Invited Speaker.

1998- Third International Conference on Pediatric Pulmonology (CIPP IV): "Pulmonary Hypertension," Nice, France.

1998 - XXII International Congress of Pediatrics: "NO and the Lung". Invited Speaker. Amsterdam, Netherlands.

1998 - American Physiological Society Conference, "Endothelial Regulation of Vascular Tone: Role of ET and NO in the Developing Lung." Invited Speaker. Augusta, GA.

1998 - American Heart Association IXth Pulmonary Circulation Conference: "Ontogeny of NO Activity." Invited Speaker. Deckers, CO.

1998 - Hot Topics in Neonatology, "Update on inhaled NO therapy", Invited Speaker, Washington, DC.

1998- European Society of Intensive Care/European Society for Pediatric Intensive Care- “Role of the Endothelium in Pulmonary Hypertension,” Invited Speaker, Stockholm, Sweden.

1998- XXth Central American and Caribbean Pediatric Congress and the VIIIth National Congress on Perinatal Medicine, Invited Speaker, Panama City, Panama.

1998- Nobel Symposium in honor of the Awardees of the Nobel Prize in Medicine or Physiology, Invited Speaker, “Inhaled NO in the Hypoxemic Newborn.” Stockholm, Sweden.

1999- Royal Australian College of Physicians, “Role of NO in the Pathophysiology and Treatment of Persistent Pulmonary Hypertension of the Newborn,” Invited Speaker, Perth, Australia.

1999- Federation of the American Society for Experimental Biology, “Clinical Disorders of Abnormal Pulmonary Vascular Development,” Invited Speaker, Washington, DC.

*1999-* Society for Pediatric Research*, E. Mead Johnson Award Lecture, “Fetal and Neonatal Pulmonary Circulation,”* San Francisco, CA.

1999- European Society for Pediatric Neonatal and Intensive Care- “Clinical Use of Inhaled Nitric Oxide in Pediatrics,” Invited Speaker, Italy.

1999- Neonatal Subspecialty Review Course: “Developmental Physiology of the fetal circulation;” “Persistent pulmonary hypertension fo the newborn,” Chicago IL.

1999- American Academy of Pediatrics, NeoPrep Board Review Course: "Development of the Pulmonary Circulation and the Transition," “Clinical Uses of Inhaled NO,” San Antonio, Texas.

1999- Annual Robert J. Haslam Lecture, “Role of NO in the Pathophysiologic and Treatment of Neonatal Pulmonary Hypertension,” Hospital for Sick Children, Toronto, Canada.

1999- Advances in Pediatric Care, “Neonatal Respiratory Failure: an Integrative Approach,” KK Women’s Hospital, Singapore.

1999- Symposium on Pediatric Pulmonary Hypertension in Congenital Heart Disease, “Inhaled NO therapy of congenital heart disease,” American Heart Association National Meeting, Atlanta GA.

2000- Update on Pediatric Critical Care, “NO in Acute Lung Injury,” Society for Critical Care Medicine, Orlando FL.

2000- Symposium on “New Developments of Hypoxemic Respiratory Failure in the Newborn,” Society for Critical Care Medicine, Orlando, FL.

2000- Postgraduate Course, “Inhaled NO Therapy,” American Thoracic Society International Scientific Meeting, Toronto, Canada.

2000- Symposium on Abnormal Lung Development, “Abnormal Gene Expression in Neonatal Pulmonary Hypertension,” American Thoracic Society International Scientific Meeting, Toronto, Canada.

2000- Third World Congress on Pediatric Intensive Care, “Lung Vascular Injury” (plenary session); “Persistent Pulmonary Hypertension of the Newborn” (plenary session), and “How I Use Inhaled Nitric Oxide” (workshop); Montreal, Canada.

2000- Symposium on “Role of Inhaled NO in the Treatment of Hypoxemic Respiratory Failure in the Newborn,” Third World Congress on Pediatric Intensive Care, Montreal, Canada.

2000- Workshop on Chronic Lung Disease of Infancy, NIH Heart Lung Blood Institute, “Inhaled NO and lung inflammation, airway function and gas exchange,” Bethesda, MD.

2000- FASEB/American Physiologic Society Conference on Perinatal Regulation of the Cardiovascular System, “Regulation of Fetal Pulmonary Circulation,” Copper Mountain, CO.

2000- Toronto Conference on Critical Care, “Inhaled NO Therapy in Preterm Infants,” Toronto, Canada.

2000- Symposium on Acute Respiratory Distress Syndrome, “Role of NO the pathophysiology and treatment of ARDS,” American Academy of Pediatrics, Chicago IL.

2000- Invited Lecture, “Inhaled NO therapy for Pulmonary Hypertension;” NIH Heart Lung Blood Institute, Workshop on Sickle Cell Disease, Bethesda MD.

2000- Symposium on “Inhaled NO Therapy,” American Heart Association National Meeting, New Orleans, LA.

1. Invited Lecture, Neonatology 2000- Challenges for the New Century, University of Miami, Florida.

2000- Chronic Lung Disease Workshop- “Role of Pulmonary Vascular Injury in the Pathogenesis of BPD,” London, UK.

2000- Hot Topics in Neonatology, “Update on Inhaled NO Therapy of Neonatal Respiratory Diseases,” Washington, DC.

2001- American Academy of Pediatrics, NeoPrep Board Review Course: "Development of the Pulmonary Circulation and the Transition," “Basic Mechanisms of Lung Development,” Boston, MA.

2001- Symposium, “Developmental Physiology of the Pulmonary Circulation,” “Inhaled NO therapy of Neonatal Respiratory Diseases,” Mead Johnson Neonatology Regional Meeting, Nemacolin, PA.

2001- ATS Symposia: “Update on Nitric Oxide Therapy,” “Pediatric Clinical Chest Rounds,” American Thoracic Society National Meeting, San Francisco, CA.

 2001- VII Congreso Argentine de Perinatologica; VI Congresso Latino Americano de Perinatologia, “Pathophysiology of PPHN;” “Update on Chronic Lung Disease of Infancy;” “Mechanical Ventilation of the Sick Newborn;” “High frequency oscillatory ventilation.” Buenos Aires, Argentina.

2001- Plenary Lecture, “Chronic NO therapy of primary pulmonary hypertension,” Third World Congress of Pediatric Cardiology and Cardiovascular Surgery, Toronto, Canada.

1. Plenary Lecture, “Influencing cardiovascular function through nitric oxide,” European Society for Pediatric Research, Helsinki Finland.

2001- Plenary Lecture, “Mechanisms of abnormal vascular development in neonatal pulmonary hypertension,” New Frontiers in Neonatology, Heidelberg, Germany.

2001- Lecture, “New Developments in the Treatment of Neonatal Pulmonary Hypertension,” American Heart Association National Meeting, Anaheim CA.

2001- Lecture, “Pathogenesis and Treatment of Neonatal Pulmonary Hypertension,” 40Th Anniversary Celebration, Division of Neonatology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT.

2001- Lecture, “Role of NO in the Pathogenesis and Treatment of Neonatal Pulmonary Hypertension,” Jerry Elliot Memorial Lectureship, SUNY-Stoneybrook, Mineola, NY.

1. Lecture, “Pulmonary Circulation in BPD,” Lung Injury in the Newborn Keystone Symposium (LINKS) Meeting, Keystone, CO. (Conference Co-Organizer and Moderator).

2002- Lecture, “Role of angiogenesis in alveolar development in BPD,” NIH Workshop on Mechanisms of Alveolarization, Bethesda MD.

2002- Drew Wiltsie Memorial Lectureship, “Role of Inhaled NO in the Treatment of Neonatal lung Disease,” Department of Pediatric Grand Rounds, University of Pittsburgh Medical School, Pittsburgh, PA.

2002- Invited Lecture, “Inhaled NO in Cardiorespiratory Disease,” Grand Rounds, Department of Critical Care, University of Pittsburgh Medical School, Pittsburgh, PA.

2002- Invited Lecture, “Role of Inhaled NO therapy in the sick newborn,” Department of Pediatrics, Mercy Children’s Hospital, University of Kansas School of Medicine, Kansas City, MO.

2002- Invited Lecturer, “Role of NO in the pathogenesis and pathophysiology of PPHN,” “An update on inhaled NO therapy in children,” and “Role of Impaired Angiogenesis in BPD,” Symposium on Fetal and Neonatal Pulmonary Biology, University Hospital Maastricht, Maastricht, The Netherlands.

2003- Invited Lecturer, “NO and the Perinatal Lung Circulation,” Perinatal Society of Australia and New Zealand, 7th Annual Congress; Hotel Grand Chancellor, Hobart, Tasmania.

2003- Invited Lecturer, “Regulation of Pulmonary Vascular Tone in the Perinatal Period,” “BPD- A Vascular Hypothesis,” “Clinical Approach to Inhaled NO in the Newborn;” Ipokrates International Meeting on Neonatal Lung Injury, Paris, France.

2003- American Academy of Pediatrics, NeoPrep Board Review Course: "Development of the Pulmonary Circulation," “Basic Mechanisms of Lung Development,” “Treatment of PPHN.” Vancouver, Canada.

2003- Invited Lecture, “Role of NO in the Pathogenesis and Pathophysiology of Neonatal Lung Disease,” Grand Rounds, Department of Pediatrics, University of Manitoba, Winnipeg, Canada.

2003- Barry Smith Memorial Lectureship, “Roles of NO in the Developing Lung,” Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto Canada.

2004- Invited lecture, “Pulmonary circulation in BPD,” 20th Annual CNMC Symposium on ECMO and Advanced Therapies for Respiratory Failure, Keystone, CO.

2004- 6th International Congress on Pediatric Pulmonology (CIPP), “Lung Development,” “Neonatal Pulmonary Hypertension: A Physiologic Approach to Treatment,” Lisbon, Portugal.

2004- 7th European Conference on Pediatric and Neonatal Ventilation, “BPD- A Vascular Hypothesis,” “Inhaled NO in Neonatal Respiratory Failure,” Montreux Switzerland.

1. Invited Lecture, “Lung Vascular and Alveolar Interactions in the Pathogenesis of Bronchopulmonary Dysplasia,” Pediatric Academies Society Meeting, San Francisco, CA.

2004- Invited Lecture, “Early Experience with Chronic Inhaled NO therapy for the Treatment of Pulmonary Arterial Hypertension,” American Thoracic Society, Orlando FL.

2004- Dunlevie Family Lectureship, “Role of NO in the Pathogenesis and Treatment of Neonatal Lung Disease,” Department of Pediatrics, Stanford University, Palo Alto, CA.

2004- Invited Lecture, “Role of Endothelial NO Synthase,” Science of Pulmonary Hypertension Conference, San Antonio, Texas.

2004- Seizo Iwai Lectureship, “Inhaled NO Therapy in Pediatrics: Scientific Basis for Therapy,” 10th Meeting of the Japanese Society of Pediatric Anesthesiology, Tsu City, Japan.

2005- Invited Lecture, “Nitric Oxide- State of the Art,” Western Society for Pediatric Research, Carmel, CA.

2005- Symposium, “Career Development in Pediatric Pulmonary Medicine,” Pediatric Academic Societies, Washington DC.

2005- Invited Lecture, “NO-cGMP signaling in Neonatal Pulmonary Hypertension,” International cGMP Symposium, Potsdam, Germany.

2005- Invited Lecture, “Drug Therapy for PPHN,” and “Drug Therapy for BPD,” Neonatal Pharmacology, Seattle, WA.

2005- Invited Lecture, “NO in Neonatal Lung Disease: Recent Advances,” Recent advances in Neonatal Medicine, Wurzberg, Germany.

2005- Invited Lecture, “Future Clinical Uses of Inhaled NO,” 5th International Society for Medical Gas Meeting, Stockholm, Sweden.

2005- Invited Lecture, “BPD: from bench to bronchus,” Grand Rounds, Dept of Pediatrics, University of Colorado School of Medicine, Denver, CO.

2005-Invited Lecture, “NO in the pathophysiology and treatment of neonatal lung disease,” Academic Day for Neonatologists of Southern California, Neonatal Meeting, Los Angeles, California.

2006- Invited Lecture, “Impaired Angiogenesis in BPD,” Western Perinatal Research Meeting, Banff, Canada.

2006- Hot Topics Symposium, “Lung angiogenesis and its dysregulation in BPD,” Pediatric Academies’ Society Meeting, San Francisco, CA.

2006- Plenary Speaker, “NO in the pathogenesis and treatment of BPD,” *Eastern Society for Pediatric Research*, Old Greenwich, CT.

2006- Invited Lecture, “NO in the pathogenesis and treatment of BPD,” *Jerry Elliott Memorial Lecture*, Western Conference on Perinatal Research, CA.

2006- Invited Lecture, “Treatment of Pulmonary Hypertension in BPD,” Keystone ECMO Conference, Keystone, CO.

2006- Invited Lecture, 7th International Congress on Pediatric Pulmonology (CIPP), “Pulmonary Hypertension in the Older Child: A Physiologic Approach to Treatment,” Montreal, Quebec, Canada.

2006- Invited Lecture, 4th International Conference on the Biology, Chemistry and Therapeutic Applications of Nitric Oxide, “NO in the pathogenesis and treatment of neonatal lung disease,” Monterey CA.

2006- Invited Lecture, “Development of the pulmonary circulation. Implications for congenital diaphragmatic hernia.” International workshop on pathophysiology and management of abnormal lung development, Faculte de medecine Henri Warembourg, Universite de Lille, France.

2006- Invited Lecture, “The ‘new’ approach to bronchopulmonary dysplasia,” European Society for Pediatric Research, Barcelona, Spain.

2007- Invited Lecture, “BPD: New Ideas on Etiology, Pathogenesis and Genetic Susceptibility” ATS National Meeting, San Francisco, CA.

2007- Invited Lecture, “Neonatal Lung Injury,” “Controversies in the use of inhaled NO,” 5th World Congress on Pediatric Critical Care, Geneva, Switzerland.

2007- Invited Lecture, “Advances in the Pathobiology and Treatment of Persistent Pulmonary Hypertension of the Newborn,” *Nils W. Svenningsen Memorial Lecture,* 22nd International Workshop on Surfactant Replacement, Ancona, Italy, 2007.

2007- Invited Lecture, “NO in the Pathogenesis and Treatment of BPD,” Society of Neonatology, Taiwan.

2007- Invited Lecture, “Pulmonary Vascular Disease in the Newborn,” European Society for Pediatric Research, Prague, Czechoslovakia.

2007- Invited Lecture, “Nitric oxide in neonatal lung disease,” Colorado Chapter of the American Academy of Pediatrics, Denver, CO.

2007- Invited Lectures, “Inhaled NO in premature newborns” and “New Therapies for PPHN,” XXI National Congress for Perinatal Mediicne of the Spanish Society of Neonatology and the IVth Congresso Iberoamericano de Neonatologia (SIBEN), Granada, Spain.

2008- Invited Lecture, “Impaired angiogenesis and pulmonary hypertension in BPD,” 24th Children’s National Medical Center Symposium: ECMO and the Advanced Therapies for Respiratory Failure, Keystone CO.

2008- Invited Lectures, “Is there a role for inhaled NO in the Prevention of BPD?,” “Mechanical Ventilation in Severe BPD,” “Pulmonary hypertension in BPD,” International Congress on Pediatric Cardiology, Madrid Spain.

2008- Keynote Address, “Pulmonary vascular disease in BPD,” Neonatal Fellows’ Research Symposium, Harvard University Medical School, Boston MA.

2008- Invited lecture, “Developmental physiology of the pulmonary circulation and neonatal pulmonary hypertension,” Postgraduate Course on “PULMONARY CIRCULATORY PHYSIOLOGY AND PATHOPHYSIOLOGY,” International Conference of the American Thoracic Society, May 16-21, 2008, Toronto, Ontario, Canada.

2008- Invited Lecture, “Pulmonary Vascular Disease in BPD,” Wells Center for Research, Riley Children’s Hospital, Indiana University School of Medicine, Indianapolis, IN.

2008- Invited lecture, “VEGF and development of the pulmonary circulation,” Grover Conference of the American Thoracic Society, Lost Valley Ranch, Deckers, Colorado.

2008- Invited lecture, “Recent advances in the pathogenesis and treatment of PPHN,” Reason 2008, Birmingham England.

2008- Invited lecture, “Impaired NO-cGMP signaling in neonatal pulmonary hypertension: novel mechanisms and treatments,” 5th International Conference on Nitric Oxide, Bergenz, Austria.

2008- Invited lecture, “Pulmonary vascular disease in children,” The David Schiff Memorial Lectureship, Department of Pediatrics, Stollery Children’s Hospital, University of Alberta, Edmonton, Canada.

2008- Invited lecture, “Recent Advances in the Pathogenesis and Treatment of BPD,” The Sprague Lecture in Pulmonary Medicine, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia PA.

2008- Invited lecture, “Pediatric pulmonary hypertension: an historical perspective,” Pediatric Cardiac Intensive Care Symposium, Miami, FL.

2009- Invited lecture, “Vascular-Epithelial interactions during lung development and clinical implications,” 2nd International Conference on Neonatal and Childhood Pulmonary Vascular Disease, San Francisco, CA.

2009- Invited Lecture and Professorship. “Recent concepts in the pathogenesis and treatment of BPD,” The Gordon Forbes Scholar, Department of Pediatrics, University of Rochester Medical Center, Rochester, NY.

2009- Invited lecture, “Recent advances in the pathogenesis and treatment of BPD,” Department of Pediatrics, Mount Sinai School of Medicine, New York, NY.

2009- Invited Lectureship, “Pulmonary vascular disease in children,” Fyler Memorial Lecture, Children’s Hospital, Boston MA.

2009- Invited lectures, “The Effect Of Oxygen Tension On The Molecular And Cellular Events That Mediate Pulmonary Vascular Development,” Postgraduate Course on “PATHOBIOLOGY OF OXYGEN EXPOSURE DURING DEVELOPMENT: BEDSIDE TO BENCH AND BACK TO BEDSIDE,” International Conference of the American Thoracic Society, San Diego CA.

2009- Speaker, “VEGF Receptors in Pulmonary Angiogenesis,” Workshop on Postnatal Angiogenesis, American Thoracic Society International Conference, San Diego, CA.

2009- Invited lecture, “Pediatric Year In Review: Pulmonary Hypertension,” International Conference of the American Thoracic Society, San Diego CA.

2009- Invited Lecture, “Acute management of patients with BPD associated with congenital heart defects,” Kids Hearts 2009 Symposium, The Children’s Hospital, Denver CO.

2009- Invited lecture, “Impaired NO-cGMP Signaling in Neonatal Pulmonary Hypertension,” 4th International cGMP Symposium, Regensburg, Germany.

2009- Invited lecture, "Pulmonary Vascular Disease during Development: Mechanisms and Clinical Implications," 7th Annual Retreat of the International Graduate Program on Molecular Biology and Medicine of the Lung, International Max Planck Research School for Heart and Lung Research, Giessen Germany.

2009- Invited lecture, “Advances in Pediatric Pulmonary Hypertension,” and “Impaired vascular growth in the Pathogenesis of BPD,” Grand Rounds, Department of Pediatrics, University of Wisconsin, Milwaukee, WI.

2009- Invited lecture, “New Thoughts on the Pathogenesis of BPD,” Advances in Neonatology, Children’s Hospital of Philadelphia, Philadelphia PA.

2010- Invited lecture, “Role of Inhaled NO in Premature Infants,” NEO Meeting, Orlando FL.

2010- Invited Lecture, First Annual Maddie Morgan - Butterflies for Maddie Pulmonology Lectureship, “Update on Pulmonary Hypertension and Veno-Occlussive Disease in Pediatrics,” University of Louisville School of Medicine, Louisville, Kentucky.

2010- Invited lectures, “Defining research priorities for acute neonatal and pediatric lung disease in the year 2010,” (Plenary Talk); “Pulmonary Circulation: How to assess, how to control;” “Ventilating the BPD patient;” and “Angiogenesis in BPD;” 10th European Conference on Neonatal and Pediatric Ventilation, Montreux, Switzerland, 2010.

2010- Invited lecture, “Pediatric Patients in Clinical Trials for Pulmonary Hypertension Therapies,” Pulmonary Vascular Research Institute, Lisbon, Portugal.

2010- Invited Lecture, “Abnormal lung vascular growth in premature infants,” 3rd International Conference on Neonatal and Pediatric Pulmonary Hypertension, Banff, Canada.

2010- Invited lecture, “New Advances in the Pathogenesis and Treatment of Childhood Pulmonary Hypertension,” Pediatric Academic Societies International Conference, Vancouver, BC, Canada.

2010- Organizer, Speaker and Workshop Moderator, “Crafting Successful Clinician-Scientists in Child Health Research," Pediatric Academic Societies International Conference, Vancouver, BC, Canada.

2010- Invited speaker, “Determinants of Pulmonary Blood Flow in Health and Disease,” Post-Graduate Course on “A Physiologic Approach to Pediatric Lung Disease,” American Thoracic Society International Conference, New Orleans, LA.

2010- Invited lecturer, “Impaired Pulmonary Vascular Growth in BPD,” The William H. Tooley Professorship, Division of Neonatology and Cardiovascular Research Institute, UCSF, CA.

2010- Invited lecture, “BPD: new thoughts on pathogenesis and treatment,” and “Abnormal Vascular Development in BPD,” *The Frank Sterner Lectureship*, Department of Pediatrics and the Cardiovascular Research Center, University of Wisconsin, Milwaukee WI.

2010- Invited speaker, “Knowns and Unknowns of Administering NO Therapy,” National Institute of Child Health and Development Consensus Development Conference, Bethesda MD.

2010- Invited lecture, “Strategies for the Management of Severe BPD,” Neonatal Organization of Georgia, Atlanta, GA.

2010- Invited Lecture, “Evolving Concepts in Bronchopulmonary Dysplasia,” Grand Rounds, Department of Pediatrics, Emory University, Atlanta, Ga.

2010- Invited Lecture, “Impaired angiogenesis and parenchymal injury in BPD,” Division of Neonatology, Emory University, Atlanta Ga.

2010- Invited Lecture, “Pathogenesis of Bronchopulmonary Dysplasia,” 3rd Annual Respiratory Care Symposium, Colorado Respiratory Care Society, Aurora CO.

2010- Invited Lecture, “Emerging Concepts in BPD,” Neonatology Conference, Children’s Hospital of Philadelphia, Philadelphia, PA.

2010- Invited Lecture, “New thoughts on the pathogenesis and treatment of BPD,” Grand Rounds, Department of Pediatrics, University of Chicago, Chicago IL.

2011- Invited lecture, “The New BPD: thoughts on pathogenesis and therapy,” Grand Rounds, Department of Pediatrics, Johns Hopkins University, Baltimore, MD.

2011- Speaker and Organizer, Conference on “Crafting Successful Clinician-Scientists in Child Health Research,” Federation of Pediatric Organizations, The Woodlands, Texas.

2011- Invited lecture, “Newer therapeutics for BPD and other chronic lung diseases,” NEO conference, Orlando, Florida.

2011- Invited lecture, “Home therapy using a novel pulsed nasal NO delivery system in child pulmonary hypertension,” and “Pulmonary hypertension in chronic lung disease of prematurity,” Cardiology 2011- 15th Annual Update on Pediatric Cardiovascular Disease, Scottsdale AZ.

2011- Invited lecture, “Mechanisms of Pulmonary Vascular Disease in BPD,” National ECMO Conference, Keystone CO.

2011- Invited Speaker, “Role of NO in the pathogenesis and treatment of BPD,” and “Clinical approach to pulmonary hypertension in BPD,” Turkish Neonatology Society 19th National Neonatology Congress (UNEK019), Marmaris, Turkey.

2011- Invited Speaker, “Inhaled NO in premature infants” and “New Therapies for BPD,” 8th Neonatology Congress, Seville. Spain.

2011- Speaker, “Crafting the Clinician-Scientist: patching holes in the pipeline,” Grand Rounds, Resident Research Day, Department of Pediatrics, Children’s Hospital Colorado, Aurora, CO.

2011- Invited Speaker, Dharmapuri Vidyasagar Lecturer and Visiting Professor, Department of Pediatrics, University of Illinois at Chicago, Chicago IL.

2011- Invited Speaker, Phil George Lectureship, Le Bonheur Children’s Hospital and University of Tennessee Health Sciences Center, Memphis TN.

2011- Invited Speaker, “New Thoughts on the Pathogenesis and Treatment of BPD,” Frontier in Pregnancy Research Symposium, Department of Obstetrics-Gynecology, University of Colorado and the March of Dimes- Colorado Chapter, Aurora CO.

2011- Invited Speaker, “Translating Discovery into ICU Therapies,” 33rd Annual George Tauber Memorial Lecture, Dept. of Pediatrics, Washington DC.

2011- Invited Speaker, Joint Program of Neonatology and Pulmonology, “The Vasculature in Chronic Lung Disease: Assessment and Treatment of Cor Pulmonale,” and “Workshop on Infant PFTs,” American Academy of Pediatrics National Meeting, Boston MA.

2011- Invited Speaker, “Novel thoughts on the Pathogenesis of BPD,” Department of Pediatric Grand Rounds, Chu Sainte Justine, Montreal Canada.

2012- Invited Speaker, “Pulmonary vascular disease in BPD,” Joint Neonatology Fellows Conference. Loma Linda University Medical Center, Loma Linda, CA.

2012- Invited Speaker, Symposium on Angiogenesis: “Role of VEGF in Lung Angiogenesis,” Pediatric Academic Societies International Conference, Boston MA.

2012- Invited Speaker, Issues in Perinatal and Neonatal Care Symposium, 35th Annual Seminar, Women and Infants Hospital, Alpert Medical School of Brown University, Providence, RI.

2012- Invited Speaker, “Pulmonary Hypertension: Approach and Management,” “Pulmonary Hypertension in Obstructive Sleep Apnea,” “Living with Pulmonary Hypertension at High Altitude,’ “Pediatric Obstructive Sleep Apnea,” Columbian Congress on Pediatric Respiratory Medicine and Asthma, Medellin, Colombia.

2012- Invited Speaker, “Pulmonary circulation in chronic lung disease,” American Heart Association International Conference, Los Angeles, CA.

2012- Invited Speaker, “Update on persistent pulmonary hypertension of the newborn,” “New approaches towards understanding BPD,” Division of Neonatology, Vanderbilt University, Nashville, TN.

2013- Invited Speaker, “Pulmonary vascular disease in BPD,” *5th Pulmonary Hypertension Professorship* and Pediatric Grand Rounds, Baylor University, Houston TX.

2013- Invited Speaker, “Drug therapy of chronic pulmonary hypertension,” NEO Conference, Orlando FL.

2013- Symposium Moderator and Speaker, “Care of the Child with Pulmonary Hypertension,” Pediatric Academic Societies’ Annual Meeting, Washington DC.

2013 – Invited Speaker, “Pediatric Research Training,” Federation of Pediatric Organizations Workshop in Child Health Research, Pediatric Academic Societies’ Annual Meeting, Washington DC.

2013- Invited Speaker, “Developmental Physiology of the Pulmonary Circulation,” Postgraduate Course on Pediatric Pulmonary Physiology, American Thoracic Society, Philadelphia, PA.

2013- Invited Speaker, “BPD and Pulmonary Hypertension,” Pediatric Pulmonary Core Curriculum, American Thoracic Society, Philadelphia, PA.

2013- Invited Speaker, “Pediatric Task Force Report to the 5th World Symposium on Pulmonary Hypertension,” Pediatric Pulmonary Hypertension Meeting, San Francisco, CA.

2013- Invited Speaker, “Differences between the fetal, newborn and adult pulmonary circulation: relevance for age-specific therapy,” Robin Barst Lecturer, American Heart Association Grover Conference, Lost Valley Ranch, Deckers, CO.

2013- Invited Speaker, “Pulmonary Vascular Disease in BPD,” First European Conference on Neonatal and Pediatric Pulmonary Vascular Disease,” Groningen, Netherlands.

2013- Invited Speaker, “BPD and Pulmonary Vascular Disease: pathogenesis and a different approach to ventilation,” and “Treatment of Pulmonary Hypertension: Roles for Sildenafil and NO therapy in Preterm Infants,” Civadele, Italy.

2013- Invited Speaker, “Inhaled Nitric Oxide- Useful or Not?,” Neonatology Symposium, American Academy of Pediatrics National Conference, Orlando FL.

2013- Invited Speaker, “Role of Impaired Lung Vascular Growth in the Development of BPD,” and “Diagnostic and Therapeutic Approach to Pulmonary Hypertension in BPD,” Current Topics in Neonatal Nutrition and Advances in Neonatal Care, Children’s Hospital at Albany Medical Center, NY.

2013- Invited Speaker, “Management of Severe BPD in the ICU Setting,” Pediatric Critical Care Society Colloquium, Washington DC.

2013- Invited Speaker, “Controversies in the Management of Severe BPD,” and “Pulmonary Vascular Disease in BPD,” Miami Neonatology 2013, Miami FL.

2014- Invited Speaker, “Persistent Pulmonary Hypertension of the Newborn,” NEOPREP, San Diego, CA.

2014- Invited Speaker, “Current and Future Therapy of Pediatric Pulmonary Hypertension,” ECCPS/Pulmonary Vascular Research Institute Symposium, Bad Nauheim, Germany.

2014- Invited Speaker, “Rationale for Establishing a Pediatric Pulmonary Hypertension Network,” Pediatric Task Force, Pulmonary Vascular Research Institute International Conference, Giessen, Germany.

2014- Invited speaker, “Recent advances in pediatric pulmonary hypertension and its treatment,” Grand Rounds, Department of Pediatrics, University of Texas Southwestern, Dallas TX.

2014- Invited speaker, “Pediatric Pulmonary Hypertension: An Update,” Pulmonary Symposium, Pediatric Academic Societies International Conference, Vancouver, CA.

2014- Invited Speaker, “Experimental Basis and Clinical Application of Inhaled NO and cGMP Agonists in Pediatric Pulmonary Hypertension,” International Conference on Nitric Oxide-Nitrite/Nitrate, Cleveland Ohio.

2014- Invited Speaker, “Pulmonary circulation and pulmonary hypertension in term and preterm infants,” “BPD: current concepts in pathogenesis and prevention;” 5th International Conference on Clinical Neonatology, Torino, Italy.

2014- Invited Speaker, “Pulmonary Arterial Hypertension: the ‘other’ hypertension,” 21st Annual Pediatric Critical Care Colloquium, Huntington Beach, CA.

2014- Invited Speaker, “Pulmonary Hypertension in BPD,” Thomas Hazinski Memorial Lecture and Grand Rounds, University of Vanderbilt, Nashville TN.

2014- Invited Speaker, “Pulmonary vascular disease in BPD” and “Management of Severe BPD,” Asan Neonatology Symposium, Seoul, South Korea.

2015- Invited Speaker, “Pulmonary vascular development and BPD,” and “Impaired NO-cGMP Signaling in PPHN,” 21st Annual Meeting of the Japanese Society of Pediatric Pulmonary Circulation, Tokyo Japan.

2015- Chairman and speaker, Oxygen Therapy in Preterm Infants Workhop, Madrid Spain.

2015- Moderator and Speaker, “Neonatal Lung Development and Adult Lung Homeostasis: Common Molecular Mechanisms in Lung Disease,” Experimental Biology, Boston MA.

2015- Invited Speaker, “Pulmonary vascular physiology,” The “Art” of Pediatric Respiratory Physiology: form and function,” ATS Postgraduate Course, Denver CO.

2015- Post Graduate Course Organizer and Moderator, “Pediatric Pulmonary Hypertension,” ATS Postgraduate Course, Denver CO.

2015- Invited Speaker, “External Stimuli in the Pathogenesis of BPD,” Pediatric Academic Society Symposium, San Diego, CA.

2015- Invited speaker, “Improving Diagnosis and Treatment Outcomes of Pulmonary Hypertension in Preterm Infants,” PAS Satellite Symposium, San Diego, CA.

2015- Invited Speaker, “Pulmonary Hypertension in BPD,” Canadian Pediatric Society, Toronto, Canada.

2015- Invited Speaker, “Pulmonary Vascular Disease in BPD,” and “Controversies in the Management of Severe BPD,” European Neonatology Conference, Avignon, France.

2015- Invited Speaker, “Treatment Guidelines for Pediatric Pulmonary Hypertension,” “An Update on the Pathophysiology and Treatment of Persistent Pulmonary Hypertension of the Newborn,” Mechanisms of Pulmonary Vascular Injury in Pediatrics,” “Pulmonary Vascular Disease in BPD,” South American Conference on Neonatology, Cardiology and Pulmonology, Children’s Hospital Garrahan, Buenos Aires, Argentina.

2015- Invited Speaker, “Challenges to Improve Outcomes of Children with Pulmonary Hypertension,” NHLBI Workshop on Accelerating Scientific Advancement for Pediatric Rare Lung Diseases, Bethesda MD.

2015- Invited Speaker, “Bioinformatics and Phenotyping of Pediatric Pulmonary Vascular Disease,” Grover Conference, American Heart Association, Deckers, CO.

2015- Co-chair and Moderator, Neonatal Cardiopulmonary Young Investigators Symposium, Chicago, IL.

2015- Invited Speaker, “Improving Ouctomes in Pediatric Pulmonary Hypertension: Role of Non- Parenteral Protanoids,” Actelion Symposium, Zurich Switzerland.

2015- Invited Speaker, “BPD is a fetal disease,” New England Conference on Perinatal Research, AAP Section on Neonatal-Perinatal Medicine, Cape Cod, MA.

2015- Invited Speaker, “Early pulmonary vascular disease in neonates with BPD,” Second European Conference on Neonatal and Pediatric Pulmonary Vascular Disease, Groningen, Netherlands.

2015- Panel discussant, “Immunity and the pathogenesis of pulmonary arterial hypertension,” Wall Center Symposium, Stanford University, Palo Alto, CA.

2015- Invited speaker, “Proteomic markers of high risk for chronic lung disease after preterm birth,” Proteomics Symposium, Aurora CO.

2015- Invited Speaker: “Ongoing challenges of pulmonary vascular disease in BPD,” Annual Memorial Lectureship Honoring Stanley James, William Silverman and Joan Regan, NY Presbyterian Morgan Stanley Childrens Hospital, Columbia University Medical Center, NYC, NY.

2015- Invited Speaker, “Characterizing the Problem: the risk and etiologies of pulmonary hypertension in preterm infants,” Symposium on Tackling Pulmonary Hypertension in Preterm Infants-from Identification to Improving Outcomes, Hot Topics in Neonatology, Washington DC.

2016- Invited Speaker, “Challenge of Persistent Pulmonary Hypertension of the Newborn,” “BPD: Early Events/Late Outcomes,” and “Pulmonary Vascular Disease in BPD,” International Neonatology Symposium, Bangkok, Thailand.

2016- Invited speaker, “*Mary Ellen Avery Award Acceptance Lecture*,” Pediatric Academic Societies, Baltimore MD.

2016- Invited speaker: “Joint AHA/ATS Guidelines for Pediatric Pulmonary Hypertension: Reading between the (guide)lines,” 9th Annual Neonatal and Pediatric Pulmonary Vascular Disease Conference, San Francisco, CA.

2016- Invited Speaker, “Data Fusion: a sustainable, open source registry advancing pediatric pulmonary vascular disease,” Enhanced Phenotyping of Pulmonary Vascular Disease, American Thoracic Society, San Francisco CA.

2016- Invited Speaker, “Cardiopulmonary Interactions,” Enhanced Phenotyping of Pulmonary Vascular Disease, Resident Boot Camp, American Thoracic Society, San Francisco CA.

2016- Invited Speaker, “Guidelines for pediatric pulmonary hypertension,” ATS Documents Symposium, American Thoracic Society, San Francisco CA.

2016- Invited speaker, “Improving Outcomes of Children with Pulmonary Hypertension,” and “Early Pulmonary Vascular Disease in Preterm Infants at risk for BPD,” CIPP XV- the 15th International Congress on Pediatric Pulmonology, Naples Italy.

2016- Invited speaker, “Management of Neonatal Pulmonary Hypertension,” Innovations in Neonatal Care, San Antonio TX.

2016- Invited speaker, “Pulmonary Hypertension in Chronic Lung Disease: Etiology, Diagnosis, Management,” American Academy of Pediatrics, District VI Meeting, Chicago, IL.

2016- Invited speaker, “Ventilator Management of Severe BPD” and “Recommendations for the Care of Children with Neonatal Pulmonary Hypertension,” Vermont-Oxford Network Annual Meeting, Chicago IL.

2016- Invited Speaker, “Vascular Origins of Bronchopulonary Dysplasia,” European Society for Pediatric Research *Bengt Robertson Award Lecture*, European Academy of Paediatric Societies, Geneva, Switzerland, 2016.

2016- Invited Speaker, “Improving Outcomes in Pediatric Pulmonary Vascular Disease,” Interdisciplinary Symposium, European Academy of Paediatric Societies, Geneva, Switzerland, 2016.

2016- Invited Speaker, “BPD: early events, late outcomes,” Grand Rounds, Department of Pediatrics, Yale University School of Medicine, New Haven CT.

2016- Invited Speaker, “Neonatal Pulmonary Hypertension: Reading Between the (Guide)lines,” Neonatal Assocation of Orange County, Loma Linda University, California.

2017- Invited Speaker, “BPD: Too Little but Not Too Late,” Pediatric Grand Rounds, Florida Hospital, Orlando FL.

2017- Invited Speaker, “Chronic Outpatient Management of BPD- a Pulmonologist’s Perspective,” NEO conference, Orlando FL.

2017- Invited Speaker, “Mechanical ventilation of infants with severe BPD and Pulmonary Hypertension,” and “Pulmonary Hypertension in Pediatric Lung Diseases,” 10th Annual Neonatal and Pediatric Pulmonary Vascular Diseases Conference, San Francisco, CA.

2017- Invited Speaker, “Neonatal Pulmonary Vascular Disease- the Science Behind our Therapies,” NeoHeart: CV Management of the Neonate,” San Diego CA.

2017- Invited Speaker, “BPD: Too Early but not Too Late,” Grand Rounds, Department of Pediatrics, Northwestern University Medical School, Chicago IL.

2017- Invited speaker, “BPD and Pulmonary Hypertension,” Pediatric Respiratory Physiology Post-Graduate Course, American Thoracic Society, Washington DC.

2017- Invited speaker, “Chronic Ventilation of Infants with Severe BPD,” Mechanical Ventilation in the NICU, PICU, and at Home: What the Pediatric Pulmonologist Should Know,” American Thoracic Society, Washington DC.

2017- Invited speaker, “T32 Training Programs in Academic Pediatric Pulmonary Medicine,” NHLBI T32 Directors Meeting, American Thoracic Society, Washington DC.

2017- Invited speaker, “Identification of gaps in knowledge in the care of the patient with severe BPD,” Pediatric Academic Societies Meeting, San Francisco, CA.

2017- Invited speaker, “Antenatal Origins of BPD,” Building Better Babies Symposium, UCD-Anschutz Medical Center, Aurora CO.

# 2017- Invited speaker, “Meeting the challenges of Persistent Pulmonary Hypertension of the Newborn,” and “Pulmonary Hypertension in BPD,” Recent Advances in Neonatal Medicine VIII International Symposium, Wurzburg, Germany.

2017- Invited speaker, “Prevention of pulmonary hypertension in BPD,” 3rd European Conference on Neonatal and Pediatric Pulmonary Vascular Disease, Groningen, The Netherlands.

2017- Invited speaker, “Pulmonary hypertension in preterm infants and BPD,” XI SWAN Conference, Baylor Scott and White, Temple Texas.

2017- Arvo Yllpo Award Recipient Lecture, “Improving Neonatal Outcomes through the Pulmonary Circulation,” *Arvo Ylppo Medal Award Ceremony*, Great Hall, University of Helsinki, Helsinki Finland.

2017- Invited Speaker, “BPD: Too Little but not Too Late,” Department of Pediatrics Grand Rounds, Helsinki Childrens Hospital, Helsinki Finland.

2017- Invited Speaker, “Prevention of BPD and Pulmonary Hypertension in Preterm Infants” Department of Pediatrics Grand Rounds, Oulu Childrens Hospital, Oulu Finland.

2017- Invited Speaker, Plenary Talk: “BPD: Too Little but not Too Late;” and “Physiologic Approach to Pulmonary Hypertension in Preterm Infants,” 37th Annual Conference in Neonatology, Vanderbilt University, Nashville TN.

2017- Invited Speaker, *Thomas H. Pauly Memorial Lectureship* Grand Rounds: “BPD: Too Little but not Too Late,” and Neonatology Section Talk: “Physiologic Approach to Pulmonary Hypertension in Preterm Infants,” University of Kentucky School of Medicine, Lexington KY.

2017- Invited speaker, “The Vasculature as a Determinant of Lung Growth,” Bronchopulmonary Dysplasia: Then and Next- a Symposium Honoring William Northway, MD, Stanford University, Palo Alto, CA.

2018- Invited speaker, “Pediatric Task Force Report,” 6th World Symposium on Pulmonary Hypertension, Nice France.

2018- Invited speaker, “Update on Pediatric Pulmonary Hypertension,” Scientific Leadership Committee Meeting, Pulmonary Hypertension Association, Silver Springs, MD.

2018- Invited Speaker, “BPD-Associated Pulmonary Hypertension,” 4th Annual Chronic Lung Disease Conference, Children’s Hospital of Philadelphia, Philadelphia PA.

2018- Invited speaker, “Management of Pulmonary Hypertension in Infants and Children,” *Robert DeLemos Memorial Lectureship*, 35th Annual Advances in Respiratory Care Snowbird Conference, 2018.

2018- Invited speaker, “Perinatal Origins of Pulmonary Vascular Disease,” *Robin Barst Keynote Lecture*, 11th Annual Neonatal and Pediatric Pulmonary Vascular Disease Conference, San Francisco, CA.

2018- Invited speaker, “Perinatal origins of pulmonary vascular disease,” Symposium on Developmental Origins of Health and Disease, Pediatric Academic Societies Meeting, Toronto Canada.

2018- Invited Speaker, “Annual review of pediatric lung disease,” Symposium from the American Journal of Respiratory and Critical Care Medicine Editors, American Thoracic Society, San Diego CA.

2018- Invited Speaker, “Pulmonary Vascular Disease in the Pathogenesis of BPD" and "Physiologic Approaches to the Care of Children with Severe BPD," 25th Anniversary Meeting of the Korean Society of Neonatology, Seoul South Korea.

2018- Invited speaker, “Care of the Child with Severe BPD,” Department of Pediatrics Grand Rounds, University of Minnesota School of Medicine, Minneapolis, MN.

2018- Invited speaker, “Pulmonary Hypertension in the Pediatric Population: Insights from the PPHNet Registry,” Pulmonary Hypertension Association Scientific Meeting, Orlando FL.

2018- Invited keynote speaker, T35 Predoctoral Training Program, Cincinnati Childrens Hospital and Medical Center, Cincinnati OH.

2018- Invited speaker, “Pulmonary vascular disease in the developing lung: early and long-term implications,” Department of Pediatrics, University of California San Diego, San Diego CA.

2018- Invited speaker, “Physiology driven approach to pulmonary hypertension in preterm infants” and “BPD: interactions between the heart and lungs,” 6th Monash Cardiovascular Symposium (Fetal, Neonatal and Pediatric), Melbourne Austalia.

2018- Invited speaker, “Building interdisciplinary collaborative networks,” Monash University Medical Center, Melbourne Australia.

2018- Invited keynote speaker, NHLBI T32 Joint Training Program in Pediatric and Adult Pulmonary Medicine, University of Indiana School of Medicine, Indianapolis IN.

2018- Invited speaker, “Evaluation and management of pulmonary hypertension in infatns with BPD,” HCA Neonatology Symposium, Kansas City KS.

2018- Invited Speaker, “What is new in therapy for BPD-Associated Pulmonary Hypertension?” Hot Topics in Neonatology, Washington DC.

2019- Invited Speaker, “Pulmonary Vascular Disease in BPD: Pathophysiology and Treatment,” BPD 2019, Cincinnati Childrens Hospital Medical Center, Cincinnati OH.

2019- Invited Speaker, “Pulmonary hypertension in BPD: from bench to bedside,” 21st Annual Conference: “A Day with the Newborn,” St. Christopher’s Hospital for Children, Philadelphia, PA.

2019- Invited Speaker, “Role of Cardiac Cathetherization in Assesssing PH in preterm infants,” 12th annual Neonatal and Pediatric Pulmonary Vascular Disease Conference, San Francisco, CA.

2019- Invited Speaker, “Cross-disciplinary Training in Pediatric Pulmonary Hypertension,” 12th annual Neonatal and Pediatric Pulmonary Vascular Disease Conference, San Francisco, CA.

2019- Invited Speaker, “Controversies in BPD: linking vascular disease with respiratory outcomes,” BPD Collaborative Meeting, Philadelphia PA.

2019- Invited Speaker, “The BPD Collaborative: Re-focusing our Mission,” BPD Collaborative Meeting, Philadelphia PA.

2019- Invited Speaker, “Infant and Child Lung Disorders: Genetics, Diagnostics and Tomorrow’s Care,” Pediatric Respiratory Symposium, Stanford University Medical School, Palo Alto, CA.

2019- Invited Speaker, “Precision medicine: how clinical heterogeneity should alter our decision making in acute pulmonary hypertension,” NeoHeart 2019, Huntington Beach, CA.

2019- Invited Speaker, “Pulmonary vascular disease in the developing lung: early and long-term implications,” Department of Pediatrics Grand Rounds, University of California San Diego, San Diego CA.

2019- Invited Speaker and Moderator, “Just Say NO to iNO in preterms. Really?” Pediatric Academic Society State of the Art Plenary, Baltimore MD.

2019- Speaker, “Pulmonary Vascular Disease in Preterm Infants: Pathobiology,” Treatment of Pulmonary Hypertension in Premature Neonates Symposium, Pediatric Academic Society, Baltimore MD.

2019- Invited Speaker, “BPD: Keeping Pace with an Evolving Disease,” Symposium on Clinical Studies of BPD, American Thoracic Society, Dallas TX.

2019- Invited Speaker, “Pulmonary Vascular Phenotypes of Prematurity,” The Neonatal and Developing Lung Interest Group Lecture, American Thoracic Society, Dallas TX.

2019- Invited Speaker, “Biomarker Discovery for Pediatric Pulmonary Vascular Diseases,” Symposium on Novel Biomarkers for the Diagnosis, Phenotyping, and Management of Pediatric Lung Diseases, American Throacic Society International Conference, Dallas TX.

2019- Invited lecture, “Pulmonary Vascular Disease in Severe BPD: Matching Physiology with Therapy” and “Career Development in Academic Neonatology,” Columbia University, NY, NY.

2019- Invited Speaker, “Current Management of Pulmonary Arterial Hypertension in the BPD Infant,” Innovations in Neonatal Care, Austin TX.

2019- Invited Speaker, “Fetal Origins of Pulmonary Vascular Disease,”  t[he 4th European Conference on Neonatal and Pediatric Pulmonary Vascular Disease](https://pediatricpvd.com/home/), Groningen, NL.

2019- Invited lectures, “Management of BPD-Associated Pulmonary Hypertension,” “Pulmonary Vascular Phenotypes of Prematurity,” “Building Interdisciplinary Programs in Pulmonary Hypertension,” and “Career Development in Academic Pediatrics,” Johns Hopkins University, Baltimore MD.

2019- Invited Speaker, “Old BPD, New BPD and Current Severe BPD,” and “Current Understanding of BPD-Associated Pulmonary Hypertension,” 2019 International Infant Chronic Lung Diseae Forum, Guangzhou, China.

2020- Invited Speaker, “Pulmonary Hypertension and BPD Phenotypes,” Cincinnati BPD Symposium 2020: Advances in Diagnosis and Management, Cincinnati Children’s Hospital Medical Center, Cincinnati OH.

2020- Invited Speaker, “Bronchopulmonary Dysplasia: a Continuing Dilemma” and “Dilemmas of Pulmonary Hypertension,” International Neonatology Symposium: Bangkok 2020, Mahidol University, Bangkok Thailand.

2020- Invited Speaker, “Ask the Expert,” Chronic Lung Disease Symposium, Philadelphia, PA.

2020- Keynote speaker, “Pulmonary Vascular Endothelial Control of Cardio-Pulmonary Diseases: Molecular Opportunities for Novel Treatments,” Experimental Biology, San Diego, CA. CANCELLED DUE TO CORONAVIRUS PANDEMIC.

2020- Invited speaker, Edwin Kendig Symposium on Pediatric Pulmonary Medicine, Virginia Commonwealth University, Richmond Virginia. CANCELLED DUE TO CORONAVIRUS PANDEMIC.

2020- Invited Speaker and Moderator, “Down syndrome patient registries,” NIH-NICHD Clinical Trials in Down Syndrome for Co-occurring Conditions Across the Lifespan Workshop. (Held as virtual workshop meeting due to Coronavirus pandemic).

2020- Invited speaker, “Pulmonary hypertension in BPD,” MEDNAX Seminar (held as virtual grand rounds).

2020- Invited speaker, “Inhaled NO- just say NO?,” Royal Hospital for Women, Randwick, Australia (held as virtual grand rounds).

2020- Invited Speaker, “Keeping Pace with Bronchopulmonary Dysplasia,” and “Pulmonary Vascular Phenotypes of Prematurity,” Neonatology Day 2020, University of Iowa School of Medicine. (virtual lectures).

2020- Invited Speaker, “Building an Academic Career,” and “Interactive Case Presentations,” Section of Neonatology and Department of Pediatrics, University of Iowa.

2020- Invited speaker, “Pathobiology of pulmonary hypertension in BPD: novel insights” and “Pulmonary vein stenosis in preterm infants: an overview on a diagnosis commonly overlooked,” NeoHeart Meeting, Columbia University, NY, NY. (virtual meeting).

2020- Invited Speaker, “Organizing to Promote Diversity, Equity and Inclusion,” Environmental Influences on Child Health Outcomes Fall Meeting (virtual).

2020- Invited speaker, Plenary Session, “Advanced therapeutic strategies for pediatric pulmonary hypertension.” Asian Paediatric Pulmonology Society, Taiwan.

2020- Invited speaker, “Pulmonary Hypertension in the First Week of Life in the Term Neonate,” 10th International Conference of the Union of European Perinatal and Neonatal Societies, Rome Italy.

2021- Invited speaker, “*The 13th Bengt Robinson Lecture*: The Lung Circulation in Development and Disease,” and “Persistent Pulmonary Hypertension of the Term Newborn,” SPIN 2021, Vilnius, Croatia.

2021- Keynote speaker, “Pulmonary Vascular Endothelial Control of Cardio-Pulmonary Diseases: Molecular Opportunities for Novel Treatments,” Experimental Biology Conference (Virtual).

# VISITING PROFESSORSHIPS

1990 - Department of Pediatrics; Buffalo Children's Memorial Hospital, Buffalo, New York

1993 - Department of Medicine; University of Minnesota, Minneapolis, Minnesota

1993 - Department of Pediatrics: British Columbia Children's Hospital, Vancouver, BC, Canada

1993 - Department of Pediatrics; Stanford University Medical Center; Palo Alto, CA.

1994 - Department of Pediatrics; Omaha Children's Hospital, Omaha, NE.

1994 - Department of Pediatrics; University of Manitoba Health Sciences Center, Winnipeg, Manitoba.

1994 - Department of Pediatrics; Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Bethesda, MD.

1994 - Department of Pediatrics/Neonatology: Shaare Zedek Medical Center, Jerusalem; Rambam Medical Center, Haifa; Soroka Medical Center, Beersheva, Israel.

1995 - Departments of Neonatology and Pediatrics: Tygerberg Hospital, Groote Schuur Hospital, University of Stellenbosch; Cape Town, South Africa.

1995 - Department of Pediatrics, Emory University Medical School, Atlanta, Georgia.

1995- Departments of Anesthesiology and Pharmacology, University of Washington School of Medicine, Seattle, Washington.

1996 - Department of Pediatrics, Wyler Children's Hospital and University of Chicago School of Medicine, Chicago, IL.

1996 - Department of Anesthesia, Boston Children's Hospital, Boston, MA.

1997 - Department of Pediatrics, Department of Pediatric Anesthesia and Critical Care, The Children's Hospital, Gothenburg, Sweden.

1997- Department of Pediatrics, Children's Hospital, Shanghai Medical University, Shanghai, China.

1998 - Department of Pediatrics, Primary Children's Hospital, Salt Lake City, Utah.

1999- Department of Pediatrics, Rainbow Babies and Children Hospital, Case Western Reserve University School of Medicine, Cleveland, Ohio.

1999- Department of Pediatrics, Women’s and Children’s Hospital, Adelaide, Australia.

1999- Department of Pediatrics, Hospital for Sick Children, Toronto, Canada.

2001- Department of Pediatrics, Yale University Medical School, New Haven CT.

2002- Department of Pediatrics, and Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh PA.

1. Department of Pediatrics, Mercy Children’s Hospital and University of Kansas School of Medicine, Kansas City, MO.
2. Department of Pediatrics, University Hospital Maastricht, Maastricht, The Netherlands.

2003- Department of Pediatrics, University of Manitoba, Winnipeg, Canada.

2003- Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Canada.

2004- Department of Pediatrics, Stanford University, Palo Alto, CA.

2004- Department of Pediatrics, National Center for Child Health and Development, Tokyo, Japan.

2006- Department of Pediatrics, Columbus Children’s Hospital, Ohio State University, Columbus Ohio

2006- Department of Pediatrics, University of Texas-Southwestern Medical School, Dallas TX

2007- Department of Pediatrics, University of California, San Diego

2007- Section of Pulmonary, Critical Care and Allergy, Department of Pediatrics, Stanford University, Palo Alto, CA.

2007- Department of Pediatrics, Wake Forest University, North Carolina

2008- Division of Neonatology, Department of Pediatrics, Harvard Medical School, Boston, MA

2008- Division of Neonatology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN

2008- Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada

2008- Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia PA

2009- Department of Pediatrics, University of Rochester School of Medicine, Rochester NY

2009- Department of Pediatrics, Mount Sinai School of Medicine, NY, NY

2009- Department of Cardiology, Boston Children’s Hospital, Harvard University, Boston, MA

2009- Graduate Program on Molecular Biology and Medicine of the Lung, International Max Planck Research School for Heart and Lung Research, Giessen, Germany

2010- Department of Pediatrics, University of Louisville, Louisville KY

2010- Department of Pediatrics, University of Wisconsin, Milwaukee WI

2010- Division of Neonatology, Department of Pediatrics, and the Cardiovascular Research Institute, UCSF, CA.

2010- Department of Pediatrics, Emory University, Atlanta GA

2010- Department of Pediatrics, University of Chicago, Chicago IL

2011- Department of Pediatrics, Johns Hopkins University, Baltimore MD

2011- Department of Pediatrics, University of Illinois at Chicago, Chicago IL

2011- Department of Pediatrics, University of Tennessee, Memphis TN

2011- Department of Pediatrics, Weill School of Medicine, Cornell University, NY, NY

2011- Department of Pediatrics, CHU Sainte-Justine, Montreal, Canada

2011- Department of Pediatrics, National Children’s Hospital, Washington DC

2012- Department of Pediatrics, Brown University, Providence RI

2013- Department of Pediatrics, Texas Children’s Hospital, Baylor University, Houston Texas

2014- Department of Pediatrics, University of Texas Southwestern, Dallas TX

2014- Department of Pediatrics, Vanderbilt University, Nashville TN.

2014- Department of Pediatrics, University of Ulsan College of Medicine, Asan Medical Center Children’s Hospital, Seoul, South Korea.

2014- Department of Pediatrics, Toho University Omori Medical Center, Tokyo, Japan.

2015- Department of Pediatrics, Stanford University, Palo Alto CA.

2016- Department of Pediatrics, Yale University, New Haven CT.

2017- Department of Pediatrics, Northwestern University School of Medicine, Chicago, IL.

2017- Department of Pediatrics, Childrens Hospital, Helsinki Finland.

2017- Department of Pediatrics, Oulu Childrens Hospital, Oulu, Finland.

2017- Department of Pediatrics, University of Kentucky, Lexington, KY.

2018- Department of Pediatrics, University of Minnesota, Minneapolis MN.

2018- Department of Pediatrics, Cincinnati Childrens Medical Center, Cincinnati OH.

2018- Department of Pediatrics, Riley Hospital for Children, University of Indiana School of Medicine.

2019- Department of Pediatrics, University of California San Diego Medical School

2019- Department of Pediatrics, Columbia University, New York City, NY.

2019- Department of Pediatrics, Johns Hopkins University, Baltimore MD.

2020- Department of Pediatrics, University of Alberta, Edmonton Canada. (Cancelled due to restricted travel from COVID pandemic)

2020- Department of Pediatrics, Unversity of Iowa School of Medicine, Iowa City Iowa.

**Research Mentorship:**

# Individual Project Title Current Position

#

Barbara Chatfield MD Endothelial Regulation of Fetal Professor

(1989-91) Pulmonary Vasoreactivity Pulmonary Medicine

(deceased) Dept. of Pediatrics

 University of Utah

 Salt Lake City UT

John McQueston, MD Endothelial Function in Neonatal Professor

(1990-92) Pulmonary Hypertension Pulmonary Medicine

Dept of Pediatrics

 University of Oregon Health

 Sciences Center

 Portland OR

Steven Allen, MD Endothelin and Clinical Pulmonary Private Practice, Cardiology

(1990-92) Hypertension Wichita, Kansas

David Cornfield, MD K+ Channels in Perinatal Lung Professor,

(1990-92) Chief of Pulmonary and

 Critical Care Medicine,

 Dept of Pediatrics

 Stanford University

 Palo Alto, CA

John Kinsella, MD Inhaled NO in the Sick Newborn Professor

(1991-92) Neonatology

 Dept of Pediatrics

 University of Colorado

Ann Halbower, MD Developmental regulation of eNOS Professor,

(1992-94) Pediatric Pulmonology,

 Director, Sleep Lab,

 University of Colorado

 Denver, CO

Dunbar Ivy, MD\* Endothelin in Pulmonary Professor,

(1993-96) Hypertension Chief, Ped. Cardiology,

 Dept of Pediatrics

 University of Colorado

James Ziegler, MD cGMP Phosphodiesterase in Pulmonary Professor

(1994-96) Hypertension Pediatric Cardiology

 Dept of Pediatrics

 Brown University

 Providence, RI

Oliver W. Jones, MD Endothelin in the Hypoxic Fetus Private Practice (Ob-Gyn)

(1993-4)

Emily Dobyns, MD\* Clinical Studies of Acute Professor Emeritus,

(1992-4) Respiratory Failure in Pediatrics Critical Care Medicine,

 Dept. of Pediatrics

 University of Colorado

Thomas Parker, MD\* Hormonal Modulation of Fetal Professor,

 (1996-98) Pulmonary Circulation Neonatology

 Fellowship Training Director,

 Head of GME,

 Dept. of Pediatrics

 University of Colorado

Henry Galan, MD Role of Endothelial NO Synthase Professor and

(1996-98) in Placental Function Chief of Perinatal Medicine,

 Dept. of Ob-Gynecology

 University of Colorado

Robyn Rairigh, MD Inducible NO Synthase in the Private Practice

(1997-99) Perinatal Lung Circulation Neonatology

(deceased)

Theresa Grover, MD\* VEGF in Neonatal Pulmonary Professor,

(1998-2000) Hypertension NICU Medical Director

 Neonatology,

 Dept. of Pediatrics

 University of Colorado

Timothy D. Le Cras, PhD Regulation of Angiogenesis Professor,

(1996-2000) Division of Lung Biology

 Dept. of Pediatrics

 University of Cincinnati

 Cincinnati OH

Sarah Gebb, PhD Embryologic Mechanisms of Professor

(1998-2000) Angiogenesis Dept of Pharmacology

 University of South Alabama

 Mobile, Alabama

Jamie Wooldridge, MD NO in the CF airway Professor,

(2001) Chief of Pulmonary Medicine

 Dept of Pediatrics

 Women and Childrens Hospital

 University of Buffalo School of

 Medicine, Buffalo, NY

Jeanne Zenge, MD Regulation of Fetal Pulmonary Associate Professor,

(1999-2001) Vascular Smooth Muscle Neonatology

 Fellowship Director

 Dept of Pediatrics

 University of Colorado

Vivek Balasubramanian, MD\* Mechanisms of Angiogenesis and Associate Professor and Head,

(1999-2003) Alveolization in Development Pulmonary Medicine

 Dept of Pediatrics

 University of Wisconsin

Greg Montgomery, MD Pulmonary Hypertension in CF Associate Professor,

(2003 - 2005) Pulmonary Medicine,

 Dept of Pediatrics

 University of Indiana

 Indianapolis, IN

Anette Kunig, MD Lung Vascular-Alveolar Interactions Private Practice, NICU

(2003- 2006) St Joseph Hospital,

 Denver CO

Jason Gien, MD \* Cell-Cell Interactions in Pulmonary Associate Professor,

(2004 - 2007) Vascular Development Neonatology

 Dept of Pediatrics

 University of Colorado

Jen-Ruey Tang, MD VEGF signaling in prematurity Research Assistant Professor

(2005; 2008- 2011) Neonatology

 Dept of Pediatrics

 University of Colorado

Peter Mourani, MD\* Pulmonary Hypertension in BPD Professor

(2005 – 2010) Medical Director, CHCO

 Research Institute,

 Critical Care Medicine

 Department of Pediatrics

 University of Colorado

Chris Baker, MD\* Circulating EPCs in BPD Associate Professor

(2005 – 2008; 2012-17) Pulmonary Medicine

 Dept of Pediatrics

 University of Colorado

Jerimiah Lysinger, MD Cardiopulmonary function in CF Private Practice, Pulmonary

(2005- 2009) Billings, Montana

Vincent Muehlethaler, MD Lung development in CDH Neonatology,

(2006 - 2008) Lausanne, Switzerland

Marc Chester, MD Soluble Guanylate Cyclase Activators Private Practice, Pulmonary

(2007 – 2009) in PPHN Virginia

.

Cassidy Delaney, MD\* Serotonin signaling in PPHN Associate Professor,

(2007 – 2013) Neonatology,

 University of Colorado,

Hillary Tuttle, MD Erythropoietin in the developing lung Associate Professor

(2007 – 2010) Neonatology,

 University of Oregon

 Portland, OR

Robert Rock, MD Fetal Lung vascular development Private Practice, NICU

(2007 – 2010)

Rachel Wright, MD SOD in experimental BPD Assistant Professor,

(2009- 2011) Neonatology

 University of Colorado

K. Joseph Hurt, MD, PhD Hydrogen Sulfide in Development Associate Professor

(2010- 2012) Dept. of Obs and Gynecology

 University of Colorado

Jennifer Taylor-Cousar, MD\* Phosphodiesterase inhibitors in CF Professor,

(2010 – 2015) Dept. of Medicine

 National Jewish Center

 Denver CO

Paul Rozance, MD \* Intrauterine Growth Restriction and Professor

(2010 – 2015) Lung Hypoplasia Neonatology

 Department of Pediatrics

 University of Colorado

Clyde J. Wright, MD\* NFKB signaling in the developing lung Associate Professor,

(2011 - 2012) Neonatology

 Dept. of Pediatrics

 University of Colorado

Blair Dodson, PhD Abnormal Vasculature in IUGR Assistant Professor

 (2011 – 2017) Dept. of Surgery

 University of Colorado

Erica Mandell, MD \* Vitamin D in Lung Development Assistant Professor

 (2011 – 2014) Neonatology

 University of Colorado

Shannon Acker, MD Endothelial dysfunction in Congenital Assistant Rofessor,

(2012 – 2014) Diaphragmatic Hernia Pediatric Surgery

 Department of Surgery

 University of Colorado

Csaba Galambos, MD Vascular – Epithelial Interactions Professor,

 (2012 – 2014) Lung Growth in Down Syndrome Department of Pathology,

 University of Colorado

Bradley Wallace, MD Mechanisms of Pulmonary Vascular Resident

 (2015 – 2017) Growth Arrest in BPD Department of Surgery

 University of Colorado

Uyen Truong, MD\* MRI studies of pediatric PH Asspciate Professor

 (2015 – 2018) Pediatric Cardiology

 Richmond VA

Doug Bush, MD Pulmonary vascular diseae in Assistant Professor

 (2015 – 2017) Down Syndrome Pediatric Pulmonary Medicine

 Mt Sinai School of Medicine

 NYC, NY

Vitaly Khayfets, PhD \* Cardiac imaging in pediatric PH Assistant Professor,

(2016 - 2017) Bioengineering and Pediatric

 Cardiology, University of

 Colorado

Rony Marwan, MD Pulmonary Hypertension in CDH Assistant Professor

(2016 – 2017) Department of Surgery

 University of Colorado

Jonathon Davies, MD \* Adenosine Signaling in BPD Assistant Professor

(2017 – current) Neonatology,

 Baylor University

Dan Ehrman, MD Echocardiography in pediatric PH Fellow,

 (2017- 2019) Pediatric Cardiology,

 UCHSC

Ben Frank, MD Pulmonary Hypertension in BPD Assistant Professor,

(2017- 2019) Pediatric Cardiology,

 UCHSC

Clare Paterson, PhD Antenatal mechanisms of behavioral disorders Assistant Professor

(2018 – 2020) Department of Psychiatry

 UCHSC

Mattson, Courtney, PhD Lung mechanics with ventilator injury PhD

(2018 – current) Reaserch Assistant Professor

 Department of Engineering

 UCHSC

*\* denotes NIH K grant recipients*

**Research Sabbaticals for International Visiting Faculty:**

Eduardo Villamor, MD Neonatology, Madrid SPAIN (1995-6)

Flaminia Torielli, MD Neonatology, Genoa, ITALY (1996-7)

Sylvia Gothberg, MD Pediatric Critical Care and Anesthesia, Gothenburg, SWEDEN (1998-9)

Dug-Ha Kim, MD Neonatology, Seoul, SOUTH KOREA (1998-9)

Laurent Storme, MD Neonatology, Lille, FRANCE (1999-2000)

Jen-Ruey Teng, MD Neonatology, TAIWAN (1999; 2001)

Y-H. Lin, MD Neonatology, TAIWAN (2001-2)

Ren-Huei Fu, MD Neonatology, TAIWAN (2002-3)

Phillipe Deruelle, MD Obstetrics/Gynecology, Lille, FRANCE (2004-5)

Pierre Tourneux, MD Neonatology and Pediatric Critical Care, Amiens, FRANCE (2007-8)

Vincent Meuhlethaler, MD Neonatology and Pediatric Critical Care, SWITZERLAND (2007–9)

Hideshi Fujinaga, MD Neonatology, Tokyo, JAPAN (2007-9)

Eric Dumas De La Roque, MD Neonatology and Pediatric Critical Care, Bordeux, FRANCE (2010–11)

**Mentor for Student and Resident Projects:**

Conrad Epting, MD Pediatrics Resident; Pediatric Cardiology Fellowship, UCSF

Urszula Tjachman. MD Pediatrics Resident; Pediatric Cardiology Fellowship, Iowa

Mary Dubus, MD Pediatrics Resident; Anesthesiology Faculty, UCHSC

Jonathon Fox, BA Student; Anesthesiology Residency, Stanford

Gresham Richter, BA Student; ENT Residency, Arkansas

Malathi Jakkula, BA Student

Sonja Burbano, MD Pediatrics Resident; Chief Resident, UCHSC

Kate Ackerman, MD Pediatrics Resident; Pediatric Critical Care, Harvard

Thomas Best, MD Pediatric Resident; Pediatric Cardiology Fellow, Cincinnati

Kris Wilkerson, MD Pediatrics Resident; Heme-Oncology Fellow, UT-Southwestern

Ryan Vaughn, BS Student (MS II), UCHSC

Tyler Maxwell, BA Undergraduate Student, Baylor University

Jen-Ruey Teng, MD Pediatric Resident, University of Florida

Courtney Paterson, MD Pediatric Resident, UCHSC

Maureen Cunningham, MD Pediatric Resident, UCHSC

Emily Lich Undergraduate Student, UCD

Deandra Walker Undergraduate Student, UCD

Marlena Hartman-Filson Undergraduate Student, Carleton College

Alicia Brown Undergraduate Student, Labcoats Program, Messiah College

Anish Punjabi Arapahoe High School, Littleton CO

Rachel Wright Colorado Academy, Denver CO

Shannon Acker, MD Resident, Department of Surgery, UCHSC

Daniel Caballeros, BS Undergraduate Student, Yale University

Alex Metoxen, BS Medical Student Research Track, University of Colorado Denver

Logan Brock Undergraduate student, University of Colorado

Matt Morgan Undergraduate student, Duke University

Dominique Nguyen Undergraduate student, Notre Dame University

Amelie Peisl Medical Student Research Track; University of Colorado

Michael Cookson Medical Student Research Track, University of Colorado

Bradley Wallace Surgery Resident, University of Colorado

Christine Kim Surgery Resident, University of Colorado

Phuong Thong Undergaduate college student (UCLA), Department of Pediatrics

 Summer Research Program

Daniella Coronado Undergraduate summer college student, Princteon University

Kellen Hirsch\* Medical Student Research Track, University of Colorado

\* Recipient, ARCS Scholar Award, UCD 2017-2018 and 2018-2019

\* Recipient, 2019 Alpha Omega Alpha Carolyn L. Kuckein Student Research Fellowship Award.

Winston Lie Undergraduate summer college student research program, Princeton

 University, 2019

Carly Callahan Undergraduate summer college student research program, University of

 Southern California, 2019 - 2020.

Alison Abele Medical Student Research Track, University of Colorado, 2018-current.

* Awardee, 34th Annual student Research Forum, UC Anschutz Medical Center, 2019.

Noah Wilson Undergraduate Student, Notre Dame University, 2019.

Abigail Abikoye Undergraduate student. CU Summer Program program, Notre Dame

 University, 2019.

Kisha Thayapran Medical Student Resaerch Track, University of Colorado, 2019-current.

Adom Netsanet Medical Student Research Track, University of Colorado, 2020-currnt.

#### Thesis Reviews

1. Patrik Lassus, MD, Helsinki

2005- Graeme Polglasse, PhD, Monash University, Australia

1. Philippe Deruelle, MD, Lille, France
2. Scott Sagel, MD, University of Colorado, Denver CO.
3. Angel Luis Cogolludo Torralba, PhD, Maastricht, Netherlands.
4. Caitlin Filby, PhD, Monash University, Australia.
5. Gema Esther Gonzalez-Luis, PhD, Maastricht, Netherlands.
6. Steven Colson, MD PhD, University of Colorado, Denver, CO.

2012- Reuben Blair Dodson, PhD, Engineering, University of Colorado, Boulder, CO

2013- Robert Galinsky, PhD, Biology, Monash University, Australia

2016- Mark-Jan Ploegstra, MD, PhD, University Medical Center Groningen, Netherlands

2017- Justin Anthony Ross Lang, PhD, The Ritchie Center, Hudson Institute of Medical Research,

 Monash, University, Australia

2019- Maria Pierro, PhD, Maastricht University, Netherlands

**GRANTS:**

 American Heart Association - Squibb Clinician-Scientist Award, "Perinatal Oxidant Pulmonary Vascular Injury," $51,000, 1986-1987.

 National Institutes of Health Clinical Investigator Award, NHLBI (HLO1932) "Perinatal Oxidant Pulmonary Vascular Injury, " $260,000, 1987-1992.

 National Institutes of Health, HLBI FIRST Award, (HL41012) "Mechanisms of Abnormal Perinatal Vasoreactivity," $450,000, 1988-1993.

 University of Colorado Health Sciences Center Biomedical Research Assistance Committee, "Mechanisms of Abnormal Perinatal Pulmonary Vascular Reactivity and Structure," $13,000, 1988.

 March of Dimes Birth Defects Foundation, Basil O'Connor Starter Scholar Research Award, "Effects of Acute and Chronic Hypoxia on the Perinatal Pulmonary Circulation," $60,000, 1989-1991.

 Biomedical Research Support, The Kempe Center, The Children's Hospital, Denver, "Endothelin and Perinatal Pulmonary Circulation", $1950, 1991-1992.

 American Heart Association - Colorado: Fellowship Award, "Endothelin and Perinatal Vaso- regulation," Dr. Dunbar Ivy; 1993-94; $30,000.

 National Institutes of Health, Special Center of Research (SCOR): Developing Lung Circulation: Response to Injury (Program Director, JT Reeves); Project title, "Role of Endothelial-Derived Products in Perinatal Pulmonary Vasoregulation"; PI-Steven H. Abman; $130,000 per year; 12/91- 11/96.

 March of Dimes Birth Defects Foundation Basic Research Grant,"Role of Endothelin-1 in Perinatal Pulmonary Vasoregulation," $30,000 per year; 1992-94.

 National Institutes of Health, Research Grant (RO1 HL41012), "Mechanisms of Abnormal Perinatal Vasoreactivity," $145,000/year; 1994-1998.

 American Heart Association - Established Investigator Award, "Role of Nitric Oxide in Vasoregulation of the Perinatal Lung," $51,000 per year: 1994-99.

 Newborn Hope, Research Grant, "Inhaled Nitric Oxide Therapy for Neonatal Respiratory Distress," $10,000; December 1994.

 Wyeth Pediatric Neonatology Research Fund, "Role of Endothelin and Nitric Oxide in Development of Pulmonary Hypertension", for Tom Parker, Fellow; $3,400; 1995-96.

 American Academy of Pediatrics, "Effects of Decreased Blood Flow on Nitric Oxide Synthase Activity and Protein Content in the Fetal Pulmonary Circulation", for Urszula Tajchman, Resident; $2,000; 1995-96.

 Newborn Hope Research Grant, "Role of Inhaled NO in Neonatal Respiratory Failure and Pulmonary Hypertension," $15,000, March, 1996.

 National Institutes of Health HLBI Specialized Center of Research (SCOR)(HL-46481): Neonatal Pulmonary Hypertension (KR Stenmark, Program Director), Project Title: "NO-cGMP Cascade in Perinatal Pulmonary Circulation," SH Abman, PI, 1996-2001.

 National Institutes of Health HLBI Specialized Center of Research (SCOR): Neonatal Pulmonary Hypertension; "Clinical Core" (Rosenberg, A, PI). SH Abman, Co-Investigator, 1996-2001.

 Variety Club of Colorado "Pediatric Heart Lung Center", $35,000, 1997 Abman SH (PI),.

 Newborn Hope, "Pediatric Heart Lung Center: Acute and Long Term Effects of Inhaled NO Therapy in Sick Neonates", Abman SH (PI), $33,742, 1998.

 American Heart Association National Grant-In-Aid, "Role of Abnormal Lung Growth in the Development of Pulmonary Hypertension", Abman SH (PI), 1/1/99-12/31/01; $150,000 (total Funding, 3 years).

 Newborn Hope, "Pediatric Heart Lung Center: Inhaled NO Therapy in Neonates and Infants with Heart and Lung Disease", Abman SH (PI), 1999, $18,000.

 INO Therapeutics, Unrestricted Educational Grant to the Pediatric Heart Lung Center, Abman SH (PI), 2000, $250,000.

 March of Dimes Research Grant: “Role of NO in the Regulation of Fetal Pulmonary Vasoreactivity and Growth,” Abman SH (PI), 2000-03, $96,800/year; $351,200, total costs (3 years).

 BioTechnology General Corporation: “Role of SOD and Inhaled NO in the Treatment of Severe RDS in Premature Lambs,” Abman SH, PI; 2000-4; $225,000.

 National Institutes of Health (NIH) HLBI T32 HL07670 National Institutional Research Service Award: Academic Training in Pediatric Pulmonary Diseases, Abman SH (PI), 7/1/99-6/30/04, $360,000/year; $1,842,955, total direct costs.

 NIH HLBI RO1 HL6487: “Inhaled NO for the prevention of BPD” (Kinsella JP, PI; Abman, SH, Co-Investigator), 2000-05, $6,480,884 (total direct costs, 4 years).

 INO Therapeutics, “Development of Home Program for the Chronic Treatment of Severe Cardiopulmonary Diseases,” Abman SH (PI), 2001-5; $130,000/year.

 NIH HLBI RO1 68702, “Role of VEGF in Perinatal Pulmonary Hypertension,” Abman SH (PI), 2001-5, $`1,000,000; total direct costs.

 NIH HLBI Mentored Scientist Development Award (K08 HL04206), “Estradiol in Regulation of the Fetal Pulmonary Circulation;” Thomas Parker (PI); $590,750, 2000-5.

 NIH HLBI Mentored Scientist Development Award (K08 HL03823), “Role of Endothelin in Perinatal Pulmonary Vasoregulation;” Dunbar Ivy (PI); $508,432; 1999-2004.

 NIH HLBI Mentored Patient-Oriented Research Award (K23 RR16178): “Interactive Effects of HFOV and Inhaled NO in the Treatment of Acute Hypoxemic Respiratory Failure in Pediatrics;” Emily Dobyns (PI), $640,190; 2000-5.

 NIH HLBI Specialized Center of Research (SCOR) (P50 HL57144): Impact of Injury to the Developing Lung Circulation (KR Stenmark, Program Director), Project Title: " Inhaled NO in the Prevention of BPD,” SH Abman, (Project PI), 2001-6; $1,216,964; total direct costs

 NIH HLBI Specialized Center of Research (SCOR) (P50 HL57144): Impact of Injury to the Developing Lung Circulation (KR Stenmark, Program Director), Project Title: "Clincal Core" (Kinsella JP, PI). Abman SH, Co-PI, 2001-6.

 American Academy of Pediatrics, Marshall Klaus Award, “Endothelial cell dysfunction and impaired angiogenesis in neonatal pulmonary hypertension,” Gien J (PI); Abman SH (mentor), 2005-6, $5,000.

 American Academy of Pediatrics, Marshall Klaus Award, “Antiapoptotic effects of nitric oxide in an experimental model of BPD,” Tang JR (PI); Abman SH (mentor), 2005-6, $5,000.

 Advancing Newborn Medicine Grant Program for Fellows in Neonatology, “Endothelial cell dysfunction in PPHN,” Gien J (PI), Abman SH (mentor), 2007-8, $7500.

 Advancing Newborn Medicine Grant Program for Fellows in Neonatology, “VEGF treatment of congenital diaphragmatic hernia,” Kunig A (PI), Abman SH (mentor), 2006-7, $7500.

 American Academy of Pediatrics, Marshall Klaus Award, “Endothelial cell dysfunction and impaired angiogenesis in neonatal pulmonary hypertension,” Gien J (PI); Abman SH (mentor), 2006-7, $5,000.

 American Academy of Pediatrics, Marshall Klaus Award, “Inhaled NO prevention of apoptosis after VEGF inhibition,” Tang JR (PI); Abman SH (mentor), 2006-7, $5,000.

 NIH HLBI T32 HL07670 National Institutional Research Service Award: Academic Training in Pediatric Pulmonary Diseases, Abman SH (PI), 7/1/04-6/30/09, $350,293/year.

 NIH HLBI Mentored Scientist Development Award (K08): “Role of VEGF - NO Signaling in Lung Growth;” Vivek Balasubramaniam (PI). Abman SH (Mentor); 2003-2008, $121,000 direct costs per year.

 INO Therapeutics, Advancing Newborn Medicine Fellowship Grant Program, “Soluble Guanylate Cyclase in PPHN,” Marc Chester (PI), Abman SH (Mentor), 2007-8. $7500.

 Bayer Health Care, “Soluble guanylate cyclase activators in PPHN,” Abman SH, PI, $50,000.

 NIH HLBI Mentored Scientist Development Award (K08): “VEGF in Perinatal Pulmonary Hypertension;” Theresa Grover (PI), Abman SH (Mentor); 2004-2009. \* Selcted for award and additional support from the Pulmonary Hypertension Association.

 NIH R21 Grant, “SOD treatment of PPHN,” (Kinsella JP, PI; Abman SH Co-PI); 2006-2011

 Thrasher Foundation (PN200601-194): “Novel Strategies for the Prevention and Treatment of Chronic Lung Disease in Premature Newborns.” Abman SH (PI); 2006-2010, $441,786 total direct costs.

 NIH HLBI UO1 (HL081335-01): Clinical Proteomics Center in Lung Disease (Accurso FJ, PI), Abman SH (Co-PI), 1/1/06 – 12/31/09, $4,166,102 total direct costs.

 American Thoracic Society Award, Transitional Faculty Award, Baker C (PI), Abman SH (mentor), 2008 – 2010.

 NIH HLBI Mentored Patient-Oriented Research Award (K23): “Pathogenetic Mechanisms of BPD;” Peter Mourani (PI), Abman SH (Mentor); 2005-2010.

 Entelligence Mentored Scientist Award, Actelion (sponsor), Gien J (PI), Abman SH (Mentor), 2010 – 2011, $100,000.

 NIH K12 Award, “Genetic differences between premature and term endothelial progenitor cells,” Baker C (PI), Abman SH (mentor), 2008 – 2011.

 NIH SCCOR Program, “Injury to the Developing Lung Circulation,” Stenmark KR (PI); Abman SH (Co-PI); 2006–2012; $2.5 million/year direct costs. Specific projects include: “Clinical Research Skills Development Core,” Abman SH (Core Leader); “Hypoxia-Inducible Factors in Neonatal Pulmonary Hypertension,” White C (Project #5 Leader), Abman SH (Co-investigator); “Inhaled NO and Non-invasive Ventilation of Premature Newborns,” Kinsella JP (Project #1 Leader), Abman SH (Co-investigator).

 NIH HLBI RO1 HL68702, “Role of VEGF in Perinatal Pulmonary Hypertension,” Abman SH (PI), 2007-11, $1,084,201 total direct costs.

 NIH HLBI T32 HL07670 National Institutional Research Service Award: Academic Training in Pediatric Pulmonary Diseases, Abman SH (PI), 7/1/11-6/30/15, $350,293/year.

 NIH RO1 Award, “Endothelial Progenitor Cells in BPD,” Balasubramaniam V (PI), Abman SH (Collaborator); 2008-2012.

 NIH/SBIR R34 “A novel means to establish free radical balance in the neonatal premature lung”

 Salzman, A (PI), Abman SH (co-investiagor), 08/01/2011-07/31/2012

 NIH/SBIR R34HL110374 “Bifunctional Redox Agent for the Treatment of PPHN” Southan, G, (PI), Abman SH (co-investigator), 9/01/2011-08/31/2012.

 Gilead Sciences Research Scholars Program in Pulmonary Hypertension Award, “Role of serotonin in the pathobiology of neonatal pulmonary hypertension,” Delaney C (PI), Abman SH (Mentor), 2010-2012, $130,000 direct costs.

 NHLBI U01 HL102235 Phase II Clinical Trials of Novel Therapies for Lung Diseases, “Phase II Trial of Sildenafil in Newborns with Persistent Pulmonary Hypertension,” (Abman SH, Kinsella JP, Steinhorn RH (co-PIs), $1,293,473 direct costs per year, 9/17/2010 – 6/30/2013.

 NIH K12 Child Health Resarch Award, “Role of Serotonin in the Pathogenesis of Neonatal Pulmonary Hypertension,” Delaney, Cassidy (PI), Abman SH (mentor), 2012-2013.

 NIH K08, “Nuclear Factor kappa B Regulation and Oxidative Stress,” Wright Clyde (PI), Abman SH (mentor), 2010 - 2015.

 NIH K08 Award, “Rho Kinase in Neonatal Pulmonary Hypertension,” Gien J (PI), Abman SH (Mentor), 2010 - 2015.

 NICHD K08 HD060688, “Pancreatic beta-cell endothelial cell function and signaling in intrauterine growth restriction,” Rozance P (PI); Abman SH (co-mentor), 09/01/09-08/31/14

 Gerber Foundation, “Microbiome and Cytokine Biomarkers in BPD,” PI: Peter Mourani; Abman SH (Collaborating Investigator). 2013-2015

 Gilead Young Investigator Award for Pulmonary Hypertension, “Role of vitamin D in the pathogenesis and treatment of pulmonary hypertension in BPD,” Mandell E (PI), Abman SH (Mentor), $130,000; 2014- 2016.

 NIH T35 HL112930 Short Term Institutional Support for Clinician Scientists, “Pediatric Pulmonology and Hematology Research Training for Medical Students,” Abman SH (PI), Dipaolo J (co-PI), $94,000 (direct costs), 2011-2015.

 American Academy of Pediatrics, Marshall Klaus Award, “Vitamin D in experimental chorioamnionitis,” Mandell E (PI); Abman SH (mentor), 2013 - 2014, $5,000.

 NHLBI RO1 HL085703 Award, “Genetic Basis for Impaired Angiogenesis in BPD,” Abman SH (PI); 2007-2013, $545,384 per year; $3,500,000 total costs.

 NIDDK R01 DK088139, “Nutrient coordination of pancreatic vasculature and beta-cells” Rozance P (PI), Abman SH (co- investigator), 2011-2016.

NIH K23 HL103801 Award, “Use of phosphodiesterase inhibitors to evaluate the pathobiology of CF,” Taylor-Cousar, J (PI), Abman SH (mentor), 2011 – 2016.

 Jérôme Lejeune Foundation, “Role of Impaired Angiogenesis in the Pathogenesis of Severe Cardiopulmonary Disease in Children with Down Syndrome,” Galambos C (PI), Abman SH (Collaborator), $50,000/year x 2 years, 2014 -2016.

 Entelligence Award for Pulmonary Hypertension Research, “Hemodynamic Stress in the Pathophysiology of Neonatal Pulmonary Hypertension,” Dodson RB (PI), Abman SH (mentor), $100,000.

 NIH K23 Award, “Endothelial Progenitor Cells in BPD,” Baker, C (PI), Abman SH (mentor), 2014 – 2017*.*

 University of Colorado School of Medicine, Dean’s Scientific Research Committee, “Establishment of the Developmental Angiogenesis Program,” Abman SH (PI); Powell T(Co-PI), Janssons T (Co-PI), $10,000; 2015 - 2017.

 United Therapeutics, “Role of treprostinil therapy for pulmonary hypertension in BPD,” Abman SH (PI), $62,500, Jan 2017- Jan 2018.

NHLBI RO1 Award, “The Microbiome, Virome and Host Responses Preceding Ventilator-Associated Pneumonia,” Mourani PM (PI); Abman SH (collaborator), 2014 – 2018.

 SBIR Grant1R44HL134429-01: “Iridium-electrode inhaled nitric oxide generator for hypoxic respiratory failure in neonates.” Third Pole/NIH-NHLBI  (PI: Silkoff, PE; Abman SH, Collaborator), Grant total: $1,499,218 09/01/2016 – 08/31/2018 .

 NHLBI 2R56 HL68702-13, “Role of VEGF in Perinatal Pulmonary Hypertension,” Abman SH (contact PI), Shepherd DS (MPI), $500,000; 2018-2019 ($500,000 direct costs).

 Shire Pharmaceuticals, “Antenatal Mechanisms of Neonatal Lung Injury,” Abman SH (PI), $248,000.

 Shire Pharmaceuticals, “Insulin-Like Growth Factor-1/Binding Protein 3 Studies,” Abman SH (PI), $100,000 (supplement). 2017 – 2019.

 United Therapeutics, “Role of treprostinil therapy for pulmonary hypertension in BPD,” Abman SH (PI), $80,000.

 NIH K12 Program Department of Pediatrics, Awardee: Erica Mandell, Abman SH (Mentor), 2017 – 2019.

 NHLBI T32 HL07670 National Institutional Research Service Award: “Academic Training in Pediatric Pulmonary Diseases,” Abman SH (PI), 12/1/15 - 11/2019, $390,000/year direct costs. No cost extension.

 NIH T32HL07670-30S1 National Institutional Research Service Award, “Academic Training in Cardiopulmonary Disease in Down Syndrome,” Abman SH (PI), Response to RFANOT-OD-18-194, $190,000 direct costs.

 NIH Supplement for U01 HL12118*,*  “Comprehensive Characterization of Pulmonary Hypertension in Down Syndrome,*”* Abman SH (PI), Response to RFANOT-OD-18-194, $500,000 direct costs.

**Current Support:**

 NHLBI RO1 HL68702-14, “Role of VEGF in Perinatal Pulmonary Hypertension,” Abman SH (PI), Shepherd DS (MPI), $421,000/year; 2019 – 2022.

 NHLBI R01 HL145679-01A1 Award, “Physiologic Phenotyping of Respiratory Outcomes in Infants Born Premature,” Tepper R, Abman SH (Mult-PIs), 2019-2023***.***

 NHLBI U01 HL12118-01, “Data fusion: a sustainable, open source registry advancing pediatric pulmonary vascular disease research,” (RFA HL14-005); Abman SH (contact PI); Mandl KD (Co-PI), $1.8 M/year x 4 years (7/01/14 – 04/30/2020). No Cost Extension Period.

 NIH R38 Program, “StARR Resident Research Training Program at the University of Colorado,” Schwartz D (PI), Abman SH, Di Paola J, Buttrick P (multi-MPIs). ***funded***.

 NIH NCATS ECHO Program, “Early life exposome and childhood health- the Colorado Healthy Start program,” Debalea D (PI); Abman SH (Co-investigator). Grant total: $990,774 direct costs. Dates: 09/01/16-08/31/23.

 Food and Drug Administration (FDA) Proposal: “Investigation of Actigraphy, an Exercise Measure Device, as a Novel, Well-defined, Reliable, Feasible, Easy-to-use, and Non-invasive Study Endpoint to Facilitate Pediatric Pulmonary Arterial Hypertension Trials and Drug Development.” Haiho Sun (PI), Abman SH (Co-PI), ($300,000).

 United Therapeutics, “Human MSC Exosome Therapy to Promote Lung Growth and Repair in a Novel Rat Model of Bronchopulmonary Dysplasia (BPD) Associated with Preeclampsia (PE) and Antenatal Inflammation,” Abman SH, Kourembanas S (Multi-PI), $300,000.

 NIH T32 HL07171 Award, “Respiration and Circulation during Hypoxia,” Stenmark KR (PI), Abman SH, Mentor.

 NIH T32 HL007085, “Multidisciplinary Respiratory Diseases Research Training,” (Schwarz MI, PI), Abman SH, Mentor.

NHLBI K23 Mentored Patient-Oriented Research Career Development Award***, “***Cardiac MR imaging in pediatric pulmonary hypertension,” Truong UT (PI), Abman SH (Mentor). 2017-2021.

 NIH K08, Mentored Clinician-Scientist Award, Mandell EW (PI), Abman SH (mentor), 2019-2023, ***funded.***

 SBIR Grant 1R44HL134429 (competitive renewal): “Iridium-electrode inhaled nitric oxide generator for hypoxic respiratory failure in neonates.” Third Pole/NIH-NHLBI  (PI: Silkoff, PE; Abman SH, Collaborator), ***funded.***

**Submitted Grants in Review:**

 NHLBI T32 HL07670-31 National Institutional Research Service Award: “Academic Training in Pediatric Pulmonary Diseases,” Abman SH (PI), ***in review***.

 NHLBI T32 HD101388-01, “Multicenter Training in Pediatric Pulmonary Vascular Disease,” Fineman J, Austin E, Abman SH (multi-PIs), ***in review***.

 NHLBI UG3/UH3 Proposal: “Combination versus monotherapy for pediatric pulmonary hypertension,” Romer L, Abman SH, Berman-Rosenzweig E (multi-PIs), ***in review***.

 NHLBI RO1, “Genetics of Pediatric Pulmonary Hypertension,” Chung W (contact PI); Abman SH (collaborator), ***In Review.***

LeDucq Foundation Transatlantic Networks of Excellence Programin Cardiovascular and Neurovascular Research, “Establishing the **T**ransatlantic **R**esearch **A**lliance for **P**ediatric Pulmonary Hypertension (TRAP) to Improve Outcomes of Children with Pulmonary Vascular Disease,” Abman SH (contact PI), Berger RF mutliPI), **In review**.

**Patents**

Application No. PCT/US16/26420 (Abman, Seedorf)

Title: Anti-sFLT-1 Antibodies in Treating Bronchopulmonary Dysplasia

Filed: 4/7/2016

CU TTO File No. CU4114H-PCT1

**Publications (Peer-Reviewed): (current H-index: 78)**

1. Jacob HS, Yawata Y, Matsumoto N, Abman SH, White J. Cyclic-nucleotide-membrane protein interaction in the regulation of erythrocyte shape and survival: Defect in hereditary spherocytosis. In, Erythrocyte Structure and Function. Brewer GT (ed), pp 235-247, 1975.
2. Cole RB, Abman SH, Aziz K, Bharati S, Lev M, Paul MH. Prolonged PgE-1 infusion: Histologic effects on the PDA, Pediatrics 67:831,1981.

3. Abman SH, Warady BA, Lum GM, Koops Bl. Systemic hypertension in infants with BPD. J. Pediatr 104:928-931,1984.

1. Abman SH, Accurso FJ, Bowman CM. Unsuspected cardiopulmonary abnormalities complicating

 BPD. Arch Dis Child 59:966-970, 1984.

5. Abman SH, Accurso FJ, Koops Bl. Experience with home oxygen in the management of infants with BPD. Clin Ped 23:471-476, 1984.

6. Abman SH, Fan LL, Cotton EK. Emergency treatment of foreign body obstruction of the upper airway in children. J Emer Med 2:7,1984.

7. Abman SH, Wolfe RR, Accurso FJ, Koops BL, Bowman CM, Wiggins JW. Pulmonary vascular

 response to oxygen in infants with severe BPD. Pediatrics 75:80-84, 1985.

8. Abman SH, Reardon MC, Accurso FJ, Hammond KB, Sokol R. Hypoalbuminemia as marker for severe respiratory course in infants with CF identified by newborn screen. J Pediatr 107:933 935, 1985.

1. Abman SH, Accurso FJ, Bowman CM. Persistent morbidity and mortality of protein calorie malnutrition in young infants with CF. J. Pediatr Nutr Gastr. 5:393-397, 1986.
2. Abman SH, Accurso FJ, Ward RM, Wilkening RB. Adaptation of fetal pulmonary blood flow to local infusion of tolazoline. Pediatr Res 20:1131-1135,1986.
3. Abman SH, Accurso FJ, Wilkening RB, Meschia G. Persistent fetal pulmonary hypoperfusion after acute hypoxia. Am J Physiol 22:H941-H948, 1987.
4. Abman SH, Schaffer M, Wiggins J, Washington R, Manco-Johnson M, Wolfe RR. Pulmonary vascular extraction of circulating norepinephrine in infants with bronchopulmonary dysplasia. Pediatr Pulmonology 3:386-391, 1987.
5. Accurso FJ, Abman SH, Reardon MC, Hammond KB. Early abnormalities in infants with CF diagnosed through newborn screening. Pediatric Pulmonology, S1, 83-85,1987.
6. Abman SH, Accurso FJ. Acute and chronic fetal pulmonary hypertension alters pulmonary vasoreactivity. Chest 93:117S-119S, 1988.
7. Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ. Role of respiratory syncytial virus in early hospitalizations for respiratory distress in young infants with cystic fibrosis. J. Pediatr 113:836-380,1988.
8. Abman SH, Accurso FJ. Acute effects of partial compression of the ductus arteriosus on the fetal pulmonary circulation. Am J Physiol 257:626-634,1989.
9. Abman SH, Shanley PF, Accurso FJ. Failure of postnatal adaptation of the pulmonary circulation after chronic intrauterine pulmonary hypertension in fetal lambs. J Clin Invest, 83:1849-58, 1989.
10. Abman SH, Burchell MF, Schaffer MS, Rosenberg AA. Late sudden unexpected deaths in hospitalized infants with bronchopulmonary dysplasia. AJDC, 143:815-819,1989.
11. Sokol RJ, Reardon MC, Accurso FJ, Stall C, Narkewicz M, Abman SH, Hammond KB. Fat-soluble vitamin status during first year of life in infants with cystic fibrosis identified by newborn screen. Am J Clin Nutr, 50:1064-1071,1989.
12. Abman SH, Chatfield BA, Hall SL, McMurtry IF. Role of endothelium-derived relaxing factor during the transition of the pulmonary circulation at birth. Am J Physiol, 259:H1921-1927, 1990.
13. Accurso FJ, Abman SH, Wilkening RB, Worthen S, Henson P. Fetal pulmonary vasodilatation following exogenous platelet-activating factor. J Appl Physiol, 70:778-787,1991.
14. Abman SH, Accurso FJ. Sustained fetal pulmonary vasodilation during prolonged infusions of arterial natriuretic factor and 8-bromo-GMP. Am J Physiol, 260:H183-H192, 1991.
15. Abman SH, Chatfield BA, Rodman DM, Hall SL, McMurtry IF. Maturational changes in endothelium-dependent relaxation of ovine pulmonary arteries in vitro. Am J Physiol, 260:L280-L285, 1991.
16. Abman SH, Ogle JW, Harbeck RJ, Butler-Simon N, Hammond KB, Accurso FJ. Early bacteriologic, immunologic and clinical course of young infants with CF identified by newborn screening. J. Pediatr, 119:211-7, 1991.
17. Chatfield BA, McMurtry IF, Hall SL, Abman SH. Hemodynamic effects of endothelin-1 on the ovine fetal pulmonary circulation. Am J Physiol, 261:R182-R187, 1991.
18. Hammond KB, Abman SH, Sokol, RJ, Accurso FJ. Efficacy of state-wide screening for cystic fibrosis based on immunoreactive trypsinogen. N Engl J Med, 325:769-774, 1991.
19. Accurso FJ, Sokol RJ, Hammond KB, Abman SH. Early respiratory course in infants with CF: Relevance to newborn screening. Pediatr Pulmonol, (supplement 7): pp 42-45, 1991.
20. Sokol RJ, Reardon MC, Accurso FJ, Stall C, Narkewicz MR, Abman SH, Hammond KB. Fat soluble vitamins in infants identified by CF newborn screening. Pediatr Pulmonol, (supplement 7): pp 52-55, 1991.
21. Abman SH, Stenmark KR. Changes in lung eicosanoid content during the normal and abnormal transition in perinatal lambs. Am J Physiol, 262:L214-222, 1992.
22. Cornfield DN, Chatfield BA, McQueston JA, McMurtry IF, Abman SH. Effects of birth-related stimuli on L-Arginine dependent vasodilation in the ovine fetal lung. Am J Physiol, 262:H1474-1481, 1992.
23. Bronstein M, Sokol RH, Abman SH, Chatfield BA, Hammond KB, Stall CD, Seltzer W, Accurso FJ. Pancreatic insufficiency, growth and nutrition in infants identified with CF by newborn screening. J Pediatr, 120:533-540, 1992.
24. Cornfield DN, McQueston JA, McMurtry IF, Rodman DM, Abman SH. Role of ATP-sensitive K+-channels in ovine fetal pulmonary vascular tone. Am J Physiol, 263:H1363-68, 1992.
25. Kinsella JP, McQueston JA, Rosenberg AA, Abman SH. Effects of inhaled nitric oxide on the ovine transitional pulmonary circulation. Am J Physiol, 263:H875-880, 1992.
26. Kinsella JP, Neish SR, Shaffer E, Abman SH. Effect of low dose inhalational nitric oxide in pulmonary hypertension of the newborn. Lancet, 340:819-820, 1992.
27. McQueston JA, Cornfield DN, McMurtry IF, Abman SH. Effects of O2 and Exogenous L-Arginine on EDRF activity in the fetal pulmonary circulation. Am J Physiol, 264:H865-871, 1993.
28. Rusakow LS, Hammond KB, Abman SH, Sokol RJ, Seltzer W, Accurso FJ. Immunoreactive trypsinogen in infants with CF complicated by meconium ileus. Screening, 2:13-17, 1993.
29. Allen SW, Chatfield BA, Koppenhafer SL, Schaffer MS, Wolfe RR, Abman SH. Circulating immunoreactive endothelin-1 in children with pulmonary hypertension associated with acute hypoxic pulmonary vasoreactivity. Amer Rev Resp Dis, 148:519-522, 1993.
30. Mohon RT, Wagener JA, Abman SH, Seltzer W, Accurso FJ. Relationship of genotype and growth to early pulmonary function in infants with CF identified by newborn screening. J Pediatr, 122:550-555, 1993.
31. Kinsella JP, Toews WH, Henry D, Abman SH. Selective and sustained pulmonary vasodilation with inhaled nitric oxide therapy in a child with idiopathic pulmonary hypertension. J Pediatr, 122:803-6, 1993.
32. Cornfield DN, Stevens T, McMurtry IF, Abman SH, Rodman DM. Acute hypoxia increases intracellular calcium content in fetal pulmonary artery smooth muscle cells. Am J Physiol, 265:L53-56, 1993.
33. Rosenberg AA, Kennaugh J, Koppenhafer SL, Loomis M, Chatfield BA, Abman SH. Increased immunoreactive endothelin-1 levels in persistent pulmonary hypertension of the newborn. J Pediatr, 123:109-114, 1993.
34. Kinsella JP, Neish SR, Ivy DD, Shaffer E, Abman SH. Clinical response to prolonged treatment of persistent pulmonary hypertension of the newborn with low dose inhaled nitric oxide. J Pediatr, 123:103-108, 1993.
35. Kinsella JP, Abman SH. Inhalational nitric oxide for persistent pulmonary hypertension of the newborn. Pediatr, 91:997-998, 1993.
36. Kinsella JP, Abman SH. Methemoglobin levels during nitric oxide therapy with high frequency ventilation. Lancet, 342:615, 1993.
37. Abman SH, Kinsella JP, Schaffer MS, Wilkening RB. Inhaled nitric oxide therapy in the management of a premature newborn with severe respiratory distress and pulmonary hypertension. Pediatrics, 92:606-609, 1993.
38. Abman SH. Pathogenesis and treatment of neonatal and postnatal pulmonary hypertension.

 Current Opinions in Pediatrics, 6:239-247, 1994.

1. Jones OW, Abman SH. Pulmonary and systemic hemodynamic effects of big endothelin-1 (proendothelin-1) and phosphoramidon in the late-gestation ovine fetus. Am J Physiol, 266:R929-R935, 1994.
2. Ivy DD, Kinsella JP, Abman SH. Physiologic characterization of endothelin A and B receptor activity in the ovine fetal lung. J Clin Inves, 93:2141-2148, 1994.
3. Halbower AC, Mason RJ, Abman SH, Tuder RM. Agarose infiltration improves morphology of cryostat sections of lung. Lab Invest, 71:149-153, 1994.
4. Cornfield DN, Stevens T, McMurtry IF, Abman SH, Rodman DM. Acute hypoxia causes membrane depolarization and calcium influx in fetal pulmonary artery smooth muscle cells. Am J Physiol, 266:L469-L475, 1994.
5. Abman SH, Griebel J, Schmidt J, Parker D, Swanton D, Kinsella JP. Acute effects of inhaled nitric oxide in severe hypoxemic respiratory failure in pediatrics. J Pediatr, 174:681-688, 1994.
6. Halbower AC, Tuder RM, Pollock JS, Forstermann U, Abman SH. Maturation-related changes in endothelial nitric oxide synthase immunolocalization in the developing ovine lung. Am J Physiol, 267:L585-91, 1994.
7. Kinsella JP, Ivy DD, Abman SH. Ontogeny of NO activity and response to inhaled NO in the developing ovine pulmonary circulation. Am J Physiol, 267:H1955-61, 1994.
8. Ivy DD, Wiggins JW, Badesch D, Kinsella JP, Kelminson LL, Abman SH. Treatment of an infant with severe primary pulmonary hypertension using inhaled nitric oxide and prostacyclin. Am J Cardiol, 74:414-6, 1994.
9. McQueston JA, Kinsella JP, Ivy DD, McMurtry IF, Abman SH. Chronic pulmonary hypertension in utero impairs endothelium-dependent vasodilation. Am J Physiol, 268:H288-294, 1995.
10. Kinsella JP, Ivy DD, Abman SH. Inhaled nitric oxide improves gas exchange and lowers pulmonary vascular resistance in severe experimental hyaline membrane disease. Pediatr Res, 36:402-408, 1994.
11. Kinsella JP, Abman SH. Efficacy of inhalational nitric oxide therapy in the management of persistent pulmonary hypertension of the newborn. Chest, supplement. 105(3): 92-4, 1994.
12. Rosenberg AA, Kinsella JP, Abman SH. Cerebral hemodynamics and distribution of systemic blood flow during inhalation of nitric oxide. Critical Care Med, 23:1391-1397, 1995.
13. Ziegler JW, Ivy DD, Fox J, Kinsella JP, Clarke WR, Abman SH. Dipyridamole, a cGMP phosphodiesterase inhibitor, causes pulmonary vasodilation in the ovine fetus. Am J Physiol, 269:H473-479, 1995.
14. Kinsella JP, Schmidt J, Griebel J, Abman SH. Use of inhaled nitric oxide treatment for stabilization and emergency transport of critically ill newborns and infants. Pediatrics, 95:773-776, 1995.
15. Kinsella JP, Abman SH. Recent developments in the pathophysiology and treatment of persistent pulmonary hypertension of the newborn. J Pediatrics, 126:853-864, 1995.
16. Kinsella JP, Toriella F, Ziegler JW, Ivy DD, Abman SH. Dipyridamole augmentation of the response to inhaled NO. Lancet, 346:647-8, 1995.
17. Abman SH, Kinsealla JP. Inhaled NO for PPHN: The Physiology Matters! Pediatrics, 1153-

 1155, 1995.

1. Ivy DD, Kinsella JP, Wolfe RR, Abman SH. Atrial natriuretic peptide and NO in children with pulmonary hypertension and congenital heart disease. Am J Cardiology, 77:102-104, 1996.
2. Abman SH. Oxygen sensing, potassium channels and the ductus arteriosus. J Clin Invest. 98:1945-1946, 1996.
3. Ivy DD, Ziegler JW, Dubus MF, Fox JJ, Kinsella JP, Abman SH. Chronic intrauterine pulmonary hypertension alters endothelin receptor activity in the ovine fetus. Pediatr Res, 39:335-342, 1996.
4. Fox JJ, Ivy DD, Ziegler JW, Halbower AC, Kinsella JP, Abman SH. Role of NO-cyclic GMP in regulation of ductus arteriosus tone in the ovine fetus. Am J Physiol, 271:H2638-2645, 1996.
5. Ivy DD, Kinsella JP, Abman SH. Endothelin blockade augments pulmonary vasodilation in the ovine fetal lung. J Appl Physiol, 81:2481-2487, 1996.
6. Parker TA, Ivy DD, Kinsella JP, Torielli F, Ruyle SZ, Thilo EH, Abman SH. Combined therapy with inhaled NO and intravenous prostacyclin in an infant with alveolar-capillary dysplasia. Am J Resp Crit Care Med, 155:743-746, 1996.
7. Abman SH, Ivy DD, Ziegler JW, Kinsella JP. Mechanisms of abnormal vasoreactivity in persistent pulmonary hypertension of the newborn. J Perinatol 16(2):518-23, 1996.
8. Kinsella JP, Abman SH. Clincal pathophysiology of PPHN and the role of inhaled NO therapy. J Perinatol, 16(2):524-27, 1996.
9. Kinsella JP, Abman SH. Clinical approaches to the use of high frequency oscillatory ventilation in neonatal respiratory failure. J Perinatol, 16(2):552-55, 1996.
10. Kennaugh JM, Kinsella JP, Abman SH, Hernandez JA, Moreland SJ, Rosenberg AA. Impact of new treatments for neonatal pulmonary hypertension on ECMO utilization and outcome. J Perinatology, 17:366-369, 1997.
11. Kinsella JP, Parker TA, Galan H, Sheridan BC, Halbower AC, Abman SH. Effects of inhaled NO on pulmonary edema and lung neutrophil accumulation in severe experimental HMD. Pediatr Res, 41:457-463, 1997.
12. Villamor E, Le Cras TD, Horan M, Halbower AC, Tuder R, Abman SH. Chronic intrauterine pulmonary hypertension impairs endothelial nitric oxide synthase in the ovine fetus. Am J Physiol, 272: L1013-1020, 1997.
13. Tajchman UW, Tuder R, Horan M, Parker T, Abman SH. Persistent endothelial NO synthase in lung hypoplasia caused by left pulmonary artery ligation in the ovine fetus. Am J Physiol, 16: L969-978, 1997.
14. Ivy DD, Parker TA, Ziegler JW, Galan HL, Kinsella JP, Tuder RM, Abman SH. Prolonged endothelin A receptor blockade attenuates chronic pulmonary hypertension in the ovine fetus. J Clin Invest, 99:1179-86, 1997.
15. Kinsella JP, Troug W, Walsh W, Goldberg R, Bancalari E, Mayock D, Redding G, Delemos R, Sardesai S, McCurnin D, Moreland S, Cutter G, Abman SH. Randomized multicenter trial of inhaled nitric oxide and high frequency oscillatory ventilation in severe PPHN. J Pediatr, 131:55-62, 1997.
16. Rosenberg AA, Kennaugh JM, Moreland S, Fashaw L, Hale K, Torielli F, Abman SH, Kinsella JP. Longitudinal follow-up of a cohort of newborns treated with inhaled nitric oxide for persistent pulmonary hypertension. J Pediatr, 131:70-75, 1997.
17. Parker TP, Kinsella JP, Abman SH. Response to inhaled NO in PPHN: relationship to baseline oxygenation. J Perinatology, 18:221-5, 1998.
18. Rairigh R, Le Cras TD, Ivy DD, Kinsella JP, Richter G, Horan M, Fan I, Abman SH. Role of inducible NO Synthase in regulation of pulmonary vascular tone in the ovine fetus. J Clin Invest. 101:15-21, 1998.
19. Ivy DD, Kinsella JP, Ziegler JW, Abman SH. Dipyridamole attenuates rebound pulmonary hypertension after withdrawal of inhaled NO. J Cardiov Thor Surg, 115:75-82, 1998.
20. Le Cras TD, Tyler RC, Horan MP, Morris KG, McMurtry IF, Johns RA, Abman SH. Effects of chronic hypoxia and hemodynamics on endothelial nitric oxide synthase expression in the adult rat lung. J Clin Invest, 101:795-801, 1998.
21. Ivy DD, Neish SR, Knudson DA, Schaffer MS, Wiggins JW, Tyson RW, Abman SH, Shaffer EM, Valdez-Cruz L. Morphologic characterization and vasoreactivity of the pulmonary vasculature in children with pulmonary hypertension. A study of intravascular ultrasound. Am J Cardiol, 81:740-8, 1998.
22. Kinsella JP, Abman SH. Inhaled NO and high frequency oscillatory ventilation in PPHN. Eur J Pediatrics, 157:1026-9, 1998.
23. Ziegler JW, Ivy DD, Fox J, Kinsella JP, Clarke WR, Abman SH. Dipyridamole potentiates acetylcholine and nitric oxide induced pulmonary vasodilation in the ovine fetus. Am J Resp Crit Care Med, 157:1104-10, 1998.
24. Ivy DD, LeCras TD, Horan MP, Abman SH. Increased lung prepro-endothelin-1 and decreased endothelin B receptor gene expression after chronic pulmonary hypertension in the ovine fetus. Am J Physiol, 274:L535-541, 1998.
25. Ivy DD, Kinsella JP, Parker TA, Abman SH. Endothelin A receptor blockade decreases pulmonary vascular resistance and improves oxygenation in severe experimental respiratory distress syndrome. Pediatr Res, 44: 175-80, 1998.
26. Ivy DD, Griebel JL, Kinsella JP, Abman SH. Acute hemodynamic effects of pulsed delivery of low flow nasal NO in children with pulmonary hypertension. J Pediatrics, 133:453-56, 1998.
27. Ziegler JW, Ivy DD, Wiggins JW, Kinsella JP, Clarke WR, Abman SH. Hemodynamic effects dipyridamole and inhaled NO in children with severe pulmonary hypertension. Am J Resp CCM, 158:1388-1395, 1998.
28. LeCras TD, Tyler RC, Horan MP, Morris KG, Johns RA, McMurtry IF, Abman SH. Effects of chronic hypoxia and altered hemodynamics on endothelial NOS and PPET-1 expression in the adult rat lung. Chest 114:355-365, 1998.
29. Ivy DD, LeCras TD, Abman SH. Chronic intrauterine pulmonary hypertension increases prepro ET-1 and decreases ET B receptor in RNA expression in the ovine fetal lung. Chest 114:655, 1998.
30. Parker TA, Galan HL, Kinsella JP, Richter G, Horan MP, Abman SH. Chronic estradiaol treatment causes a marked and sustained increase in pulmonary blood flow in the late gestation ovine fetus. Chest 114:695, 1998.
31. Hanson KA, Ziegler JW, Rybalkin SD, Miller J, Abman SH, Clarke WR. Chronic pulmonary hypertension increases lung cGMP phosphodiesterase activity by post-translational modification in the ovine fetus. Am J Physiol, 275: L931-41, 1998.
32. Storme L, Rairigh RL, Parker TP, Cornfield DN, Kinsella JP, Abman SH. Potassium channel blockade attenuates shear stress-induced pulmonary vasodilation in the ovine fetus. Am J Physiol, 276:L220-8, 1999.
33. Dobyns EL, Cornfield DN, Anas NG, Fortenberry JD, Tasker RC, Lynch A, Liu P, Eells PL, Griebel J, Baier M, Kinsella JP, Abman SH. Multicenter randomized trial of the effects of inhaled NO therapy on gas exchange in children with acute hypoxemic respiratory failure. J Pediatr, 134:406-412, 1999.
34. Tuder RM, Wang J, Cool CD, Abman SH, Wright L, Gerair MW, Badesch DB, Voelkel NF. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Resp Crit Care Med, 159:1925-32, 1999.
35. Storme L, Rairigh RL, Parker TA, Kinsella JP, Abman SH. Acute intrauterine pulmonary hypertension impairs endothelium-dependent vasodilation in the ovine fetus. Pediatr Res, 45:575-581, 1999.
36. Storme L, Rairigh RL, Parker TA, Kinsella JP, Abman SH. In vivo evidence for a myogenic response in the fetal pulmonary circulation. Pediatr Res. 45:425-431, 1999.
37. Rairigh RL, Storme L, Parker TA, Abman SH. Inducible NO synthase inhibition attenuates shear stress-induced pulmonary vasodilation in the ovine fetus. Am J Physiol. 276:L513-521, 1999.
38. Kinsella JP, Parker TA, Galan H, Sherican BC, Abman SH. Independent and combined effects of inhaled nitric oxide, liquid perfluorochemical and high frequency oscillatory ventilation in severely premature lambs with RDS. Am J Resp Crit Care Med. 159:1220-7, 1999.
39. Tyler RC, Muramatsu M, Abman SH, Stelzner TJ, Rodman DM, Block KD, McMurtry IF. Variable expression of endothelial NO synthase in three forms of rat pulmonary hypertension. Am J Physiol, 276: L297-303, 1999.
40. Fagan KA, Fouty BW, Tyler RC, Morris KG, Helper LK, Sato K, LeCras TD, Abman SH, Weinberger HD, Huang PL, McMurtry IF, Rodman DM. The pulmonary circulation of mice with either homozygous or heterozygous disruption of endothelial NO synthase is hyper-responsive to chronic hypoxia. J Clin Invest, 103:291-299, 1999.
41. Dobyns EL, Eells T, Griebel J, Abman SH. Elevated plasma endothelin-1 and cytokine levels in children with severe acute respiratory distress syndrome. J Pediatr, 135:246-9, 1999.
42. Dobyns EL, Griebel J, Kinsella JP, Abman SH, Accurso FJ. Infant pulmonary function during follow-up after inhaled NO therapy in the neonatal period. Pediatric Pulmonol. 28:24-30, 1999.
43. Holcomb RG, Tyson RW, Ivy DD, Abman SH, Kinsella JP. Congenital pulmonary venous stenosis presenting as persistent pulmonary hypertension of the newborn. Pediatric Pulmonol 28:301-6, 1999.
44. Kinsella JP, Walsh WF, Bose C, Gerstmann DR, Labella JJ, Sardesai S, Walsh-Sukys M, Mcaffrey M, Cornfield DN, Bhutani V, Cutter GR, Abman SH. Randomized controlled trial of inhaled nitric oxide in premature neonates with severe hypoxemic respiratory failure. Lancet, 354:1061-1065, 1999.
45. Le Cras TD, Kim DH, Gebb S, Markham NE, Shannon JM, Tuder RM, Abman SH. Abnormal lung growth and the development of pulmonary hypertension in the Fawn-Hooded Rat. Am J Physiol, 277: L709-718, 1999.
46. Kinsella JP, Abman SH. Clinical approach to inhaled nitric oxide therapy in the hpoxemic newborn. J Pediatr. 136:717-726, 2000.
47. Parker TA, Le Cras TD, Kinsella JP, Abman SH. Developmental changes in endothelial NO synthase expression in the ovine fetal lung. Am J Physiol. 278:L202-208, 2000.
48. Rairigh RL, Storme L, Parker TA, Le Cras TD, Jakkula M, Abman SH. Role of neuronal nitric oxide synthase in regulation of vascular and ductus arteriosus tone in the ovine fetus. Am J Physiol. Lung Cell Mol Physiol. 278:L105-110, 2000.
49. Parker TA, Ivy DD, Galan HL, Kinsella JP, Abman SH. Effects of chronic estradiol treatment on pulmonary hemodynamics and structure in experimental perinatal pulmonary hypertension. Am J Physiol. Lung Cell Mol Physiol. 278:L374-381, 2000.
50. Tang J-R, Le Cras TD, Jakkula M, Abman SH. Brief perinatal hypoxia increases the severity of pulmonary hypertension after re-exposure to hypoxia in infant rats. Am J Physiol. Lung Cell Mol Physiol. 278: L356-364, 2000.
51. Le Cras TD. Markham NS, Morris KG, Ahrens CR, McMurtry IF, Abman SH. Neonatal dexamethasone treatment causes lung hypoplasia and increases the severity of pulmonary hypertension in adult rats. Am J Physiol Lung Cell Mol Physiol. 278: L822-829, 2000.
52. Gothberg S, Parker TA, Abman SH, Kinsella JP. Effects of high frequency oscillatory ventilation and partial liquid ventilation after acute lung injury in premature lambs with severe respiratory distress syndrome. Crit Care Med, 28:2450-6, 2000.
53. Parker TA, Kinsella JP, Galan HL, Richter G, Abman SH. Prolonged infusions of estradiol dilate the ovine fetal pulmonary circulation. Pediatr Res, 47:89-96, 2000.
54. Ivy DD, Le Cras TD, Parker TA, Zenge JP, Jakkula M, Markham NE, Abman SH. Developmental changes in endothelin expression and activity in the ovine fetal lung. Am J Physiol. Lung Cell Mol Physiol. 278:L785-793, 2000.
55. Grover TR, Rairigh RL, Zenge JP, Abman SH, Kinsella JP. Inhaled carbon monoxide does not alter pulmonary vascular tone in the ovine fetus. Am J Physiol. Lung Cell Mol Physiol. 278:L779-784, 2000.
56. Jakkula M, Le Cras TD, Gebb S, Hirth KP, Tuder RM, Voelkel NF, Abman SH. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol. 279:L600-9, 2000.
57. Le Cras TD, Kim D, Markham NE, Abman SH. Early abnormalities in pulmonary vascular development in the fawn-hooded rat. Am J Physiol. Lung Cell Mol Physiol Lung Cell Mol Physiol. 279:L283-91, 2000.
58. Grover TR, Le Cras TD, Ackerman KL, Jobe AH, Abman SH. Repetitive prenatal glucocorticoids increase endothelial nitric oxide synthase expression in ovine fetuses delivered at term. Pediatr Res. 48:75-83, 2000.
59. Ivy DD, Parker TA, Abman SH. Prolonged endothelin B receptor blockade causes pulmonary hypertension in the ovine fetus. Am J Physiol. 279: L758-65, 2000.
60. Cornfield DN, Resnik E, Herron J, Abman SH. Calcium-sensitive K+ channel expression is reduced in an ovine model of persistent pulmonary hypertension of the newborn. Am J Physiol. 279:L857-62. 2000.
61. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman SH. Hirth PK, Waltenberger J, Voelkel NF. Inhibition of vascular endothelial growth factor receptors causes lung cell apoptosis and emphysema. J Clin Invest 106:1311-9, 2000.
62. Gothberg S, Parker TA, Griebel J, Abman SH, Kinsella JP. Lung volume recruitment in lambs during high frequency oscillatory ventilation using respiratory inductive plethysmography. Pediatr Res, 49:38-44, 2001.
63. Abman SH. Bronchopulmonary Dysplasia: a Vascular Hypothesis. Am J Resp Crit Care Med. 164:1755-6, 2001.
64. Ivy DD, McMurtry IF, Yanagisawa M, Gariepy CE, Morris KG, Le Cras TD, Jakkula M, Abman SH. Enhanced acute hypoxic pulmonary vasoconstriction in endothelin B receptor deficient rats. Am J Physiol. Lung Cell Mol Physiol, L1040-1048, 2001.
65. Galan HL, Le Cras TD, Tyson RW, Regnault TRH, Anthony RV, Wilkening RW, Abman SH. Cotyledon and binucleate cell nitric oxide synthase expression in an ovine model of fetal growth restriction. J Appl Physiol. 90:2420-6, 2001.
66. Rairigh RL, Parker TA, Ivy DD, Kinsella JP, Fan I, Abman SH. Role of inducible nitric oxide synthase in the transition of the pulmonary circulation at birth. Circ Res. 88:721-6, 2001.
67. Parker TA, Afshar S, Kinsella JP, Ivy DD, Shaul PW, Abman SH. Effects of chronic estrogen receptor blockade on the pulmonary circulation in the late gestation ovine fetus. Am J Physiol. Heart Circ Physiol. 281:H1005-14, 2001.
68. Zenge JP, Rairigh RL, Grover TR, Storme L, Parker TA, Abman SH. NO and prostaglandins modulate the pulmonary vascular response to hemodynamic stress in the late gestation fetus. Am J Physiol. Lung Cell Mol Physiol. 281:L1157-63, 2001.
69. Epting CL, Wolfe RR, Abman SH, Deutsch GH, Ivy DD. Reveral of pulmonary hypertension associated with plexiform lesions in congenital heart disease. Pediatr. Cardiol. 23:182-5, 2002.
70. Kinsella JP, Griebel J, Schmidt JM, Abman SH. Use of inhaled NO during inter-hospital transport of newborns with hypoxemic respiratory failure. Pediatrics. 109: 9-12, 2001.
71. Ivy DD, Tanzawa K, Abman SH. Developmental changes in lung endothelin converting enzyme expression in the ovine fetus. Biol Neonate 81:139-144, 2001.
72. Storme L, Rairhig RL, Parker TA, Kinsella JP, Abman SH. Chronic pulmonary hypertension abolishes flow-induced vasodilation and increases the myogenic response in the ovine fetal pulmonary circulation. Am J Physiol, 282:L56-66, 2002.
73. Dobyns EL, Anas NG, Fortenberry JD, Deshpande J, Cornfield DN, Tasker RC, Liu P, Eells PL, Griebel J, Kinsella JP, Abman SH. Interactive effects of HFOV and inhaled NO in children with acute hypoxemic respiratory failure. Crit Care Med, 30:2425-29, 2002.
74. Le Cras TD, Markham NE, Tuder RM, Voelkel NF, Abman SH. Brief neonatal treatment with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure in adult rats. Am J Phyiol. Lung Cell Mol Biol, 283:L555-562, 2002.
75. Grover TR, Zenge JP, Parker TA, Abman SH. VEGF causes pulmonary vasodilation through activation of the PI3-kinase – nitric oxide dependent pathway in the late gestation ovine fetus. Pediatr Res, 52:907-912, 2002.
76. Abman SH. Monitoring cardiovascular function in infants with chronic lung disease of prematurity. Arch Dis Child. 87:F15-18, 2002.
77. Grover TR, Parker TA, Zenge JP, Markham NE, Abman SH. Intrauterine pulmonary hypertension decreases lung VEGF expression and VEGF inhibition causes pulmonary hypertension in the ovine fetus. Am J Physiol. 284: L508-17, 2003.
78. Balasubramaniam V, Le Cras TD, Ivy DD, Kinsella JP, Grover TR, Abman SH. Role of platelet-derived growth factor in the pathogenesis of perinatal pulmonary hypertension. Am J Physiol. Lung Cell Mol., 284: L826-33, 2003.
79. Balasubramaniam V, Maxey A, Plopper C, Abman SH. Mild hypoxia impairs lung growth in mice deficient in endothelial NO synthase. Am J Physiol., 284: L964-71, 2003.
80. Kinsella JP, Parker TA, Ivy DD, Abman SH. Non-invasive delivery of inhaled NO therapy for late pulmonary hypertension in newborns with congenital diaphragmatic hernia. J Pediatr, 142:397-401, 2003.
81. Ivy DD, Doran A, Parker D, Kinsella JP, Abman SH. Acute hemodynamic effects and home therapy using a novel pulsed NO delivery system in pediatric pulmonary hypertension. Am J Cardiol. 92:886-90, 2003.
82. Woolridge JL, Deutsch GH, Sontag MK, Osberg I, Chase DR, Silkoff PE, Wagener JS, Abman SH, Accurso FJ. Lower airway NO synthase II expression, NO and metabolites are similar in CF and disease control children but decrease with airway inflammation. Pediatr Pulmonol. 37:338-50, 2004.
83. Tang J-R, Markham NE, Lin Y-J, Kinsella JP, McMurtry IF, Abman SH. Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth after neonatal treatment with a VEGF receptor inhibitor. Am J Physiol, 287: L344-51, 2004.
84. Atwood CW, McCrory D, Garcia JGN, Abman SH, Ahearn GS. Pulmonary arterial hypertension and sleep apnea: ACCP evidence based guidelines for clinical practice. Chest. 126:72S-77S, 2004.
85. Badesch DB, Abman SH, Ahearn G, Barst RJ, McCrory D, Simonneau G, McLauhglin VV. Medical Therapies for pulmonary arterial hypertension: ACCP evidence based guidelines for clinical practice. Chest 126:35S-7S, 2004.
86. McLaughlin VV, Pressberg K, Doyle RL, Abman SH, McCrory D, Fortin T, Ahearn GS. Prognosis for pulmonary arterial hypertension: ACCP evidence based guidelines for clinical practice. Chest. 126:78S-92S, 2004.
87. Ivy DD, Lee D, Rairigh RL, Parker TA, Abman SH. Endothelin B receptor blockade impairs vasodilation during oxygen ventilation in fetal sheep. Biology of the Neonate, 86:155-159, 2004.
88. Mourani P, Ivy DD, Gao D, Abman SH. Pulmonary vascular effects of inhaled NO and oxygen tension in older children and adolescents with bronchopulmonary dysplasia. Am J Respir Crit Care Med. 170:1006-13, 2004.
89. Lin Y-J, Markham NE, Balasubramaniam V, Tang J-R, Maxey A, Kinsella JP, Abman SH. Inhaled NO therapy enhances distal lung growth after exposure to hyperoxia in neonatal rats. Pediatr Res. 58:22-9, 2005.
90. Grover TR, Parker TA, Balasubramaniam V, Markham NE, Abman SH. Pulmonary hypertension impairs alveolarization and lung growth in the ovine fetus. Am J Physiol. LCMP 288:648-54, 2005.
91. Rosenzweig EB, Ivy DD, Widlitz A, Doran A, Claussen LR, Yung D, Abman SH, Morganti A, Nguyen N, Barst RJ. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol. 46:697-704, 2005.
92. Grover TR, Parker TA, Abman SH. VEGF improves pulmonary vascular reactivity and structure in an experimental model of chronic pulmonary hypertension in fetal sheep. Chest 128 (suppl 6):614S, 2005.
93. Deruelle P, Grover TR, Storme L, Abman SH. Effects of BAY 41-2272, a direct soluble guanylate cyclase activator, on pulmonary vasoreactivity in the ovine fetus. Am J Physol LCMP 288:727-33, 2005.
94. Parker TA, Grover TR, Kinsella JP, Falck JR, Abman SH. Inhibition of 20-HETE abolishes the myogenic response during NOS antagonism in the ovine fetal pulmonary circulation. Am J Physiol. LCMP, 289: L261-7, 2005.
95. Kunig A, Balasubramaniam V, Markham N, Montgomery G, Grover T, Abman SH. Recombinant human VEGF treatment enhances alveolarization during recovery after hyperoxic lung injury in neonatal rats. Am J Physiol. LCMP, 289: L529-535, 2005.
96. Grover TR, Parker TA, Hunt-Peacock C, Markham NE, Abman SH. rhVEGF treatment improves pulmonary vasoreactivity and structure in an experimental model of pulmonary hypertension in fetal sheep. Am J Physiol. LCMP, 289: L529-35, 2005.
97. Kinsella JP, Parker TA, Davis JM, Abman SH. Intratracheal administration of recombinant human superoxide dismutase improves gas exchange and pulmonary hemodynamics in premature lambs with RDS. Am J Resp Crit Care Med. 172:745-9, 2005.
98. Deruelle P, Grover TR, Abman SH. Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep. Am

 J Physiol. LCMP, 289: L788-806, 2005.

1. Parker TA, Roe G, Grover TR, Abman SH. Rho-kinase activity maintains high pulmonary vascular resistance in the ovine fetal lung. Am J Physiol. LCMP, 291: L976-82, 2006.
2. Balasubramaniam V, Maxey AM, Fouty BW, Abman SH. Nitric oxide augments fetal pulmonary artery endothelial cell angiogenesis in vitro. Am J Physiol. 291: L119-27, 2006.
3. Deruelle P, Balasubramanuam V, Kunig AM, Seedorf G, Markham NE, Abman SH. Bay 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and improves pulmonary vascular structure during chronic hypoxia in neonatal rats. Biol Neonate. 90:135-44, 2006.
4. Kinsella JP, Greenough A, Abman SH. Bronchopulmonary dysplasia. Lancet. 367:1421-31, 2006.
5. Balasubramaniam V, Maxey AM, Morgan DB, Markham NE, Abman SH. Inhaled nitric oxide restores normal lung structure in endothelial nitric oxide synthase deficient neonatal mice after exposure to mild hypoxia. Am J Physiol. 291: L119-27, 2006.
6. Montgomery GS, Sagel SS, Taylor A, Abman SH. Effects of sildenafil therapy on pulmonary hypertension and exercise tolerance in severe CF lung disease. Ped Pulmonol. 41:383-5, 2006.
7. Kunig AM, Balasubramaniam V, Markham NE, Seedorf G, Gien J, Abman SH. Recombinant human VEGF treatment transiently increases lung edema but enhances late lung structure in neonatal hypeoxic lung injury. Am J Physiol. 291: L1068-98, 2006.
8. Kinsella JP, Cutter GR, Hart C, Walsh WF, Gerstmann DR, Sekar KC, Auten RL, Bhutani VK, Gerdes JS, George TN, Bose CL, Southgate WM, Carriedo H, Couser RJ, Mammel MC, Hall DC, Pappagallo M, Sardesai S, Strain JD, Baier M, Abman SH. Early inhaled NO therapy in premature newborns with respiratory failure. N Engl J Med. 355:354-64, 2006.
9. Walsh MC, Szefler S, Davis J, Allen M, van Marter L, Abman S, Blackmon L, Jobe A. Best practice for children guidelines: summary proceedings from the bronchopulmonary dysplasia group. Pediatrics 117:52-56, 2006.
10. Balasubramaniam V, Mervis C, Seedorf G, Markham NE, Abman SH. Hyperoxia reduces bone marrow, circulating and lung endothelial progenitor cells: implications for the pathogenesis of bronchopulmonary dysplasia. Am J Physiol., 292: L1073-84, 2007.
11. Grover TR, Aiskainen TM, Kinsella JP, Abman SH. White CW. Hypoxia inducible factor (HIF)-1 alpha and HIF-2 alpha are decreased in an experimental model of severe RDS in extremely preterm neonatal lambs. Am J Physiol., 292::1345-51, 2007.
12. Thebaud B, Abman SH. Bronchopulmonary dysplasia- where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease. Am J Respir Crit Care Med, 175:978-85, 2007.
13. Gien J, Seedorf G, Balasubramaniam V, Markham N, Abman SH. Chronic intrauterine pulmonary hypertension impairs endothelial cell growth and angiogenesis in vitro. Am J Respir Crit Care Med, 176:1146-53, 2007.
14. Badesch DB, Abman SH, Gutterman D, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based guidelines for clinical practice. Chest, 131:1917-28, 2007.
15. Kinsella JP, Abman SH. Inhaled NO in premature infants. J Pediatr. 151:10-15, 2007.
16. Ivy DD, Doran A, Smith K, Mallory G, Beghetti M, Barst RJ, Brady D, Parker D, Claussen L, Abman SH. Short and long-term effects of inhaled Iloprost therapy in children with pulmonary hypertension. J Am Coll Cardiol, 51:161-9, 2007.
17. Tang JR, Balasubramaniam V, Maxey A, Markham N, Abman SH. Early inhaled nitric oxide treatment decreases apoptosis of endothelial cells in neonatal rat lungs after vascular endothelial growth factor receptor inhibition. Am J Physiol., 293: L1271-80, 2007.
18. Kunig AM, Parker TA, Nogee LM, Abman SH, Kinsella JP. ABCA3 deficiency presenting as PPHN. J Pediatr, 151:322-4, 2007.
19. Mourani PM. Sontag MK, Ivy DD, Abman SH. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in children with chronic lung disease. Pediatrics, 121:317-325, 2008.
20. Muehlethaler V, Kunig A, Seedorf G, Balasubramaniam V, Abman SH. Impaired VEGF and NO signaling after nitrofen exposure in rat fetal lung explants. Am J Physiol. 294: L110-120, 2008.
21. Mourani PM, Fagan T, Ivy DD, Rosenberg A, Abman SH. Left ventricular diastolic dysfunction in bronchopulmonary dysplasia. J Pediatrics, 152:291-3, 2008.
22. Gien J, Seedorf GJ, Balasubramaniam V, Markham N, Abman SH. Chronic intrauterine pulmonary hypertension increases endothelial rho-kinase activity and impairs angiogenesis in vitro. Am J Physiol. 295(4): L680-7, 2008.
23. Tourneux P, Chester M, Grover T, Abman SH. Fasudil inhibits the myogenic response in the fetal pulmonary circulation. Am J Physiol. 295(4):H1505-13, 2008.
24. Mourani PM, Sontag MK, Lui G, Ivy DD, Abman SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr, 154:379-84, 2009.
25. Baker CD, Ryan S, Ingram DA, Seedorf GJ, Abman SH, Balasubramaniam V. Endothelial progenitor cells from preterm infants are more susceptible to hyperoxia-induced oxidative stress. Am J Respir Crit Care Med, 180:454-61, 2009.
26. Chester M, Tourneux P, Seedorf G, Grover TR, Abman SH. Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus. Am J Physiol. 297: L318-25, 2009.
27. Castro M, Ramirez MI, Gern JE, Redding G, Hagood JS, Whitsett J, Abman S, Raj UJ, Barst R, Kato GJ, Haddad GG, Prabhaker NR, Gauda E, Martinez FD, Teper R, Wood RE, Accurso F, Teague WG, Venegas J, Cole FS, Wright FJ. Strategic plan for pediatric respiratory diseases research: an NHLBI working group report. Proceeding of the American Thoracic Society, 16:1-10, 2009.
28. Abman S, Jobe A, Chernick V, Blaisdell C et al. Strategic plan for pediatric respiratory diseases research: an NHLBI working group report. Pediatric Pulmonology, 44:2-13, 2009.
29. Tourneux P, Markham N, Seedorf G, Balasubramaniam V, Abman SH. Inhaled nitric oxide improves lung structure and pulmonary hypertension in a model of bleomycin induced bronchopulmonary dysplasia in neonatal rats. Am J Physiol, 297: L1103-11, 2009.
30. Fujinaga H, Baker CD, Ryan SL, Markham NE, Seedorf GJ, Balasubramaniam V, Abman SH. Hyperoxia disrupts VEGF-NO signaling and decreases growth of endothelial colony forming cells from preterm infants. Am J Physiol, 297: L1160-9, 2009.
31. Ferkol T, Zeitlin P, Abman S, Blaisdell CJ, O’Brodovich H. NHLBI training workshop report: the vanishing pediatric pulmonary investigator and recommendations for recovery. Lung, 187:367-74, 2009.
32. Abman SH, Matthay MA. Mesenchymal stem cells in the prevention of BPD: delivering the secretome. Am J Respir Crit Care Med, 180:1039-41, 2009.
33. Abman SH, Raj U. Towards improving the care of children with pulmonary hypertension: rationale for developing a pediatric pulmonary hypertension network. Progress in Pediatr Cardiol, 27:3-6, 2009.
34. Choi AMK, Reynolds HY, Colombini-Hatch S et al, and members of the working group. NHLBI Workshop: respiratory medicine-related research training for adult and pediatric fellows. Lung, 187:347-66, 2009.
35. Watson R, Clermont G, Kinsella J, Kong L, Arendt R, Cutter G, Linde-Zwirbie W, Abman S, Angus D. Clinical and economic effects at one year of corrected age after a randomized trial of inhaled NO in premature newborns with respiratory failure. Pediatrics, 124:1333-43, 2009.
36. Balasubramaniam V, Ryan Sl, Seedorf G, Roth EV, Heumann TR, Ingram DE, Yoder MC, Hogan CJ, Markham NE, Abman SH. Bone marrow derived angiogenic cells restore alveolar and vascular structure after neonatal hyperoxia in infant mice. Am J Physiol. 298: L315-23, 2010.
37. Gunville CF, Stratton KA, Ranade DJ, Sontag MK, Abman SH, Mourani PM. The scope and impact of early and late preterm infants admitted to the PICU with respiratory illness. J Pediatr. 157:209-14, 2010.
38. Barst RJ, Agnoletti G, Fraisse A, Baldassare J, Wessel DL for the NO Diagnostic Group. Vasodilator testing with nitric oxide and/or oxygen in pediatric pulmonary hypertension. Pediatric Cardiology, 31:598-606, 2010.
39. Tang JR, Seedorf G, Muehlethaler V, Walker DL, Markham NE, Balasubramaniam V, Abman SH. Moderate hyperoxia accelerates lung growth and attenuates pulmonary hypertension in infant rats after exposure to intra-amniotic endotoxin. Am J Physiol: Lung, 299: L735-48, 2010.
40. Olin JT, Abman SH, Grady M, Ivy DD, Lovell MA, Balasubramaniam V. A seven year old female with pulmonary hypertension. BMJ, 2011: bcr0220113843, 2011.
41. Rozance PJ, Seedorf GJ, Brown A, Gien J, Tang, J-R, Abman SH. Intrauterine growth restriction decreases pulmonary alveolar and vessel growth and causes pulmonary artery endothelial cell dysfunction in vitro. Am J Physiol. Lung, 301(6): L860-71, 2011.
42. Del Cerro MJ, Abman S, Diaz G, Freudenthal AH, Freudenthal F, Harikrishna S, Haworth DG, Ivy D, Lopez A, Raj U, Sandoval J, Stenmark K, Adatia I. Pediatric pulmonary hypertensive vascular disease: suggestions for a novel pediatric classification. Report from the PVRI Pediatric Taskforce, Panama 2011. Pulmonary Circulation. 1:286-98, 2011.
43. Chester M, Gien J, Tourneux P, Seedorf G, Grover TR, Stasch H-P, Abman SH. Cinaciguat, a soluble guanylate cyclase activator, augments cGMP production and causes potent pulmonary vasodilation in experimental persistent pulmonary hypertension of the newborn. Am J Physiol. Lung, 301(5): L755-64, 2011.
44. Delaney C, Grover TR, Gien J, Roe G, Abman SH. Pulmonary vascular effects of serotonin and selective serotonin reuptake inhibitors in the ovine fetus. Am J Physiol. 301: L937-44, 2011.
45. Mourani PM, Harris JK, Sontag MK, Robertson CE, Abman SH. Molecular identification of bacteria in tracheal aspirate fluid from intubated preterm infants. PlosOne. 6(10): e25959, 2011.
46. Tang JR, Karumanchi SA, Seedorf GJ, Markham N, Abman SH. Excess soluble vascular endothelial growth factor receptor-1 impairs lung growth in infant rats: linking preeclampsia with bronchopulmonary dysplasia. Am J Physiol. Lung Cell Molecular. 302: L36-46, 2011.
47. Baker CD, Balasubramaniam V, Mourani PM, Sontag MK, Black CP, Ryan SL, Abman SH. Cord blood angiogenic progenitor cells are decreased in preterm infants who develop BPD. Eur Respir J, 40:1516-22, 2012.
48. Robbins I, Moore T, Blaisdell C, Abman SH. NIH Workshop: Improving pulmonary vascular outcomes. Am J Respir Crit Care Med. 185:1015-20, 2012.
49. Robbins I, Moore T, Blaisdell C, Abman SH. NIH Workshop: Improving pulmonary vascular outcomes. Circulation. 125:2165-70, 2012.
50. Morrisey E, Cardoso WV, Lane R, Rabinovitch M, Abman SH, Ai X, Albertine KH, Bland R, Chapman HA, Checkley W, Epstein J, Kintner C, Kumar M, Minoo P, Mariani T, McDonald D, Mukoyama Y, Prince LS, Reese J, Rossant J, Shi W, Sun X, Werb Z, Whitsett JA, Weinmann G, Gail D, Blaisdell CJ, Gan W, Schramm C, Dirami G, Lin QS. Molecular determinants of lung development: NHLBI Workshop. Ann Am Thorac Soc, 10: S12-16, 2013.
51. Abman SH, Kinsella JP, Rosenzweig EG, Krishnan U, Kulik T, Mullen M, Wessel DL, Steinhorn R, Adatia I, Hanna B, Feinstein J, Fineman J, Raj U, Humpl T; for the Pediatric Pulmonary Hypertension Network. Implications regarding the recent FDA warning against the use of sildenafil in pediatric pulmonary hypertension. Am J Resp Crit Care Med. 187:572-5, 2013.
52. Gien J, Tseng N, Seedorf G, Markham N, Abman SH. Endothelin-1 impairs lung vascular growth through rho kinase activation in experimental persistent pulmonary hypertension of the newborn. Pediatr Research, 73:252-62, 2013.
53. Tang JR, Michaelis KA, Nozik-Grayck E, Seedorf GJ, Hartman-Filson M, Abman SH, Wright CJ. NF-kB regulates the responses of fetal pulmonary artery endothelial response to antenatal inflammation: differential roles of IkBa and IkBß. J Immunol. 190:2913-23, 2013.
54. Baker CD, Abman SH. Umbilical cord derived stem cells: ready for prime time? Thorax, 68:402-4, 2013.
55. Steinhorn RH, Kinsella JP, Abman SH. Beyond pulmonary hypertension: sildenafil for chronic lung disease of infancy. Am J Respir Cell Mol Biol, 48:1-3, 2013,
56. Baker CB, Seedorf GJ, Wisnewski BL, Black CP, Ryan SL, Balasubramaniam V, Abman SH. Endothelial colony forming cell conditioned media promotes angiogenesis in vitro and prevents pulmonary hypertension in experimental BPD. Am J Physiol. LCMP. 305: L73-81, 2013.
57. Cornfield DN, Lane R, Abman SH. Patching holes in the pipeline: creation and retention of the next generation of physician-scientists for child health research. JAMA. 309:1781-2, 2013.
58. Baker CD, Black CP, Ryan SL, Balasubramaniam V, Abman SH. Cord blood endothelial colony-forming cell levels and growth in newborns with congenital diaphragmatic hernia. J Pediatr, 163:905-7, 2013.
59. Mourani PM, Abman SH. Pulmonary Vascular Disease in BPD: pulmonary hypertension and beyond. Curr Opin Pediatrics 25:329-37, 2013.
60. Delaney C, Gien J, Roe G, Isenberg N, Kailey J, Abman SH. Serotonin contributes to high pulmonary vascular tone in a sheep model of persistent pulmonary hypertension of the newborn. Am J Physiol. 304: L894-9001, 2013.
61. Klinger JR, Abman SH, Gladwin MT. Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension. Amer J Respir Crit Care Med. 188:639-46, 2013.
62. Galambos C, Sims-Lucas S, Abman SH. Histologic Evidence of Intrapulmonary Arteriovenous Shunt Vessels in Premature Infants with Severe Bronchopulmonary Dysplasia. Ann Am Thorac Soc, 10:474-81, 2013.
63. Galambos C, Sims-Lucas S, Abman SH. Three -dimensional reconstruction identifies misaligned pulmonary veins as intrapulmonary shunt vessels in alveolar capillary dysplasia. J Pediatr. 164:192-5, 2013.
64. Acker SN, Seedorf GJ, Abman SH, Nozik-Grayck E Partrick DA, Gien J. Pulmonary artery endothelial cell dysfunction and decreased populations of highly proliferative endothelial cells in experimental congenital diaphragmatic hernia. Am J Physiol. LCMP, 305: L943-52, 2013.
65. Gadhia MM, Cutter GR, Abman SH, Kinsella JP. Effects of early inhaled NO therapy and vitamin A supplementation on the risk for bronchopulmonary dysplasia in premature newborns with respiratory failure. J Pediatr, 164:744-8, 2013.
66. Gien J, Tseng N, Seedorf G, Roe G, Abman SH. Peroxisome proliferator activated receptor gamma – rho kinase interactions regulate fetal pulmonary artery smooth muscle cell proliferation after chronic intrauterine pulmonary hypertenson. Am J Physiol LCMP, 306: L299-308, 2013
67. Mourani PM, Kinsella JP, Clermont G, Kong L, Perkins A, Cutter G, Linde-Zwirble WT, Abman SH, Angus DC, Watson RS. Intensive care unit readmission during childhood after preterm birth and mechanical ventilation. J Pediatr, 164:749-55, 2013.
68. Wolf D, Tseng N, Seedorf G, Roe G, Abman SH, Gien J. Endothelin-1 decreases PPAR gamma signaling and impairs angiogenesis afer chronic intrauterine pulmonary hypertension in fetal sheep. Am J Physiol LCMP, 306: L361-71, 2013.
69. Acker S, Kinsella JP, Abman SH, Gien J. Vasopressin improves hemodynamics in infansts with congenital diaphragmatic hernia. J Pediatr, 165:53-58, 2013.
70. Ivy DD, Abman SH, Barst RJ, Berger RMF, Bonnet D, Fleming T, Haworth SG, Raj U, Rosenzweig E, Schulze-Neick I, Steinhorn RH, Beghetti M. 5th World Symosium: Pediatric pulmonary hypertension. J Amer Coll Cardiol. 62 (25 Suppl): D117-26, 2013.
71. McEvoy C, Jain L, Schmidt B, Abman SH, Bancalari E, Aschner J. Bronchopulmonary dysplasia: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann Am Thoracic Soc, Suppl 3:S146-53, 2014.
72. Austin E, Kawut S, Gladwin MT, Abman SH. Pulmonary Hypertension: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann Am Thoracic Soc, Suppl 3:S178--85, 2014.
73. Abman SH, Baker C, Gien J, Mourani P, Galambos C. The Robin Barst Memorial Lecture: Differences between the fetal, newborn and adult pulmonary circulation: relevance for age-specific therapy. Pulm Circ, 2014.
74. Mandell E, Seedorf G, Gien J, Abman SH. Vitamin D Improves Infant Lung Injury and Structure after Intra-Amniotic Endotoxin Exposure in Rats: Potential Role for Prevention of Bronchopulmonary Dysplasia. Am J Physiol. LCMP, 306: L420-8, 2014.
75. Abman SH, Conway SJ. Developmental determinants and changing patterns of respiratory outcomes after preterm birth. Birth Defects Research A Clin Mol Teratol, 100:127-33, 2014.
76. Jiang H, Stabler SP, Allen RH, Abman SH, Maclean KN. Altered hepatic sulfur metabolism in cystationine ß-synthase deficient homocystinuria: regulatory role of taurine on competing cysteine oxidation pathways. FASEB J, 28:4044-54, 2014.
77. Kinsella JP, Cutter GR, Steinhorn RH, Nelin LD, Walsh WF, Finer NN, Abman SH. Non-invasive inhaled nitric oxide for the prevention of bronchopulmonary dysplasia in premature infants. J Pediatrics, 165:1104-8, 2014.
78. Galambos C, Sims-Lucas S, Ali N, Gien J, Dishop M, Abman SH. Intrapulmonary vascular shunt pathways in infants with alveolar capillary dysplasia and misalignment of pulmonary veins. Thorax, 70:84-5, 2014.
79. Cornfield DN, Lane R, Rosenblum N, Hostetter M, Jobe A, Albertine K, Aschner J, Abman SH. Patching the pipeline: creation and retention of the next generation of physician-scientists for child health research. J Pediatrics, 165:882-4, 2014.
80. Acker SN, Mandell EW, Sims-Lucas S, Gien J, Abman SH, Galambos C. Identification of intrapulmonary shunt vessels in congenital diaphragmatic hernia. J Pediatr, 166:178-83, 2014.
81. Dodson RB, Morgan M, Galambos C, Hunter KS, Abman SH. Chronic intrauterine pulmonary hypertension increases biaxial stiffness in main pulmonary arteries due to adventitial remodeling in fetal sheep. Am J Physiol LCMP, 307: L822-8, 2014.
82. Rozance PJ, Anderson M, Martinez M, Fahy A, Macko AR, Kailey J, Seedorf GJ, Abman SH, Hay WW, Limesand SW. Placental insufficiency decreases pancreatic vascularity and disrupts hepatocyte growth factor signaling from the pancreatic islet endothelial cell in fetal sheep. Diabetes, 64:555-64, 2015.
83. Mourani PM, Sontag MK, Younoszai A, Miller JI, Kinsella JP, Baker CD, Poindexter BB, Ingram DA, Abman SH. Early pulmonary vascular disease in preterm infants at risk for Bronchopulmonary Dysplasia. Am J Respir Crit Care Med, 191:87-95, 2015.
84. Ivy DD, Abman SH. Gaining insights into pediatric pulmonary hypertensive disorders through patient registries. Am J Respir Crit Care Med. 191:2-4, 2015
85. Jensen KM, Shmueli D, Seewald L, Davis MM, McCabe ERB, Kempe A, Abman SH. Higher elevations increase risk for hospitalizations for obstructive sleep apnea in children with Down syndrome. Chest, 147:1344-51, 2015.
86. Di Maria MV, Younoszai AK, Sontag MK, Miller JI, Poindexter BB, Ingram DA, Abman SH, Mourani PM. Maturational changes in longitudinal myocardial velocity in premature infants. *J Am Soc Echocardiography*, 28:1045 - 52, 2015.
87. Guaman MC, Gien J, Baker CD, Huayan Z, Austin ED, Collaco JM for the BPD Collaborative. Point prevalence, clinical characteristics and care patterns of infants with Severe BPD. *Am J Perinatol*, 32:960-7, 2015.
88. Sectish TC, Hay WW, Mahan JD, Mendoza FS, Spector ND, Stanton B, Szilagyi PG, Turner TL, Walker LR, Slaw and the FOPO Visioning Summit Working Groups and Planning Committee. Blueprint for action: visioning summit on the future of the workforce in pediatrics. *J Pediatrics*, 136:161-9, 2015.
89. Abman SH, Ivy DD. Hospitalizations of children with pulmonary hypertension: implications for improving care. *Pediatrics*, 136:392-3, 2015.
90. Delaney C, Wright RH, Tang J-R, Woods C, Villegas L, Sherlock S, Savani RC, Abman SH, Nozik-Grayck E. Lack of ecSOD worsens alveolar and vascular development in a neonatal mouse model of bleomycin-induced BPD and PH. *Pediatric Res*, 78:634-40, 2015.
91. Ali N, Abman SH. Galambos C. Histologic evidence of intrapulmonary bronchopulmonary anastomotic connections in neonates with fatal meconium aspiration syndrome. *J Pediatrics*, 167:1445-7, 2015.
92. Mandell E, Seedorf G, Ryan S, Gien J, Cramer S, Abman SH. Antenatal endotoxin disrupts lung vitamin D receptor and 25-hydroxyvitamin D 1 alpha hydroxylase expression in the developing rat. *Am J Physiol. LCMB*, 309:1018-26, 2015.
93. Yun EJ, Lorizio W, Seedorf G, Abman SH, Vu TH. VEGF and endothelial-derived retinoic acid regulate lung vascular and alveolar development. *Am J Physiol. LCMP*. 310: L287-98, 2015.
94. Abman SH, Hansmann G, Archer S, Ivy D, Adatia I, Chung WK, Hanna BD, Rosenzweig EB, Raj U, Cornfield DN, Stenmark KR, Steinhorn R, Thébaud B, Fineman J, Kuehne T, Feinstein JA, Friedberg M, Earing M, Barst B, Keller R, Kinsella JP, Mullen M, Deterding R, Kulik T, Mallory G, Humpl T, Wessel D. American Heart Association and American Thoracic Society Joint Guidelines for Pediatric Pulmonary Hypertension. *Circulation.* 132:2037-99, 2015.
95. Mandell E, Powers P, SeedorfG, HunterKS, Abman SH, Dodson RB. Intrauterine endotoxin- impairs pulmonary vascular function and right ventricular performance in infant rats and improvement with vitamin D treatment. *Am J Physiol. LCMB*. 309: L1438-46, 2015.
96. Baker CD, Martin S, Thrasher J, Moore HH, Baker J, Abman SH, Gien J. A standardized discharge process decreases length of stay for ventilator-dependent children. *Pediatrics,* Apr;137(4). pii: e20150637, 2016.
97. Galambos C, Simms-Lucas S, Abman SH, Cool C. Intrapulmonary bronchopulmonary anastomotic pathways and plexiform lesions in idiopathic pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 193:574-6, 2016.
98. Kinsella JP, Steinhorn RH, Krishnan U, Feinstein JA, Adatia I, Austin E,Berman-Rosenzweig E,Everett AD, Fineman J,Hanna B,Hopper R,Humpl T,Ivy DD,Keller R,Mullen M, Raj U,Wessel DL,Abman SH; on Behalf of the Pediatric Pulmonary Hypertension Network (PPHNet). Recommendations for the use of inhaled nitric oxide therapy in premature newborns with severe pulmonary hypertension. *J Pediatrics* 170:12-14, 2016.
99. Liptzin DR, Sturgill M, Kim J, Abman SH, Darst J, Ibrahim J, Browne L. An unusual etiology of hemoptysis. *Am J Respir Crit Care Med*. 193: e14-15, 2016.
100. Hopper R, Abman SH, Ivy DD. Recent challenges in pediatric pulmonary hypertension. Chest. 150:226-36, 2016.
101. Boyer D, Pittman J, Dy FJ, Arunachalam A, Dweik RA, Abman SH, Wilson KC, Thomson CC. ATS Clinical Practice Guideline Summary for Clinicians: American Heart Association and American Thoracic Society Joint Guidelines for Pediatric Pulmonary Hypertension. Ann ATS, 13:967-9, 2016.
102. Boyer D, Pittman J, Dy FJ, Arunachalam A, Dweik RA, Abman SH, Wilson KC, Thomson CC. Pediatric Pulmonary Hypertension: Self-assessment module. Companion to ATS and AHA Guidelines: Pediatric Pulmonary Hypertension. American Board of Internal Medicine Maintenance of Certification Questions. Ann Am Thorac Soc. 13:967-9, 2016.
103. Schafer M, Ivy DD, Barker AJ, Kehfets V, Shandas R, Abman SH, Hunter KS, Truong U. Characterization of CMR-derived hemodynamic data in children with pulmonary arterial hypertension. European Heart Journal Cardiovascular Imaging. 18:424-31, 2016.
104. Seedorf G,\* Metoxen A,\* Rock R, Markham N, Ryan S, Vu, T, Abman SH. Hepatocyte growth factor as a downstream mediator of vascular endothelial growth factor -dependent preservation of lung growth in experimental bronchopulmonary dysplasia. Am J Physiol. LCMP. 310:L1098-110, 2016. (\* co-first authors).
105. Libby A, Cornfield DN, Abman SH. There is no “I” in team: new challenges for career development in the era of team science. J Pediatrics, 177:4-5, 2016.

1. Abman SH, Ivy DD, Archer SL, Wilson KC for the AHA/ATS Joint Guidelines for Pediatric Pulmonary Hypertension Committee. Executive summary of the American Heart Association and American Thoracic Society Joint Guidelines for Pediatric Pulmonary Hypertension. Am J Respir Crit Care Med. 194:898-906, 2016.
2. Galambos C, Minic AD, Nguyen D, Bush D, Dodson RB, Seedorf G, Abman SH. Increased lung expression of anti-angiogenic factors in Down syndrome: potential role in the pathogenesis of abnormal lung development and high risk for pulmonary hypertension. PlosOne, 11(8)e:0159005, 2016.
3. Gao Y, Cornfield DN, Stenmark KR, Thebaud B, Abman SH, Raj JU. Unique aspects of the developing lung circulation: structural development and regulation of vasomotor tone. Pulmonary Circulation, 6:407-25, 2016.

1. Gien J, Tseng N, Seedorf G, Kuhn K, Abman SH. Endothelin-1 – Rho Kinase interactions impair lung structure and cause pulmonary hypertension after bleomycin exposure in neonatal rats. Am J Physiol, 311: L1090-1100, 2016.
2. Lynch AM, Wagner BD, Mandava N, Palestine AG, Mourani PM, McCourt EA, Oliver SC, Abman SH. The relationship of novel plasma proteins in the early neonatal period with retinopathy of prematurity. Invest Ophthalmol Vis Sci, 57:5076-82, 2016.
3. Del Cerro MJ, Moledina S, Haworth SG, Ivy Dd, Al Dabbach M, Banjar H, Diaz G, Heath-Freudenthal A, Galal AN, Humpl T, Kulkarni S, Lopes A, Mocumbi AO, Puri GD, Rossouw B, Harikrishnan S, Saxena A, Udo P, Caicedo L, Tamimi O, Adatia I. (for the Pediatric Task Force, PVRI). Cardiac catheterization in children with pulmonary hypertensive vascular disease: consensus statement from the pulmonary vasucular research institute. Pulm Circ. 6:118-25, 2016.
4. Gien J, Kinsella JP, Grenolds A, Thrasher J, Abman SH, Baker CD. Retrospective analysis of an interdisciplinary care program intervention on survival of infants with ventilator-dependent BPD. *Am J Perinatol*. 34:155-63, 2017.
5. Goss K, Everett A, Mourani PM, Baker CD, Abman SH. Addressing the challenges of phenotyping pediatric pulmonary vascular disease. Ann Amer Thoracic Soc. 7:7-19, 2017.
6. Maron BA, Abman SH. Translational advances in the field of pulmonary hypertension. Focusing on developmental origins and disease inception to prevent pulmonary hypertension. Am J Respir Crit Care Med. 195:292-301, 2017.
7. Schafer M, Ivy DD, Abman SH, Barker AJ, Browne Lorna, Fonseca B, Hunter KS, Truong U. Apparent aortic stiffness in children with pulmonary arterial hypertension: existence of vascular interdependency. Circ Cardiovasc Imaging, Feb;10(2). pii: e005817, 2017.
8. Ryan DC, Gould E, Seedorf G, Singh J, Parsa P, Abman S, Vijayaraghavan S, Macklin W, Restrepo D, Shepherd DP. C-DSLM: cleared tissue digital scanned light sheet microscopy. Nature Commun. 2017 Sep 20;8(1):612. doi: 10.1038/s41467-017-00514-7.
9. Abman SH, Collaco JM, Keszler M, Welty SE, Lynch S, Truog WE, McGrath-Morrow S, Gratny L, Zhang H, Dysart K, Kirpalani H, Gien J, Baker C, Donohue P, Moore PE, Cuevas M, Shepherd EG, Rhein L, amd Nelin LD; for the BPD Collaborative.Interdisciplinary Care of Children with Severe Bronchopulmonary Dysplasia*.* J Pediatr, 181:12-28, 2017.
10. Newman JH, Rich S, Abman SH, Alexander JH, Barnard J, Beck GJ, Alexander JH, Benza RL, Bull TM, Chan SY, Chun HJ, Doogan D, Dupuis J, Emerson SS, Erzurum SC, Frantz RP, Geraci M, Gillies H, Gladwin M, Gray MP, Hemnes A, Herbst RS,Hernandez AF, Hill NS, Horn EM, Hunter K, Jing ZC, Johns R, Kaul S, Kawut S, Lahm T, Leopold JA, Lewis GD,Mathai SC, McLaughlin VV, Michelakis ED, Nathan SD, Nichols W, Page G, Rabinovitch M, Rich J, Rischard F, Rounds S, ShahS, Tapson VF, Lowy N, Stockbridge N, Weinmann G, Xiao L. Enhancing Treatments for Pulmonary Vascular Diseases (PVD) Through Precision Medicine. A Joint NHLBI-CMREF Workshop Report. Am J Respir Crit Care Med, 195(12):1661-1670, 2017.
11. Abman SH, Banacalari E, Jobe AH. The evolution of bronchopulmonary dysplasia after 50 years. Am J Respir Crit Care Med. 195:421-4, 2017.

1. Wagner BD, Sontag MK, Harris JK, Miller JI, Whitfield L, Robertson CE, Stephens M, Poindexter BB, Abman SH, Mourani PM. Airway microbial community turnover differs by BPD severity in ventilated preterm infants. *PlosOne*, 12(1): e0170120, 2017.
2. Wagner BD, Sontag MK, Harris JK, Miller JI, Whitfield L, Robertson CE, Stephens M, Poindexter BB, Abman SH, Mourani PM. Prenatal complications are associated with the postnatal airway host response and microbiota in intubated preterm infants. J Matern Fetal Neonatal Med, Nov 28:1-8. doi: 10.1080/14767058.2017.1407310. [Epub ahead of print] 2017.
3. Carlton EF, Sontag MK, Younoszai A, DiMaria M, Miller JI, Abman SH, Mourani PM. Systematic evaluation and inter-rater reliability of echocardiogram indicators of pulmonary hypertension in preterm infants at risk for bronchopulmonary dysplasia. J Pediatrics, 186:29-33, 2017.
4. Morrow L, Wagner B, Ingram DA, Poindexter BB, Schibler K, Cotton M, Dagle J, Sontag MK, Mourani PM, Abman SH. Antenatal determinants of increased risk for bronchopulmonary dysplasia and late respiratory disease in preterm infants. Am J Respir Crit Care Med, 196:364-74, 2017.
5. Mandell EW, Abman SH. Fetal vascular origins of Bronchopulmonary Dysplasia. J Pediatrics. 185:7-10, 2017.
6. Matthay M, Abman SH. Mesenchymal stromal cell therapy for the prevention of BPD: is it the Exosome? Am J Respir Crit Care Med. 2017.

1. Steinhorn R, Davis JM, Gopel W, Jobe A, Abman S, Laughon M, Bancalari E, Aschner J, Ballard R, Greenough A, Tomson M, Ariagno R, Turner M. Chronic pulmonary insufficiency of prematurity: developing optimal endpoints for drug development. J Pediatrics, 191:15-21, 2017.
2. Krishnan U\*, Feinstein J\*, Adatia I, Austin E, Mullen M, Hopper R, Hanna B, Romer L, Keller R, Steinhorn R, Kinsella J, Ivy DD, Rosenzweig EB, Fineman J, Humpl T, Raj U, Abman SH; for the Pediatric Pulmonary Hypertension Network (PPHNet). Evaluation and management of pulmonary hypertension in children with bronchopulmonary dysplasia. J Pediatrics, 188:24-34, 2017.
3. Singh JN, Nowlin T, Seedorf GJ, Abman S, Shepherd DP. Quantifying 3-dimensional rodent retina vascular development using optical tissue clearing and light sheet microscopy. J Biomed Opt. 2017 Jul 1;22(7):76011. doi: 10.1117/1.JBO.22.7.076011.
4. Schafer M, Ivy DD, Abman SH, Barker AJ, Browne LP, Fonseca B, Kehyfats V, Hunter KS, Truong U. Apparent aortic stiffness in children with pulmonary arterial hypertension: existence of vascular interdependency? Circ Cardiovasc Imaging 2017 Feb;10(2). pii: e005817. doi: 10.1161/CIRCIMAGING.116.005817.
5. Schafer M, Ivy Dd, Barker AJ, Kheyfets V, Shandas R, Abman SH, Hunter KS, Truong U. Characterization of CMR-derived hemodynamic data in children with pulmonary arterial hypertension. Eur Heart J Cardiovasc Imaging. 18:424-31, 2017.
6. Wagner BD, Babinec AE, Carpenter C, Gonzalez S, O’Brien, Rollock K, Williamson K, Mourani P, Abman SH. Proteomic profiles with early echocardiogram evidence of pulmonary vascular disease in preterm infants. Am J Respir Crit Care Med, 197:394-7, 2017.
7. Geva A, Gronsbell JL, Cai T, Murphy SN, Lyons JC, Heinz MM, Natter MD, Patibandia N, Bickel J, Mullen MP, Mandl KD; Pediatric Pulmonary Hypertension Network and NHLBI Pediatric Pulmonary Vascular Disease Outcomes Bioinformatics Clinical Coordinating Center. A Computable Phenotype improves cohort ascertainment in a pediatric pulmonary hypertension registry. J Pediatr, 188:224-231, 2017.
8. Liptzin DR, Abman SH, Giesenhagan A, Ivy DD. An approach to children with high altitude pulmonary edema. High Altitude Medicine and Biology. 19:91-98, 2018.
9. Schafer M, Collins KK, Browne LP, Ivy DD, Abman S, Friesen R, Frank N, Fonseca B, DiMaria M, Hunter KS, Truong U, von Alvensleben J. Effect of electrical dyssynchrony on left and right ventricular mechanics in children with pulmonary arterial hypertension. J Heart Lung Transplant, 37:870-8, 2018.
10. Wallace B,\* Peisl A,\* Seedorf G, Nowlin T, Kim C, Bosco J, Keefe D, Abman SH. Anti-sFlt-1 monoclonal antibody therapy preserves lung alveolar and vascular growth in antenatal models of BPD. Am J Respir Crit Care Med, 197:776-87, 2018. (\*co-first authors).
11. Schafer M, Truong U, Browne LP, Morgan GJ, Ross M, Hunter KS, Kheyfats VO, Abman SH, Ivy DD, Wilson N. Measuring flow hemodynamic indices and oxygen consumption in chidren with pulmonary hypertension: comparison of catheterization and phase contrast MRI. Pediatr Cardiol. 39:268-74, 2018.
12. Kinsella JP, Steinhorn RH, Mullen MP,Hopper RK,Keller RL,Ivy DD, Austin ED, Krishnan US, Rosenzweig EB, Fineman JR,Everett AD, Hanna B,Humpl T, Raj JU,Feinstein JA, Abman SH;on Behalf of the Pediatric Pulmonary Hypertension Network (PPHNet). The Left Ventricle in Congenital Diaphragmatic Hernia: Implications for the Management of Pulmonary Hypertension. J Pediatrics, 197:17-22, 2018.
13. Travers CP, Abman SH, Carlo W. Cardioventilatory control in preterm born children and the risk of obstructive sleep apnea. Am J Respir Crit Care Med. 197:1518-20, 2018.
14. Cookson M, Ryan S, Seedorf G, Abman SH, Mandell EW. Antenatal vitamin D preserves placental vascular and fetal growth after intra-amniotic endotoxin exposure. Am J Perinatol, 35:1260-1270, 2018.
15. Collaco JM, Abman SH. Evolving challenges in pediatric pulmonary medicine: new opportunities to re-invigorate the field. Am J Respir Crit Care Med, 198:724-729, 2018.
16. McGraw MD, Sherlock LG, Bailey KL, Abman SH. Developmental origins of chronic lung disease: mechanical stretch, mi-RNAs and hydrogels. Am J Resp Mol Biol, 59:267-70, 2018.
17. Dodson RB, Powers KN, Gien J, Rozance P, Seedorg Astling GD, JonesK, CrombleholmeTM, AbmanSH, Alvira CM. Intrauterine growth restriction decreases nuclear factor-kappa B signaling in fetal pulmonary artery endothelial cells of fetal sheep. Am J Physiol. Lung. 315:L348-359, 2018.
18. Friesen RM, Schafer M, Ivy DD, Abman SH, Stenmark KR, Browne LP, Barker AJ, Hunter KS, Truong U. Proximal pulmonary vascular stiffness as a prognostic factor in children with pulmonar arterial hypertension. Eur Heart J Cardiovascular Imaging, 20:209-217, 2018.
19. Alvira C, Steinhorn R, Balistreri W, Finemen J, Oishi P, Padbury J, Kinsella JP, Abman SH. Enhancing the development and retention of physician-scientists in academic pediatrics: strategies for success. J Pediatr. 200:277-84, 2018.
20. Bush D, Galambos C, Ivy DD, Abman SH, Hickey F. Clinical Characteristics and Risk Factors for Developing Pulmonary Hypertension in Children with Down Syndrome. J Pediatr, 202:212-9, 2018.
21. Ehrmann DE, Mourani PM, Abman SH, Poindexter B, Morrow LA, Wagner B, diMaria MV. Echocardiographic measurements of right ventricular mechanics in infants with bronchopulmonary dysplasia at 36 weeks postmenstrual age. J Pediatr, 203:210-7, 2018.
22. Schäfer M, WilsonN, Ivy DD, Ing R, Abman S, Browne LP, MorganG, Ross M, McLennan D, Barker AJ, Fonseca B, Di Maria M, Hunter KS, Truong U.Non-invasive Wave Intensity Analysis Predicts Functional Worsening in Children with Pulmonary Arterial Hypertension, Am J Physiology: Heart Circ Physiol. 315:H968-977, 2018.
23. Mourani PM,\* Mandell EW,\* Younoszai A, Morrow LA, Wagner BD, Meier MA, Brinton JT, Poindexter BB, Abman SH. Early echocardiogram evidence of pulmonary vascular disease after preterm birth is assocated with respiratory outcomes during early childhood. Am J Respir Crit Care Med, 199:1499-1506, 2018. (\* co-first authors)
24. Abman SH, Maron B, Lovering AT. Pulmonary vascular disease across the life span: the need to link pediatric and adult cardiopulmonary research and care. Am J Respir Crit Care Med, 2018.

1. Galambos C, Bates ML, Bush D, Abman SH. Prominent bronchopulmonary vascular anastomoses in fatal childhood asthma. Ann ATS, 15:1359-62, 2018.
2. Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Haworth S, Ivy DD, Berger RM. Pediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir Journal, 2019.
3. Taglauer E, Abman SH, Keller R. Recent advances in antenatal factors predisposing to BPD. Sem in Perinatol. 42:413-24, 2018.
4. Pammi M, Lal CV, Wagner BD, Connett GJ, Mourani PM, Lohmann P, Lung RA, Sissons A, Shivanna B, Hollister EB, Abman SH, Versalovic J, Bhandari V, Ambalavanan N. Airway microbiome and development of bronchopulmonary dysplasia in preterm infants: a systematic review. J Pediatr, 204:126-133, 2019.
5. Hayes D, Wilson KC, Krivchenia K, Hawkins SMM, Balfour-Lynn IM, Gozal D, Panitch HB, Splaingard ML, Rhein LM, Kurland G, Abman SH, Hoffman TM, Carroll CL, Cataletto ME, Tumin D, Oren E, Martin RJ, Baker J, Porta GR, Kaley D, Gettys A, Deterding R, on behalf of the American Thoracic Society Assembly on Pediatrics. Home Oxygen Therapy for Children: An Official ATS Clinical Practice Guideline. Am J Respir Crit Care Med., 199:e5-e23, 2019.
6. Frank BS, Schafer M, Grenolds A, Ivy DD, Abman SH, Darst J. Acute vasoreactivity testing during cardiac catheterization in Infants with BPD-associated pulmonary hypertension. J Pediatrics208:127-133, 2019
7. Frank BS, Runciman M, Manning WA, Ivy DD, Abman SH, Howley L. Pulmonary hypertension secondary to scurvy in a developmentally typical child. J Pediatrics, 208:291,2019.
8. Galambos C, Mullen MP, Shieh JT, Schwerk N, Ullmann N, Boldrini R, Stucin-Gantar I, Haass C, Bansal M, Kielt MJ, Agrawal PB, Johnson J, Cutrera R, Griese M, Pauciulo M, Nichold W, Ivy DD, Abman SH, Austin ED, Olivier Danhaive. TBX4 Rare Genetic Variants Presenting as Neonatal Hypoxic Respiratory Failure and Severe Persistent Pulmonary Hypertension. Eur Respir J, 2019. (\* Awarded the Enid Gilbert Barness Prize by Society of Ped Path)
9. Galderisi A. Calabrese F, Fortarezza F, Abman S, Baraldi E. Airway pathology of adolescent BPD survivors. J Pediatr, 211:215-218, 2019.
10. Schafer M, Ivy DD, Abman SH, Stenmark KR, Browne L, Barker AJ, Mitchell MB, Morgan GJ, Wilson N, Shah A, Kolengode M, Naresh N, Fonseca B, DiMaria M, Buckner JK, Hunter, KS, Fenster BE, Truong U. Differences in pulmonary arterial flow hemodynamics between children and adults with pulmonary arterial hypertension as assessed by 4D-flow CMR Imaging. Am J Physiol Heart Circ Physiol, 310:H1091-1104, 2019.

1. Ong MS, Abman SH, Austin ED, Feinstein JA, Hopper RK, Krishnan US, Mullen MP, Natter MD, Raj UJ, Rosenzweig EB, Mandl K for the PPHNet and NHLBI Pediatric Pulmonary Vascular Disease Outcomes Bioinformatics Clinical Coordinating Center Investigators. Racial and ethnic differences in pediatric pulmonary hypertension: an analysis of the Pediatric Pulmonary Hypertension Network (PPHNet) Registry. J Pediatrics, 211:63-71, 2019.
2. Thebaud B, Laughon M, Whitsett J, Abman S, Steinhorn R, Aschner J, Davis P, McGrath-Morrow A, Goss KN, Soll R, Jobe A. Neonatal lung inury and bronchopulmonary dysplasia. Nat Rev Dis Primers, 2019.
3. Abman SH, Sun X. Mechanistic Insights into Lethal Lung Developmental Disorders: the Rare Informs the Common. Am J Respir Crit Care Med, 2019;200(9):1087–1089.
4. Bush D, Wolter-Warmerdam K, Wagner BD, Galambos C, Ivy DD, Abman SH, McMorrow D, Hickey F. Angiogenic profile identifies pulmonary hypertension in children with Down syndrome. Pulm Circulation, 2019.
5. Lakshminrusimha S, Kinsella J, Krishnan U, van Meurs K, Edwards E, Bhatt D, Chandrasekharanan P, Oei J-L, Manja V, Ramanathan R, Abman SH. Just say NO to iNO in preterms- Really? J Pediatrics, 2019.
6. Caicedo L, Hopper RK, Garcia H, Ivy DD, Haag D, Fineman J, Humpi T, Al-Tamimi O, Feinstein J, Berger RM, Berman-Rosenzweig E, Kashour T, Diaz GF, Mendoza A, Bobhate P, Handler S, Lopes AA, Barwad P, Kumar Rahit M, Krishnan U, Adatia ITK, Moledina S, Abman S, Cerro Marin MJD. Acute vasoreactivity testing in pediatric idiopathic pulmonary arterial hypertension: an international survey on current practice. Pulm Circ. 2019 May 30:2045894019857533.

1. Arjaans S,\* Wagner B,\* Mourani PM,\* Mandell E, Poindexter BB, Berger RMF, Abman SH. Early changes in circulating angiogenic biomarkers are associated with high risk for bronchopulmonary dysplasia and pulmonary hypertension in preterm infants. Am J Physiol: LCMP, 2019 (\* co-first authors)
2. Levy PT, Jain A, Nawaytou H, Teitel D, Keller K, SteinhornR, Abman SH, McNamara PJ,  for the Pediatric Pulmonary Hypertension Network. Risk Assessment and Monitoring of Chronic Pulmonary Hypertension in Premature Infants . J Pediatrics, 217:199-209, 2020.
3. Kim C, Seedorf G, Abman SH, Shepherd D. Heterogeneous response of endothelial cells to IGF-1 treatment is explained by spatially clustered sub-populations. Biol Open, 2019 Nov 4;8(11):bio045906. doi: 10.1242/bio.045906.
4. Geva A, Abman SH, Manzi SF, Ivy DD, Mullen MP, Griffin J, Lin C, Savova GK, Mandl KD. Detection of adverse drug events in pediatric pulmonary hypertension: natural language processing of clinical notes versus payor claims data. J Am Med Inform Association, 27:294-300, 2020.
5. Frank BS, Schäfer M, DouwesJM, Ivy DD, Abman SH, Burzlaff S, Mitchell MB,. MorganGJ, Browne LP, Barker AJ, Truong U, von Alvensleben JC. Novel Measures of Left Ventricular Electromechanical Dyssynchrony Predict Clinical Outcomes in Children with Pulmonary Arterial Hypertension. Am J Physiol Heart Circ Physiol, 2019.
6. Le Cras TD, Abman SH. Early Disruption of VEGF Receptor Signaling and the Risk for Adult Emphysema: A Response to the Letter to the Editor entitled “Emphysema is- at most- only a mild phenotype in the Sugen-hypoxia rat model of pulmonary arterial hypertension,” Am J Respir Crit Care Med, 2019.
7. Mandell EW, Ryan S, Seedorf G, Gonzalez T, Fleet J, Abman SH. Fetal vitamin D deficiency impairs lung structure and increases susceptibility to neonatal hyperoxia. Am J Resp Cell Mol Biol, In Press, 2020.
8. Mandell EW, Ryan S, Seedorf G, Gonzalez T, Abman SH, Fleet J. Maternal Vitamin D Deficiency Induces Transcriptomic Changes in Newborn Rat Lungs. Journal of Steroid Biochemistry and Molecular Biology, 63:79-91, 2020.
9. Polverino F, Hysinger EB, Gupta N, Olin T, Abman SH, Woods JC. Imaging the underlying pathologies of long-term BPD and early COPD. Am J Med, 133:757-60, 2020.
10. Seedorf G,\* Kim C,\* Wallace B, Nowlin T, Mandell E, Shepherd D, Abman SH. Recombinant human insulin-like growth factor-1/binding protein 3 enhances lung structure and prevents pulmonary hypertension in experimental models of bronchopulmonary dysplasia. *Am J Respir Crit Care Med.* 201:1120-34, 2020. (\* = co- first authors)
11. McKinney RL, Keszler M, Truog W, Norberg 4, Sindelar R, Wallström L, Schulman B, Gien J, Abman SH on behalf of the Bronchopulmonary Dysplasia Collaborative. Multicenter Experience with Neurally Adjusted Ventilatory Assist in Infants with Severe Bronchopulmonary Dysplasia. *Am J Perinatol*, In Press, 2020.
12. Maron BA, Maron JL, Abman SH. The case for bridging birthweight to adult medicine. *Am J Cardiology*, 127:191-2, 2020.
13. Galambos C, Wartchow E, Weinman JP, Abman SH. Pulmonary interstitial glygogenosis cells express mesenchymal stem cell markers. *Eur Resp J,* In Press, 2020.
14. Hirsch K, Taglauer E, Seedorf G, Callahan C, Mandell EW, White CW, Kourembanas S, Abman SH. Perinatal Stabilization of Hypoxia-Inducible Factor Preserves Lung Alveolar and Vascular Growth in Experimental BPD. *Am J Repir Crit Care Med*, 2020, doi: 10.1164/rccm.202003-0601OC.
15. Gaston B, Laguna T, Noah T, Hagood J,  Voynow J, Ferkol T, Hershenson M, Boyne K,   Delacaris A, Ross K, Gozal D, Celedon J, Abman S, Moore P, Davis S, Cornfield D, Murphy T. A Proposal for Addressing the needs of the pediatric pulmonoary work force. *Pediatric Pulmonology*, 55:1859-67, 2020.
16. Abman SH, Baker S, Bogue CW, Carlo W, Daniels SR, Debaun M, Fike C, Gordon CM, Leonard MD, Steinhorn RH, Walker-Harding LR, Davis S, Armstrong S, Chalak L, Frazer L, Gibson K, Gill M, Glass H, Goyal M, Hirschhorn J, Holtz L, Hunstad D, Maitre N, Markham L, McAllister-Lucas L, Orange J, Shah P, Simon T, Tarini B. The American Pediatric Society and Society for Pediatric Research Joint Statement Against Racism and Social Injustice. *Pediatric Resea*rch, In Press, 2020.
17. Abman SH, Bogue CW, Carlo W, Daniels SR, Debaun MR, Fike C, Gordon CM, Leonard MB, Steinhorn RH, Walker-Harding LR. Racism and social injustice as social determinants of child health: the American Pediatric Society Issue of the Year. *Pediatric Research*. In Press, 2020.
18. Abman SH, Davis S. American Pediatric Society and Society for Pediatric Research Virtual Chats: Challenges of Academic Pediatric Medicine. *Pediatr Research,* In Press, 2020.
19. Abman SH. Holistic promotion of scholarship and academic advancement. *Pediatric Research*. In Press, 2020.
20. Coker TR, Keller D, Davis S, Abman S. APS/SPR Virtual Chats: race, racism, and child health equity in academic pediatrics. *Pediatric Research*. In Press, 2020.
21. Duke JJ, Lewandowski A, Abman SH, Lovering AT. Physiologic aspects of cardiopulmonary sequelae and exercise in adults born preterm. *Am J Respir Crit Care Med*, Submitted.
22. GuamanMC, PishevarN, Abman SH, Keszler M, Truog WE, Nelin LD. Invasive Ventilation at 36 weeks Corrected Age is Associated with Poor Outcomes in Severe Bronchopulmonary Dysplasia. In Review.
23. Sindelar R, Shepherd EG, Agren J, Panitch HB, Abman SH, Nelin LD and the BPD Collaborative. Established Severe BPD- is there a way out? Change of ventilatory pardimgs and an inter-disciplinary approach. *Pediatric Research*. In Review.
24. Schafer M, Frank BS, Ivy DD, Abman SH, Stenmark KR, Mitchell MB, Browne LP, Barker AJ, Hunter KS, Kheyfets V, Miller-Reed K, Ing R, Morgan GH, Truong U. Inhaled NO improves immediated right ventricular flow hemodynamics in children with pulmoanry arterial hypertension: 4D-Flow MRI Study. *Circulation: Cardiovascular Imaging*, In review.
25. Pierro M, Villamor-Martinez E, Wetering-Kroon E, Alvarez-Fuente M, Abman SH, Villamor E. Association of the dysfunctional placentation phenotype of prematurity with BPD: A systematic review, meta-analysis and meta-regression. In review.
26. Mandell EW, Mattson C, Seedorf G, Ryan S, Gonzalez T, Allbank A, Bye EM, Abman SH, Smith B. Antenatal endotoxin exposure impairs lung mechanics and increases sensitivity to ventilator-induced lung injury in newborn rat pups. In Review.
27. Abman SH, Mullen M, Sleeper L, Austin ED, Rosenzweig EB, Kinsella JP, Ivy DD, Hopper R, Raj JU, Fineman J, Keller RL, Bates A, Krishnan U, Avitale K, Davidson A, Natter MD, Mandl KM. Characterization of Pediatric Pulmonary Hypertensive Vascular Disorders from the Pediatric Pulmonary Hypertension Network Registry. In Review.
28. NawaytouH, Fineman JR, Moledina S, Ivy DD, Abman SH, Del Cerro MJ. Practice Patterns of Pulmonary Hypertension Secondary to Left Heart Disease among Pediatric Pulmonary Hypertension Providers. In review.

**IN PREPARATION:**

1. Maron BA, Abman SH, Elliott CG, Frantz RP, Hopper RK, Horn WM, Nicolls MR, Shlobin OA, Shah SJ, Kovacs G, Olschewski H, Rosenzweig EB. The Dawn of Preventive Medicine in Pulmonary Arterial Hypertension. In review.
2. Mirza H, Mandell E, Kinsella HP, Abman SH. Pulmonary vascular phenotypes of prematurity. J Pediatrics, In preparation.
3. Varghese N, Handler S, Rosenzweig EB, Fineman J, Abman SH. Constitution of an optimal pediatric pulmonary hypertension center: consensus statement from the Pediatric Pulmonary Hypertension Network. In preparation.
4. Cornfield DN, Abman SH. The Pulmonary Vasculature in Development, Injury and Repair: a Summary of the 2019 Grover Conference. In Preparation.
5. DiMaria M, Morgan G, Abman SH, Galambos C. Prominent Intrapulmonary BronchopulmonaryAnastomoses in Children with Single Ventricle Heart Disease. In preparation.
6. Morrow LA, Wagner BD, Mourani PM, Abman SH. Longitudinal joint model of premature infant respiratory medication use and number of hospitalizations over the first two years of life. Inpreparation.

**REVIEW ARTICLES, CHAPTERS AND LETTERS:**

1. Koops BL, Abman SH, Accurso FJ. Outpatient management and follow-up of BPD. Clin Perinatal 11:101,1984.
2. Hammond KB, Reardon MC, Accurso FJ, Abman SH, Cotton EK, Pinney M, Fisher C, Sokol RJ, Ask CG, Watts DC, Bonner AM. The early detection of CF in newborns: The Colorado experience. In, Carter TP, Willey AM (eds), Genetic Disease: Screening and Management. NY:Alan R. Liss, Inc. pp 81-101,1986.
3. Abman SH. Pulmonary hypertension in infants with bronchopulmonary dysplasia: clinical aspects. In, Stocker JT, Bancalari E (eds), Bronchopulmonary Dysplasia. Washington: Hemisphere Publishing Corp, 1988, pp 220-236.
4. Accurso FJ, Reardon MC, Abman SH, Pinney M, Cotton E, Sokol R, Hammond K. Early abnormalities in infants with cystic fibrosis diagnosed through newborn screening. Insights in Pediatrics: Clinical Implications of Screening for Cystic Fibrosis in the Newborn. Proceedings of a meeting held in Peterborough, UK, June 1986,1:29-33,1987.
5. Abman SH. Aspen conference on bronchopulmonary dysplasia. Pediatric Pulmonology, 3:185-196, 1987.
6. Graham L, Abman SH. Management of upper airway foreign-body obstruction in young children. In, Barkin RM (ed), The Emergently III Child: Dilemmas in Assessment and Management. Maryland: Aspen Publishers, Inc., 1988.
7. Stenmark KR, Abman SH, Accurso FJ. Etiologic mechanisms in the pathogenesis of persistent pulmonary hypertension of the newborn. In, Pulmonary Vascular Physiology and Pathophysiology. Weir EK, Reeves JT (eds). New York: Marcel Dekker, pp 355-402, 1988.
8. Abman SH, Rosenberg AA, Lum GM. Management of hyponatremia in infants with bronchopulmonary dysplasia. J Pediatr, 113:789-980, 1988.
9. Accurso FJ, Helton J, Hammond K, Abman SH. Newborn screening for cystic fibrosis - Pro. Pediatric Pulmonology, (Supplement 2):51-53,1988.
10. Abman SH. The respiratory tract. In Handbook of Pediatrics, 16th edition. Merenstein GB, Kaplan DW, Rosenberg AA, (eds). San Mateo: Lange. 1991.
11. Larsen GL, Abman SH, Fan LL, White CW, Accurso FJ. The respiratory tract and mediastinum. In, Current Pediatric Diagnosis and Treatment, 10th Edition. Hathaway WE, Hay WW, Groothuis JR, Paisley JW (eds). San Mateo: Lange. 1991.
12. Hagedorn MI, Gardner SL, Abman SH. Respiratory disorders. In, The Handbook of Neonatal Intensive Care, 2nd edition. Merenstein GB, Gardner SL (eds). St. Louis: Mosby, 1989, pp 365-426.
13. Moores R, Abman SH. Bronchopulmonary Dysplasia: persistent cardiopulmonary sequelae of neonatal respiratory distress and its treatment. Sem. Resp Med. April 1990.

1. Sokol RJ, Accurso FS, Abman SH, Hammond KB. Do CF patients need fat-soluble vitamins? Peds Pulmonol. Suppl 4, 1989. Pp 63-65.
2. Abman SH, Sokol RJ, Accurso FJ. Hypoalbuminemia in young infants with CF. J Pediatr. 1990.
3. Sokol RJ, Accurso FJ, Abman SH, Hammond K, Stall C. Nutritional issues in cystic fibrosis. Pediatric Gastroenterology. Balistreri WF and VanderHoff JA (eds). NY: Chapman and Hall,1990 pp 273-295.
4. Abman SH, Sondheimer H. Pulmonary circulation and cardiovascular sequelae of bronchopulmonary dysplasia. In, Diagnosis and Treatment of Pulmonary Hypertension. Weir EK, Archer SL, Reeves JT (ed). pp. 155-180, 1992.
5. Larsen GL, Abman SH, Fan LL, White CW, Accurso FJ. The respiratory tract and mediastinum. In, Current Pediatric Diagnosis and Treatment,11th Edition. Hathaway WE, Hay WW, Groothuis JR, Paisley JW (eds). San Mateo: Lange. 1992.
6. Koff PB, Abman SH. Respiratory disease in children. In, Foundations of Respiratory Care. Kacmarek R, Pierson D(eds). PP 395-406, 1992.
7. Abman SH. Book Review: Pulmonary Circulation and acute lung injury (Said SI, ed). Pediatr Pulmonol, 13:189-190, 1992.
8. Abman SH. Respiratory tract. In, Handbook of Pediatrics, 17th Edition. Merenstein G, Kaplan D, Rosenberg A (eds) San Mateo: Lange. PP 511-536, 1994.
9. Hagedorn MI, Gardner SL, Abman SH. Respiratory Disorders. In, Handbook of Neonatal Intensive Care, 3rd Edition. Merenstein GB, Gardner SL(eds). St. Louis: Mosby, pp 311-364, 1993.
10. Abman SH, Cornfield DN, Kinsella JP. Role of endothelial-derived nitric oxide in perinatal pulmonary vasoregulation. In, Weir EK (ed) Role of ion flux in pulmonary vascular control. NY: Plenum, 1993.
11. Abman SH, Kinsella JP. Inhaled nitric oxide therapy in persistent pulmonary hypertension of the newborn. Neonatal Monitor. Issue #7, pp2-6, 1993.
12. Abman SH, Groothuis, JR. Pathophysiology and treatment of BPD: current issues. In, Pediatric Respiratory Medicine. Wilmott R(ed). Pediatric Clinics of North America. Philadelphia: WB Saunders. 41:277-315, 1994.
13. Roberts JD, Abman SH. Physiology of nitric oxide in the perinatal lung. In, New Treatments for Neonatal Respiratory Failure: A Physiologic Approach. Boynton BR, Carlo WA Jobe A (eds). PP:339-346, 1994.
14. Reeves JT, Kinsella, JP, Abman SH. Nitric Oxide in treatment of persistent pulmonary hypertension of the newborn. Seminars in Respiratory and Critical Care Medicine. 15:495-507, 1994.
15. Kinsella JP, Abman SH. Management of persistent pulmonary hypertension of the newborn. In, Gellis and Kegan's Current Pediatric Therapy, 15th edition. 1994.
16. Larsen GL, Abman SH, Fan LL, White CW, Accurso FJ. The respiratory tract and mediastinum. In, Current Pediatric Diagnosis and Treatment, 12th Edition. Hay WW, Groothuis JR, Hayward A. Levin M(eds). San Mateo: Lange. pp493-543, 1994.
17. Abman SH, Kinsella JP. Nitric oxide in the pathophysiology and treatment for neonatal pulmonary hypertension, Monographs in Neonatal Respiratory Disease, Volume 4, 2:1-11, 1994.
18. Kinsella JP, Abman SH. NO and bleeding time, reply. (letters) Pediatrics, Vol: 135, 1994.
19. Kinsella JP, Abman SH. Role of inhaled NO in PPHN. In, Acute Respiratory Care, Askin DK(ed). 1995.
20. Roberts JD, Kinsella JP, Abman SH. Inhaled nitric oxide in neonatal persistent pulmonary hypertension and severe RDS: experimental and clinical studies. Nitric Oxide in Lung Diseases, Zapol WM (ed). NY:Marcel Dekker, pp 333-364, 1996.
21. Abman SH. Cor pulmonale and pulmonary complications of cardiac abnormalities. In, Textbook of Pediatric Respiratory Medicine. Taussig LM, Landau LI (eds). Mosby. In Press, 1995.
22. Abman SH, Kinsella JP. Inhaled NO therapy of pulmonary hypertension and respiratory failure in premature and full term neonates. Adv Pharmacol, 34:457-474, 1995.
23. Ziegler JW, Ivy DD, Kinsella JP, Abman SH. Role of nitric oxide, endothelin, and prostaglandins in the transitional pulmonary circulation. Clin Perinatol, 22:387-404, 1995.
24. Abman SH, Kinsella JP. Nitric Oxide and the hypoxic newborn. Hypoxia and the Brain. Sutton JR, Houston CS, Coates G.(eds), Burlington: Queen City Printers, 211-223, 1995.
25. Abman SH. (Symposium Editor) Novel approaches to neonatal respiratory failure. J Perinatol, 16(2):51, 1996.
26. Mercier JC, DinhXuan AT, Abman SH. Persistent pulmonary hypertension of the newborn. In, Role of nitric oxide in sepsis and ARDS. Fink MD, Payen D (eds), Berlin: Springer, pp 355-379, 1995.
27. Abman SH. Inhaled NO Therapy of Severe Neonatal Pulmonary Hypertension. Acta Anaesthesiologica Scandinavia, 105:65-68, 1995.
28. Abman SH, Kinsella JP. Nitric oxide in the developing pulmonary circulation; experimental and clinical aspects. 4th Congress in Pediatric Emergency Medicine and Critical Care. 1995.
29. Villamor E, Halbower AC, Tuder RM, Moro M, Abman SH. Reduccion de la oxido nitrico sintetasa endotelial en la hipertension pulmonary experimental por compresion cronica intrauterina del ductus arteriosus. Proceedings of 15th National Congress of Perinatal Medicine, 1995.
30. Abman SH. Therapeutic use of nitric oxide in pediatric lung disease. Current Concepts in Pediatric Critical Care, 1996.
31. Ivy DD, Neish SH, Abman SH. Control of pulmonary circulation. In, Science and Practice of Pediatric Cardiology, 1996.
32. Reeves JT, Abman SH. NO as the perinatal endothelium-dependent relaxing factor. In, Pulmonary circulation: moving from passive to active control. Pinsky MR, Dhinaut, Arteggs (eds). Harcourt Brace, London. pp17-31, 1996.
33. Abman SH. Book Review: The pulmonary circulation and gas exchange. Pediatr Pulmonol., 1996.
34. Cornfield DN, Abman SH. Inhalational NO in pulmonary parenchymal and vascular diseases. Lab Clin Med, 1996.
35. Abman SH. Inhaled nitric oxide therapy in neonatal and pediatric cardiorespiratory disease. Update in Intensive Care and Emergency Medicine, (vol 25). Intensive care in childhood: A challenge to the future. Tibboel D, VanderVooot, E (ed5). Berlin: Springer, pp 322-336,1996.
36. Ivy DD, Wolfe RR, Abman SH. Pulmonary hypertension in children with congenital heart disease. Pulmonary Circulation: A Handbook for Clinicians. Peacock, AJ(ed). London: Chapman and Hall,pp 449-466,1996.
37. Kinsella JP, Abman SH. Persistent pulmonary hypertension of the newborn. Strategies in clinical management. Pulmonary Circulation: A Handbook for Clinicians. Peacock AJ(ed). London: Chapman and Hall, pp 437-448,1996.
38. Abman SH. Pulmonary hypertension in pediatrics: a brief overview. In, Pulmonary Circulation: A Handbook for Clinicians. Peacock AJ (ed). London: Chapman and Hall, pp 291-300,1996.
39. Reeves JT, Abman SH, Stenmark KR: Fetal lung circulation - a time of changes. In, Pulmonary Circulation: A Handbook for Clinicians. Peacock AJ(ed). London: Chapman and Hall,pp 291-300,1996.
40. Abman SH, Stevens T. Perinatal pulmonary vasoregulation: implications for the pathophysiology and treatment of neonatal pulmonary hypertension. In, Tissue Oxygen Deprivation: Developmental, Molecular and Integrative Function. Haddad G, Lister G. (eds). NY: Marcel Dekker, pp. 367-432, 1996.
41. Kinsella JP, Abman SH. Therapeutic and physiologic role of nitric oxide in the transitional pulmonary circulation. In, Nitric Oxide and Radicals in the Pulmonary Vasculature. Weir EK, Archer SL, Reeves JT(ed). Futura Publ.Co, pp 447-462, 1996.
42. Kirchner KK, Abman SH. Respiratory Tract. In, Handbook of Pediatrics, 18th edition. Merenstein GB, Kaplan DW, Rosenberg AA(ed). Stamford: Appleton & Lange, 485-510, 1997.
43. Kinsella JP, Abman SH. Role of Inhaled NO in PPHN. In, Acute Respiratory Care of the Neonate. Askin DF (ed). Petaluma: NICU Inc, 369-378, 1997.
44. Hagedorn MI, Gardner SL, Abman SH. Respiratory Disorders. In, Handbook of Neonatal Intensive Care, 4th edition. Merenstein G, Gardner S(eds). St. Louis: Mosby, 437-499, 1997.
45. Voelkel NF, Allard J, Abman SH. Is there a genetic susceptibility that may predispose patients to the development of ARDS. In, Pulmonary Edema. Weir EK, Reeves JT (eds). NY: Futura, 331-341, 1998.
46. Kinsella JP, Abman SH. Inhaled NO in the premature infant: animal models and clinical experince. Sem Perinatol, 21:418-428, 1997.
47. Kinsella JP, Abman SH. Controversies in the use of inhaled NO. Clin Perinatol, 25:203-217, 1998.
48. Abman SH. Role of inhaled NO in the treatment of neonatal pulmonary hypertension. Acta Pharmacologica Sinics, 18:537-556, 1997.
49. Abman SH, Kinsella JP. Role of inhaled NO in the hypoxemic neonate. Anesthesia Today, 1998.
50. Abman SH, Kinsella JP. Inhaled NO therapy of pulmonary disease in children. Curr Opin Pediatr, 1998.
51. Ivy DD, Neish SR, Abman SH. Regulation of the pulmonary circulation. In, Science and Practice of Pediatric Cardiology. Gaison A, Bricker TJ, Fisher DJ, Neish SR(ed). Baltimore: Williams and Wilkins, 1998, pp 329-348.
52. Kinsella JP, Neish SR, Abman SH, Wolf RR. Therapy for pulmonary hypertension. In, Science and Practice of Pediatric Cardiology. Gaison A, Bricker TJ, Fisher DJ, Neish SR (editors). Baltimore: Williams and Wilkins, 1998, 2345-2366.
53. Abman SH. New development in the pathogenesis and treatment of Persistent Pulmonary Hypertension of the Newborn. Pediatr Pulmonol, 1998.
54. Kins O, Kinsella JP, Abman SH. Pathways of thinking: Case studies in hypoxemic respiratory failure in the newborn (video program). Chicago, IL:Rainbow Productions International, 1998.
55. Kinsella JP, Clark R, Abman SH. Hypoxemic respiratory failure of the newborn (educational monograph), NJ: Triclinica, 1998.
56. Abman SH, Kinsella JP. Surfactant use in the term neonate with hypoxemic respiratory failure (letter). J Pediatr, 1998.
57. Abman SH, Kinsella JP, Parker TP, Storme L, Le Cras TD. Physiologic roles of nitric oxide in the perinatal pulmonary circulation. In, Weir EK, Archer SL, Reeves JT. Fetal and Neonatal Pulmonary Circulations, NY: Futura, pp. 239-260, 1999.
58. Ivy DD, Abman SH. Role of endothelin in perinatal pulmonary vasoregulation. In, Weir EK, Archer SL, Reeves JT. Fetal and Neonatal Pulmonary Circulations, NY: Futura, pp. 279-302, 1999.
59. Kinsella JP, Abman SH. Inhaled NO Therapy in the Newborn. Curr Opinion in Pediatrics, In Press, 1999.
60. Abman SH, Dobyns EL, Kinsella JP. Role of Inhaled NO in the treatment of acute hypoxemic respiratory failure in children. New Horizons. 1999.
61. Abman SH. Role of abnormal pulmonary vasoreactivity in persistent pulmonary hypertension of the newborn. Pediatr Reviews, 20(11): e103-9, 999.
62. Abman SH. Pulmonary Hypertension in chronic lung disease of infancy: pathogenesis, pathophysiology and treatment. In, Chronic Lung Disease of Early Infancy. Bland RD, Coalson JJ (eds) NY: Marcel Dekker, 1999, pp 619-668.
63. Abman SH, Kinsella JP, Mercier JC. Role of NO and endothelin in the developing lung circulation. In, Lung Development. Gaultier C, Post M (eds). NY:Oxford Press, 1999, pp. 196-220.
64. Abman SH. NO in Pediatric Lung Injury. Current concepts in pediatric critical care. Society for Critical Care Medicine, 2000.
65. Voelkel NF, Geraci MR, Abman SH. Future therapies for pulmonary hypertension. In Press, 2002.
66. Abman SH. Control of the fetal and neonatal pulmonary circulation. AHA Cardiopulmonary and Critical Care Newsletter,1:17-23, 2000.
67. Abman SH. Role of pulmonary vascular injury in the pathogenesis and pathophysiology of BPD. Biol Neonate, 2000.
68. Abman SH. Inhaled NO therapy. In, Rudolph’s Textbook of Pediatrics, 21st edition. In Press, 2002.
69. Kinsella JP, Abman SH. Inhaled NO therapy in the newborn. Sem Perinatol. In Press, 2002.
70. Abman SH, Kinsella JP. Is there a role for inhaled NO Therapy for Premature Newborns? Perspectives in Neonatology. Volume 2, Number 2, 2002. (Mosby Press).
71. Abman SH, Kinsella JP. Persistent Pulmonary Hypertension of the Newborn: pathogenesis and treatment. In, Greenough A, Milner AD (eds). Neonatal Respiratory Diseases, 2nd Edition. In press, 2003.
72. Kinsella JP, Abman SH. Inhaled NO Therapy. In, Mechanical Ventilation of the Newborn. Korotkin and Goldsmith (eds). 2003.
73. Abman SH. Perinatal Stress and the Risk for Chronic Obstructive Lung Disease in Adults. In, Chronic Obstructive Pulmonary Disease. Voelkel NF, MacNee W (eds). NY:Deckers, 2002.
74. Abman SH, Kinsella JP. Pulmonary hypertension of the newborn: strategies in clinical managment. In, The Pulmonary Circulation: Diseases and Treatment. Peacock AJ, Rubin L (eds). Second Edition, 2002.
75. Abman SH. Developmental physiology of the pulmonary circulation. In, The lung: development, aging and the environment. Harding R, Pinkerton K, Plopper C (eds). London: Academic Press, 2003.
76. Davis JM, Abman SH. Bronchopulmonary dysplasia. In, Spitzer AR et al. Neonatology, 2004.
77. Parker TA, Abman SH. Pulmonary Circulation in BPD. Bancalari, E (ed). Seminars in Neonatology. 208:51-62, 2003.
78. Hagedorn MI, Gardner SL, Abman SH. Respiratory Disorders. In, Handbook of Neonatal Intensive Care, 5th Edition. Merenstein G, Gardner S (eds). St. Louis: Mosby, 2002.
79. Abman SH, Steinhorn RH. Persistent pulmonary hypertension of the newborn: pathophysiology and treatment. In, Hypoxic Pulmonary Vasoconstriction: Cellular and Molecular Mechanisms. Yuan, J X-J (ed). In Press, 2004.
80. Abman SH, Kinsella JP. Inhaled ethyl nitrite gas for pulmonary hypertension in infants Lancet, 306:2076-7, 2002.
81. Abman SH. Vascular endothelial growth factor: not only for vessels anymore. Pediatr Res, 2002.
82. Abman SH. Neonatal pulmonary hypertension: a physiologic approach to treatment. Pediatr Pulmonol. 2004.
83. Abman SH. Role of NO in the pathophysiology and treatment of neonatal pulmonary hypertension. Jap Pediatr Anesth Assn. 2004.
84. Abman SH, Davis JM. Bronchopulmonary dysplasia. In, Kendig’s disorders of the respiratory tract in children, 7th edition. Chernick V, Boat T, Wilmott R, Bush A (eds). In press 2006.
85. Stenmark KR, Abman SH. Lung vascular development: implications for the pathogenesis of bronchopulmonary dysplasia. Ann Rev. Physiol. 67:623-61, 2005.
86. Hagedorn MI, Gardner SL, Abman SH. Respiratory Disorders. In, Handbook of Neonatal Intensive Care, 6th Edition. Merenstein G, Gardner S (eds). St. Louis: Mosby, 2005.
87. Kinsella JP, Ivy DD, Abman SH. Pulmonary vasodilator therapy in congenital diaphragmatic hernia: acute, late and chronic pulmonary hypertension. Sem Perinatol.

 29:123-8, 2005.

1. Kinsella JP, Abman SH. Inhaled NO therapy in children. Paediatr Resp Rev, 6:190-8, 2005.
2. Abman SH, Balasubramaniam V, Kinsella JP. Role of NO in the pathobiology of BPD. Biol Neonate, 2005.
3. Montgomery GS, Abman SH. Cardiovascular complications of sleep disordered breathing. In, Pediatric Sleep Disorders, Friedman and Richardson (eds), In Press.
4. Abman SH. NO-cGMP signaling in the pathogenesis and treatment of neonatal pulmonary hypertension: therapeutic basis for PDE5 inhibitors. In, PDE5 in Cardiovascular Disease; Butrous, Gohfrani, and Wilkins (eds), In Press, 2006.

105. Abman SH. Pulmonary Hypertension in Older Children: New Approaches and Therapies.Pediatr Pulmonol, In Press, 2006.

106. Abman SH. Fifty Years Ago in the Journal of Pediatrics. J Pediatr. 2006.

107. Abman SH. Persistent pulmonary hypertension of the newborn: pathophysiology and teatment. Advances in Pulmonary Hypertension, 2006.

108. Abman SH. Cor pulmonale and pulmonary complications of cardiac abnormalities. In, Taussig and Landau: Pediatric Respiratory Medicine. Clinical science and practice. 2nd edition, 2008.

109. Abman SH, Baker C, Balasubramaniam V. Growth and Development of the Lung Circulation: Mechanisms and Clinical Implications. In, Questions and Controversies in Neonatogy: Pulmonary Volume, Bancalari E (Ed), In press, 2007.

110. Abman SH. Recent advances in the pathobiology and treatment of persistent pulmonary hypertension of the newborn. Neonatology. 91:283-90, 2007.

111. Abman SH. The dysmorphic pulmonary circulation in bronchopulmonary dysplasia: a growing story. Am J Respir Crit Care Med, 2008.

112. Abman SH. Role of endothelin receptor antagonists in the treatment of pulmonary hypertension. Ann Rev Med, 60:5.1-5.11, 2009.

113. Abman SH, Mourani PM, Sontag M. Bronchopulmonary dysplasia: a genetic disease. Pediatrics, 122:658-9, 2008.

114. Tuder RM, Abman SH, Braun T, Capron F, Stevens T, Thisthlethwaite PA, Haworth SG. Development and pathology of pulmonary hypertension. J Amer Coll Cardiol. 54:S3-9, 2009.

1. Mourani PM, Mullen M, Abman SH. Pulmonary vascular disease in bronchopulmonary dysplasia. Progress in Pediatr Cardiol, In Press, 2009.
2. Abman SH. Knowns and unknowns of administering nitric oxide therapy in premature infants. NICHD Consensus Statement, 2010.
3. Mourani PM, Abman SH. Pulmonary vascular disease in BPD: physiology, diagnosis and treatment. In, Bronchopulmonary Dysplasia, Abman SH (ed), NY:Informa, 2010, pp: 347-63.
4. Abman SH. Impaired VEGF signaling in the pathogenesis of neonatal pulmonary vascular disease. In, Membrane Receptors, Channels and Transporters in the Pulmonary Circulation. Yuan J, Ward JPD (eds). NY: Springer, Adv Exp Med Biol. 661:323-35, 2010.
5. Abman SH. Pediatric pulmonary hypertension: an historical perspective. In, Proceedings of the Pediatric Cardiac Intensive Care Symposium, 11 (2 Suppl):S4-9, 2010.
6. Abman SH, Seinhorn RH. The normal fetal and neonatal pulmonary circulation. In, Textbook of Pulmonary Vascular Disease. Yuan JXJ, Garcia JGN, Hales CA, Rich S, Archer SL, West JBW(eds) NY: Springer, In Press, 2011.
7. Abman SH, Steinhorn RH, Aschner J. Persistent pulmonary hypertension of the newborn: pathophysology and treatment. In, Textbook of Pulmonary Vascular Disease. Yuan JXJ, Garcia JGN, Hales CA, Rich S, Archer SL, West JBW (eds). NY: Springer, In Press, 2011.
8. Abman SH, Steinhorn RH. Persistent pulmonary hypertension of the newborn: pathophysiology and treatment. In, Pulmonary Circulation: Diseases and Their Treatment, 3rd edition. Peacock A, Naieje R, Rubin L (eds). London:Health Sciences, 2011.
9. Abman SH, Steinhorn RH. Persistent pulmonary hypertension of the newborn. In, Avery’s Textbook of Neonatal Medicine. Gleason C (ed). 2011.
10. Abman SH. Persistent pulmonary hypertension of the newborn and congenital diaphragmatic hernia. In, Textbook of Neonatology, Buonocore G, Weindling M, Bracci R. London:Springer, 2011.
11. Abman SH, Kinsella JP, Steinhorn RH. Persistent pulmonary hypertension of the newborn. In, Pediatric Pulmonary Hypertension, Beghetti M (ed), 2011.
12. Abman SH. Bronchopulmonary Dysplasia. In, Kendig’s Pediatric Pulmonary Diseases, 2011.
13. Abman SH, Ivy DD. Recent Progress in Understanding and Treating Pediatric Pulmonary Hypertension. Curr Opin Pediatrics, 2011.
14. Abman SH, Nelin L. Management of Severe BPD. In, The Newborn Lung: Neoanatology Questions and Controversies, 2nd Edition, Bancalari E (ed), Philadelphia: Elsevier, 2012.
15. Abman SH. Approach to Pulmonary Hypertension in Premature Infants with BPD. Adv Pulmonary Hypertension, 2011.
16. Abman SH. Pulmonary vascular disease in BPD: evaluation and treatment. NeoReviews, 2011.
17. Abman SH. Inhaled NO Therapy. In, Handbook of Experimental Pharmacology: Pharmacotherapy of Pulmonary Hypertension. Humbert MA, Evgenov OV, Stasch JP (eds), 2013.
18. DiMaria M, Abman SH. Transition of the Neonatal Right Ventricle. In, The Right Ventricle in Health and Disease. Voelkel NF (ed), Springer Publications, in press, 2014.
19. Baker CD, Abman SH, Mourani PM. Pulmonary hypertension in preterm infants with BPD. Pediatric Allergy, Immunology and Pulmonology, 2014.
20. Abman SH, Dodson RB, Galambos C. Developmental physiology of the pulmonary circulation. In, Harding, Pinkerton, Plopper. The Lung: Development, Aging and Environment, 2nd edition, 2014.
21. Gien J, Abman SH, Baker CB. Interdisciplinary care for ventilator-dependent BPD. J Pediatr (letter), 2014.
22. Mandell E, Abman SH, Steinhorn RH. Persistent pulmonary hypertension of the newborn: pathophysiology and treatment. In, Pulmonary Circulation: Diseases and Their Treatment, 3rd edition. Peacock A, Naieje R, Rubin L (eds). London:Health Sciences, In Press, 2015.
23. Baker CD, Abman SH. Impaired vascular development in BPD. Neonatology, 2015.
24. Mourani PM, Abman SH. Pulmonary hypertension and vascular abnormalities in BPD. Clin Perinatol, 42:839-55, 2015.
25. Ivy DD, Abman SH. Beyond the six minute walk test for assessing pediatric pulmonary hypertension: making strides through combination endpoints. (editorial). Chest, 2015.
26. Abman SH, Ivy DD. Hospitalizations of children with pulmonary hypertension: implications for improving care (editorial). Pediatrics, 2015.
27. Abman SH, Mourani PM, Wagner B. Genomic insights into respiratory outcomes after preterm birth. Am J Respir Crit Care Med. In Press, 2015.
28. Abman SH. Charting the course of young children with CF. J Pediatr. 2015; in press.
29. Abman SH. Improving outcomes of pediatric pulmonary hypertension. *Pediatr Pulmonol*. In Press, 2016.
30. Abman SH. Pulmonary vascular disease in BPD. *Pediatr Pulmonol*. In Press, 2016.
31. Abman SH, Grenolds A, Mourani PM. Pulmonary vascular disease in BPD. *Adv Pulmonary Hypertension.* In press, 2016.
32. Abman SH. New guidelines for managing pulmonary hypertension: what the pediatrician needs to know. *Curr Opinion Pediatrics*. Bernstein D (ed), 2016
33. Steinhorn RH, Abman SH. Persistent pulmonary hypertension of the newborn. In, Avery’s Textbook of Neonatology. Gleason and Juul (eds). 2016.
34. Abman SH. Pulmonary hypertension in BPD. In, Respiratory Outcomes of Prematurity. Hibbs AM, Muhlebach M (eds). Springer, 2016.
35. Abman SH. BPD at 50 years: Introduction. J Pediatrics, 2017
36. Matthay M, Abman SH. Mesenchymal stromal cell therapy for the prevention of BPD: is it the Exosome? Am J Respir Crit Care Med. 2017.
37. Nelin L, Abman SH, Panitch HB. A Physiology-Based Approach to the Respiratory Care

#  of Children with Severe Bronchopulmonary Dysplasia. In, The Newborn Lung: Neonatology

#  Questions and Controversies, 2nd Edition, Bancalari E, Keszler M (eds), Philadelphia: Elsevier,

#  In press, 2018.

1. Kratimenos P, Mandell EW, Abman SH, Steinhorn RM. Drug therapy for the prevention and treatment of BPD. Clin Perinatol. 46:291-310, 2019.
2. Berman-Rosenzweig E, Abman SH, Berger RMF. Still puzzling about a clear definition of pulmonary arterial hypertension in newborns. Response from the authors. Eur Respir J. In press, 2019.
3. Bush D, Mandell EW, Abman SH, Baker C. Pulmonary hypertension and cardiac changes in BPD. *Bronchopulmonary Dysplasia,* Kallapur S, Pryhuber G (eds), In Press, 2019.
4. Jobe AH, Abman SH. Bronchopulmonary Dysplasia: a Continuum of Lung Disease from the Fetus to the Adult. Am J Respir Crit Care Med, In Press, 2019.
5. Gentle SJ, Abman SH, Ambalavanan N. Oxygen therapy and pulmonary hypertension in preerm infants. Clin Perinatol, 46;611-619, 2019.
6. Krishnan US, Krishnan SS, Abman SH. Reply (letter to editor), J Pediatr, 2019.
7. Abman SH, Galambos C. Pediatric Pulmonary Hypertension on the World Stage: Do We Need Separate Neonatal Guidelines? Advances in Pulmonary Hypertension, 2019.
8. Mallory G, Abman SH. The Many Challenges to the Field of Pediatric Pulmonology Posed by Pediatric Pulmonary Hypertension and the Path Forward. Pediatric Pulmonology, 2020.
9. Galambos C, Abman SH. Hypoxia and pulmonary arterial structure. In, Hypoxic Respiratory Failure in the Newborn – From Origins to Clinical Management. Dakshinamurti S, Milsom B, Lakshminrusima S, Abman SH, Chueng PY, McNamara P, Eds.Taylor & Francis Publishers *, Lung Biology in Health and Disease* series.
10. Geisinger R, Abman SH, Kinsella JP, McNamara P. Pulmonary hypertension phenotypes in the newborn. In, Hypoxic Respiratory Failure in the Newborn – From Origins to Clinical Management. Dakshinamurti S, Milsom B, Lakshminrusima S, Abman SH, Chueng PY, McNamara P, Eds.Taylor & Francis Publishers *, Lung Biology in Health and Disease* series.

### BOOKS AND MONOGRAPHS

1. Haddad G, Abman SH, Chernick V. *Basic Mechanisms of Pediatric Respiratory Disease*. *Second Edition.* Toronto: BC Decker, 2002.
2. Kinsella JP, Abman SH. *Hypoxemic Respiratory failure in the term newborn*. Bioscience Communications, 2003.
3. Polin R, Fox WW, Abman SH. *Fetal and Neonatal Physiology*, *Third Edition*, Philadelphia: Saunders, 2004.
4. Abman SH. *Bronchopulmonary Dysplasia*. NY:Informa, 2010.
5. Polin R, Fox WW, Abman SH. *Fetal and Neonatal Physiology: Clinical Correlates and Technology for the Future,* *Fourth Edition*, Philadelphia: Elsevier, 2011.
6. Jobe A, Whitsett J, Abman SH. *Fetal and Neonatal Lung Development*. London: Cambridge, 2016.
7. Polin R, Abman SH, Rowitch D, Benitz B. *Fetal and Neonatal Physiology, Fifth Edition*, Philadelphia: Elsevier, 2016.
8. Polin R, Abman SH, Rowitch D, Benitz B. *Fetal and Neonatal Physiology,* *Sixth Edition*, Philadelphia: Elsevier, in preparation, 2020.
9. Dakshinamurti S, Milsom B, Lakshminrusima S, Abman SH, Chueng PY, McNamara P. *Hypoxic Respiratory Failure in the Newborn- from Origins to Clinical Management*. In preparation, 2020.

**ABSTRACTS** (\* indicates selected for presentation)

1. Koops BL, Abman SH, Accurso FJ. Four years clinical experience with follow-up of neonates with bronchopulmonary dysplasia on home oxygen. Presented at the International Symposium on the Intensive Care of Children, Ljubljana, Yugoslavia, September, 1981. Jugoslavenska Pedijartija, vol 24,suppl 1, 1981.\*

2. Koops BL., Abman SH, Accurso FJ. Follow-up of premature infants with BPD, Pediatr Res 16;164A, 1981.\*

3. Abman SH, Accurso FJ, Koops BL. Relationship of growth to improvement in oxygenation in infants with BPD. Clin Res 30:139A,1982.

4. Abman SH, Wolfe RR, Accurso FJ, Koops BL, Wiggins JW. Pulmonary vascular reactivity in infants with severe BPD. Clin Res 31:102A, 1983. \*

5. Abman SH, Wolfe RR, Accurso FJ., Koops BL, Wiggins JW. Pulmonary vascular response to oxygen in infants with BPD. Pediatr Res 17:207A, 1983.

6. Abman SH, Wolfe RR, Accurso FJ, Bowman CM. Morbidity and mortality of protein calorie malnutrition in infants with CF. CF Club Abstracts 25:53, 1984.\*

7. Abman SH, Accurso FJ, Wilkening RB. Direct effects of tolazoline on fetal pulmonary blood flow. Clin Resp. 33:146A, 1985.\*

8. Abman SH, Accurso FJ, Ward RM, Wilkening RB. Adaptation of fetal pulmonary blood flow to local infusion of tolazoline. Pediatr Res 19:148A, 1985.\*

9. Abman SH, Wilkening RB, Accurso FJ. Temporal response of the fetal pulmonary circulation to local infusion of arachidonic acid and prostaglandins. Amer Rev Resp Dis 131:A255, 1985.\*

10. Abman SH, Accurso FJ, Wilkening RB, Meschia G. Persistent fetal pulmonary vasoconstriction following acute hypoxia. Clin Res 34:151A, 1986\* (and Pediatr Res 20:470A).\*

11. Accurso FJ, Abman SH, Wilkening RB, Worthen S, Henson PM. Exogenous platelet activating factor produces pulmonary vasodilatation in the ovine fetus. Amer Rev Resp Dis, 1986.\*

12. Stall C, Reardon MC, Hammond K, Abman SH, Sokol R, Accurso FJ. Fat malabsorption in infants with cystic fibrosis less than 3 months of age diagnose through newborn screening. CF Club Abstracts, Spring, 1986.\*

13. Abman SH, Schaffer MS, Wiggins JW, Washington R, Manco-Johnson M., Wolfe RR. Pulmonary vascular extraction of circulating norepinephrine in infants with BPD. Clin Res 35:202A, 1987 (and Pediatr Res 21:499A, 1987).\*

14. Abman SH H, Harbeck RJ, Butler-Simon NA, Reardon MC, Ogle JW, Accurso FJ. Early Pseudomonas aeruginosa (PA) colonization in young infants with cystic fibrosis (CF) identified by newborn screening. Pediatr Res 21:499A, 1987.\*

15. Accurso FJ, Abman SH, Wilkening RB. Desensitization of the fetal pulmonary circulation to vasodilator stimuli. Chest 93:184S, 1988.\*

16. Abman SH, Reardon MC, Harbeck RJ, Ogle JW, Butler-Simon N, Hammond KB, Accurso FJ. Early bacteriologic, immunologic and clinical courses of your infants with cystic fibrosis (CF) identified by newborn screening. North American Cystic Fibrosis Conference, Pediatr Pulmonol S1, 124, 1987.\*

17. Pinney MA, Abman SH, Accurso FJ. Reproductive decision-making in families of infants with cystic fibrosis (CF) diagnosed through newborn screening. North American Cystic Fibrosis Conference, Pediatr Pulmonol S1,142,1987.\*

18. Accurso FJ, Abman SH, Reardon MC, Stall CD, Pinney MA,Hammond KB, Sokol RJ. Prospective longitudinal evaluation of growth in young infants with cystic fibrosis diagnosed through newborn screening. North American Cystic Fibrosis Conference, Pediatr Pulmonol S1,138, 1987.\*

19. Abman SH, Accurso FJ. Acute effects of partial compression of the ductus arteriosus in pulmonary blood flow in the fetal lamb. Clin Res 36:238A, 1988\* (and Pediatr Res 23:560A, 1988).

20. Accurso FJ, Abman SH. Fetal pulmonary vascular responses to cyclic nucleotides, atrial natriuretic peptide (ANP), and sodium nitroprusside (SNP). Clin Res 36:239A\* and (Pediatr Res 23:561A, 1988)

21. Chatfield B, Abman SH, Stall C., Sokol R, Accurso F. Growth, fat malabsorption and nitrogen balance in young infants with cystic fibrosis. Clin Res 36:223A, 1988.

22. Burchell M, Abman SH, Rosenberg AA. Late unexpected deaths in infants with bronchopulmonary dysplasia. Clin Res 36:227A, 1988.

23. Abman SH, Shanley PF, Accurso FJ. Chronic intrauterine pulmonary hypertension alters perinatal pulmonary vasoreactivity and structure. Pediatr Res 23:561A, 1988.\*

24. Chatfield B, Abman SH, Hammond KB, Stall CD, Sokol RJ, Accurso FJ. Poor growth and steatorrhea in infants with cystic fibrosis (CF) under 3 months of age. Pediatr Res 23:300A, 1988.

25. Abman SH, Zapp LM, Stenmark KR. Perinatal lung eicosanoid content following chronic intrauterine pulmonary hypertension in the ovine lamb. Amer Rev Resp Dis.139:A175,1989.\*

26. Abman SH, Zapp LM, Stenmark KR. Effects of chronic intrauterine pulmonary hypertension on lung eiscosanoid content in newborn lamb. Clin Res 37:211A, 1989.\*

27. Accurso FJ, Abman SH, Hammond K. Newborn screening for cystic fibrosis: laboratory diagnosis and early clinical course. Amer Rev Resp Dis,139:A69,1989, and Pediatr Res, 25:363A, 1989.\*

28. Abman SH, Accurso FJ. Time-dependent effects of vasodilator stimuli on the pressure-flow relationship of the fetal pulmonary circulation. Pediatr Res, 1989\*

29. Accurso F, Hammond K, Helton J, Abman SH. Respiratory morbidity in neonates identified through newborn screening. Pediatr Pulmonol, 1989.\*

30. Abman SH, Chatfield BA, Rodman DM, Hall SL, McMurtry IF. Ontogeny of ovine pulmonary vascular responses to endothelium dependent and -independent dilators in vitro. The Physiologist, 1989.\*

31. Chatfield BA, McMurtry IF, O'Brien RF, Hall SL, Abman SH. In vitro and in vivo effects on endothelin-1 on the fetal pulmonary circulation. Amer Rev Resp Dis, A 483; 1990.\*

32. Abman SH, Chatfield BA, Rodman DM, Hall SL, McMurtry IF. Diminished endothelium-derived relaxant factor (EDRF) release by fetal pulmonary arteries in vitro. Pediatr Res, 26:351A;1990.\*

33. Chatfield BA, McMurtry IF, O'Brien RF, Hall SL, Abman SH. Fetal hemodynamic responses to intrapulmonary and systemic infusion of endothelin-1 (ET-1). Pediatr Res, 26:353A; 1990.\*

34. Abman SH, Chatfield BA, Hall SL, MCMurtry IF. Role of endothelium-derived relaxing factor (EDRF) in transition of the pulmonary circulation. Circ Res, 82(4):III-101,1990.\*

35. Rusakow L, Abman SH, Hammond K, Accurso F. Immunoreactive trypsin (IRT) in infants with cystic fibrosis (CF) complicated by meconium ileus (MI). Pediatr Pulmonol, 1990.\*

36. Cornfield D, Chatfield BA, McQueston JA, McMurtry IF, Abman SH. Effects of EDRF inhibition on birth-related stimuli in the ovine fetal lung. Pediatr Res, 29(4):312A, 1991.\*

37. Cornfield D, Chatfield BA, McMurtry IF, Abman SH. Effects of EDRF inhibition on the fetal pulmonary vascular response to partial compression of the ductus arteriosus. Pediatr Res, 29:311A, 1991.\*

38. Cornfield D, McQueston JA, Chatfield BA, Rodman DM, McMurtry IF, Abman SH. BRL34915, an ATP-sensitive potassium channel agonist, causes fetal pulmonary vasodilation. Pediatr Res, 29:58A,1991.\*

39. Mohon RT, Abman SH, Wagener JS, Accurso FJ. Pulmonary function bronchodilator responsiveness in asymptomatic infants with CF diagnosed through newborn screening. Amer Rev Resp Dis, 1991.\*

40. Sondheimer HM, Toews WH, Washington RL, Abman SH. Systemic to pulmonary collateral circulation in infants with bronchopulmonary dysplasia (BPD). Am Coll Cardiol, 1991.\*

41. Mohon RT, Wagener JS, Accurso FJ, Abman SH. Early pulmonary function and bronchodilator responsiveness in infants with cystic fibrosis (CF) diagnosed through newborn screening. Pediat Pulmonol, 1991.\*

42. Allen SW, Chatfield BA, Schaffer MS, Wiggins JW, Wolfe RR, Koppenhafer SL, Abman SH. Plasma endothelin levels and hemodynamic parameters in children with pulmonary hypertension during cardiac catheterization. Amer Coll Cardiol., 1992.\*

43. Kinsella JP, McQueston JA, Rosenberg A, Abman SH. Inhaled nitric oxide causes selective vasodilation of the transitional ovine pulmonary circulation. Clin Res, 40:36A, 1992.\*

44. McQueston JA, Cornfield DN, McMurtry IF, Abman SH. Role of endothelium-derived relaxing factor activity in 02 induced fetal pulmonary vasodilation. Clin Res, 40:8A, 1992.\*

45. Kinsella JP, McQueston JA, Rosenberg AA, Abman SH. Hemodynamic effects of exogenous nitric oxide on the immature transitional circulation. 8th Annual CNMC ECMO Symposium, Breckenridge, 1992.\*

46. Jones OW, Abman SH. Hemodynamic effects of proendothelin-1 and phosphoramidon in the late-gestational ovine fetus. Pediatr Res, 31:61A, 1992.\*

47. Allen SW, Chatfield BA, Koppenhafer SL, Schaffer MS, Wiggins JW, Abman SH. Circulating immunoreactive endothelin-1 and hypoxic pulmonary vasoconstriction in childhood pulmonary hypertension. Pediatr Res, 31:16A, 1992.\*

48. Kinsella JP, McQueston JA, Rosenberg AA, Abman SH. Inhaled nitric oxide causes selective and sustained vasodilation of the ovine transitional pulmonary circulation. Pediatr Res, 31:313A, 1992.\*

49. Cornfield DN, Rodman DM, Steven J, McMurtry IF, Abman SH. Hypoxia alters basal and stimulated cytosolic calcium in ovine fetal pulmonary artery smooth muscle cells. Pediatr Res, 31:304A, 1992.\*

50. McQueston JA, Cornfield DN, McMurtry IF, Abman SH. Role of EDRF in O2-induced fetal pulmonary vasodilation. Pediatr Res, 31:316A, 1992.\*

51. Kinsella JP, Abman SH. Sustained clinical improvement during treatment of persistent pulmonary hypertension of the newborn (PPHN) with low dose inhalational nitric oxide. European Respiratory Review, 1992. (Presented at the International Conference on Pulmonary Vasculature in Health and Disease, London, England, 1992). \*

52. Kinsella JP, Abman SH. Successful treatment of severe PPHN with low dose inhaled nitric oxide. CNMC ECMO Symposium, Keystone, Colorado, 1993.\*

53. Kinsella JP, Ivy DD, Abman SH. Maturational changes in endothelium-derived relaxing factor/nitric oxide (EDRF/NO) activity and responsiveness to inhaled NO in the developing pulmonary circulation. CNMC ECMO Symposium, Keystone, Colorado, 1993.\*

54. Ivy DD, Kinsella JP, Abman SH. BQ123, a selective endothelin-1 A receptor antagonist, causes fetal pulmonary vasodilation. CNMC ECMO Symposium, Keystone, Colorado, 1993.\*

55. McQueston JA, Kinsella JP, McMurtry IF, Abman SH. Changes in endothelium-dependent and -independent vasodilation during chronic intrauterine pulmonary hypertension in fetal lambs. CNMC ECMO Symposium, Keystone, Colorado, 1993.\*

56. Rosenberg AA, Kennaugh J, Loomis M, Abman SH. Elevated immunoreactive endothelin-1 in infants with PPHN. CMNC ECMO Symposium, Keystone, Colorado, 1993.\*

57. Kennaugh J, Kinsella J, Rosenberg A, Abman SH, Hernandez, J. Impact of new therapies for PPHN on ECMO. CMNC ECMO Symposium, Keystone, Colorado, 1993.\*

58. Halbower AC, Tuder RM, Pollack JS, Forstermann U, Horan MP, Abman SH. Maturation related changes in type III nitric oxide synthase peptide content and localization in the ovine perinatal lung. Pediatr Res, 1993.\*

59. McQueston JA, Kinsella JP, Ivy DD, McMurtry IF, Abman SH. Changes in endothelium-dependent and -independent vasodilation during chronic intrauterine pulmonary hypertension in fetal lambs. Pediatr Res, 1993.\*

60. Ivy DD, Kinsella JP, Abman SH. Characterization of endothelin A and B receptor activity in the ovine fetal pulmonary circulation. Pediatr Res, 1993.\* (Selected for 1993 Fellows Basic Science Award, SPR)

61. Kinsella JP, Abman SH. Clinical responses to prolonged treatment of persistent pulmonary hypertension of the newborn with low dose nitric oxide. Pediatr Res, 1993.\*

62. Kinsella JP, Ivy DD, Abman SH. Maturational changes in endothelium-derived nitric oxide (EDNO) activity and responsiveness to exogenous nitric oxide (NO) in the developing pulmonary circulation. Pediatr Res, 1993.\*

63. Cornfield DN, Stevens T, McMurtry IF, Abman SH, Rodman DM. Hypoxia-induced increase in fetal pulmonary artery smooth muscle cell [Ca]; is mediated by entry of Ca2+ through voltage - operated Ca2+ channels. Pediatr Res, 1993.\*

64. Rosenberg AA, Kennaugh J, Koppenhafer SL, Loomis M, Abman SH. Increased immunoreactive endothelin-1 levels in PPHN. Pediatr Res, 1993.\*

65. Kinsella J, Abman SH. Efficacy of inhalational nitric oxide therapy in the clinical management of persistent pulmonary hypertension of the newborn. 36th Annual Aspen Lung Conference, 1993.\*

66. Kinsella J, Ivy D, Abman SH. Maturational changes in endothelium-derived nitric oxide activity in the developing pulmonary circulation. 36th Annual Aspen Lung Conference, 1993.

67. Halbower A, Tuder R, Pollock J, Abman SH. Maturation-related changes in type III nitric oxide synthase protein immunolocalization in the ovine pulmonary circulation. 36th Annual Aspen Lung Conference, 1993.

68. Sokol RJ, Erskine J, Abman SH, Wagener J, Hammond K, Accurso F. Prospective study of fat-soluble vitamin status in 101 infants with CF identified by newborn screening. Seventh Annual North American CF Conference, 1993.\*

69. Ivy DD, Kinsella JP, Wolfe RR, Abman SH. Hemodynamic effects of atrial natriuretic peptide and inhaled nitric oxide in pediatric pulmonary hypertension. J Am Coll Cardiol, 1993. \*

70. Jones OW, Abman SH, Wilkening RB. Prolonged hypoxia increases plasma immunoreactive endothelin-1 levels in the ovine fetus. Soc Gynecol Invest, 1993.\*

71. Abman SH, Griebel J, Parker D, Schmidt J, Swanton D, Kinsella JP. Acute effects of inhaled nitric oxide in severe hypoxemic respiratory failure in pediatrics. IBC Conference on Nitric Oxide, 1994.

72. Ivy DD, Kinsella JP, Wolfe RR, Abman SH. Hemodynamic responses to atrial natriuretic peptide and inhaled nitric oxide in pediatric pulmonary hypertension. Pediatr Res, 35:36A, 1994.\*

73. LeFevour MF, Ivy DD, Kinsella JP, Abman SH. Endothelin-3 causes fetal pulmonary vasodilation. Pediatr Res, 35:86A, 1994.

74. Ivy DD, Kinsella JP, Abman SH. Role of endothelin in autoregulation of blood flow in the ovine fetal lung. Pediatr Res, 35:338A, 1994.\*

75. Abman SH, Griebel J, Parker D, Schmidt J, Swanton D, Kinsella JP. Acute effects of inhaled nitric oxide in severe hypoxemic respiratory failure in pediatrics. Pediatr Res, 35:48A, 1994.\*

76. Kinsella JP, Ivy DD, Abman SH. Inhaled NO improves gas exchange and lowers pulmonary vascular resistance in severe experimental hyaline membrane disease. Pediatr Res, 35:329A, 1994.\*

77. Ziegler J, Ivy D, Kinsella JP, Clarke W, Abman SH. Dipyridamole, a CGMP phosphodiesterase inhibitor, augments inhaled nitric oxide-induced pulmonary vasodilation during transition. Pediatr Res, 35:90A, 1994.\*

78. Cornfield DN, Stevens T, McMurtry IF, Abman SH, Rodman DM. Acute hypoxia causes membrane depolarization in fetal pulmonary artery smooth muscle cells. Pediatr Res, 35:329A, 1994.\*

79. Sokol RJ, Krebs NF, Bronstein MN, Stall CD, Abman SH, Hammond KB, Accurso FJ. Randomized trial of predigested formula vs standard infant formula in infants with CF identified by newborn screening. Pediatr Res, 35:136A, 1994.

80. Kennaugh JM, Moreland SG, Kinsella JP, Abman SH, Schafer EM, Rosenberg AA. Follow-up of infants with PPHN treated with inhaled NO. ECMO Conference, 1994.\*

81. Accurso FJ, Wagener JS, Abman SH, Sokol RJ, Carroll NM, Hammond KB. Growth and pulmonary function outcome in children with CF identified through newborn screening. 8th Annual North American CF Conference, 1994.\*

82. Ziegler JW, Fox JJ, Ivy DD, Kinsella JP, Abman SH. Potassium channel blockade does not inhibit inhaled nitric oxide-induced vasodilation in the ovine perinatal lung. Pediatr Res, 37:81A, 1995.\*

83. Kennaugh JM, Moreland SG, Fashaw, LM, Rosenberg AA, Kinsella JP, Abman SH. Neurodevelopmental and medical follow up of infants with PPHN treated with inhaled nitric oxide. Pediatr Res, 37:261A, 1995.\*

84. Ivy, DD, Ziegler JW, Fox JJ, Kinsella JP, Abman SH. Chronic intrauterine pulmonary hypertension alters endothelin receptor activity in the ovine fetus. Pediatr Res, 37:27A, 1995.\*

85. Ziegler JW, Ivy DD, Fox JJ, Kinsella JP, Clarke WR, Abman SH. Dipyridamole, a CGMP phosphodiesterase inhibitor, augments endothelium-dependent vasodilation in the ovine fetal lung. Pediatr Res, 37:38A, 1995.\*

86. Ziegler JW, Ivy DD, Fox JJ, Kinsella JP, Abman SH. Hemodynamic effects of CGMP phosphodiesterase inhibitors during chronic pulmonary hypertension in the ovine fetus. Pediatr Res, 37:38A, 1995.\*

87. Kinsella JP, Halbower AC, Ziegler JW, Fox JJ, Ivy DD, Abman SH. Low-dose inhaled nitric oxide improves gas exchange without increasing vascular permeability in experimental hyaline membrane disease. Pediatr Res, 37:337A, 1995.\*

88. Fox JJ, Ziegler JW, Kinsella JP, Ivy DD, Halbower AC, Abman SH. Role of nitric oxide (NO) -CGMP system in regulation of tone of the ovine ductus arteriosus. Pediatr Res, 37:76A, 1995.\*

89. Schmidt JM, Kinsella JP, Abman SH. Inhaled nitric oxide as an adjunct therapy when transporting critically ill infants and pediatrics. Snowbird Conference, 1995.\*

90. Torielli F, Ivy DD, Abman SH, Kinsella JP, Moreland S, Rosenberg AA, Valdez-Cruz L. Long-term echocardiographic follow-up of infants with PPHN after treatment with NO or HFOV. American Academy of Pediatrics Meeting, 1995.\*

91. Villamor E, Halbower AC, Tuder RM, Moro M, Abman SH. Reduccion de la oxido nitrico sistetasa endotelial en la hipertension pulmonary experimental por compression cronica intrauterina del ductus arteriosos. 15th National Congress of Perinatal Medicine, 1995.

92. Abman SH. Persistent pulmonary hypertension of the newborn: Mechanisms of abnormal pulmonary vasoreactivity. 7th European Congress on Pediatric, Surgical and Neonatal Intensive Care, 1995.

93. Abman SH. Persistent pulmonary hypertension of the newborn: Clinical management strategies. 7th European Congress on Pediatric, Surgical and Neonatal Intensive Care, 1995.

94. Villamor E, Horan M, Tuder RM, Halbower AC, Abman SH. Chronic intrauterine pulmonary hypertension impairs normal development of endothelial nitric oxide synthese protein and activity in the ovine fetus. Pediatr Res,39:354A, 1996.\*

95. Ivy DD, Parker TA, Ziegler JW, Galan HL, Kinsella JP, Abman SH. Prolonged endothelin A receptor blockade attenuates chronic intrauterine pulmonary hypertension. Pediatr Res,39:335A, 1996.\*

96. Hanson KA, Abman SH, Clarke WR. Elevation of pulmonary PDE5-specific activity in an experimental lamb model of perinatal pulmonary hypertension. Pediatr Res,39:334A, 1996.\*

97. Kinsella JP, Truog WE, Walsh WF, Goldberg RN, Bancalari E, Clark RH, Mayock DE, Redding GJ, DeLemos RA, Sardesai S, McCurnin DC, Yoder BA, Moreland SG, Cutter GR, Abman SH. Randomized multicenter trial of inhaled nitric oxide and high frequency oscillatory ventilation in persistent pulmonary hypertension of the newborn. Pediatr Res,39:354A, 1996.\*

98. Kinsella JP, Parker TA, Galan H, Ivy DD, Abman SH. High frequency oscillatory ventilation augments the response to inhaled nitric oxide in severe experimental hyaline membrane disease. Pediatr Res,39:336A, 1996.\*

99. Tajchman U, Horan M, Tuder R, Abman SH. Persistent endothelial NO synthase content in lung hypoplasia due to left pulmonary artery ligation in the ovine fetus. Pediatr Res,39:351A, 1996.\*

100. Parker TA, Kinsella JP, Abman SH. Relationship of baseline hypoxemia to the response to inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Pediatr Res,39:344A, 1996.\*

101. Torielli F, Moreland SG, Ivy DD, Abman SH, Kinsella JP, Rosenberg AA, Knudson D, Valdes-Cruz L. Long term echocardiographic follow-up of infants with severe PPHN. Pediatr Res,39:282A, 1996.\*

102. Ivy DD, Kinsella JP, Ziegler JW, Abman SH. Dipyridamole, a cGMP phosphodiesterase inhibitor, attenuates rebound pulmonary hypertension after withdrawal of inhaled nitric oxide in postoperative congenital heart disease. Pediatr Res,39:30A, 1996.\*

103. Dobyns E, Griebel J, Fashaw L, Kinsella JP, Abman SH, Accurso FJ. Follow-up pulmonary function in infants after inhaled nitric oxide treatment of persistent pulmonary hypertension. Pediatr Res,39:385A, 1996.

104. Ziegler JW, Ivy DD, Kinsella JP, Wiggins JW, Abman SH. Hemodynamic effects of dipyridamole and inhaled nitric oxide in patients with severe pulmonary hypertension. Pediatr Res,39:40A, 1996.\*

105. Ziegler JW, Ivy DD, Kinsella JP, Wiggins JW, Abman SH. Dipyridamole attenuates acute hypoxia-induced pulmonary hypertension. Pediatr Res,39:40A, 1996.\*

106. Cornfield DN, Tolarova S, Weir EK, Abman SH, Archer SL. Maturational changes in potassium channel activity of ovine pulmonary arteries in vitro. Circulation, 1996.\*

107. Tyler RC, Musamatsu M, Hepler LK, Abman SH, Stelzner TJ, Rodman DM, Bloch KD, McMurtry IF. Variability in endothelial NOS gene expression in hypoxic, monocrotaline and genetic models of pulmonary hypertension. Circulation (AHA Fall Meeting), 1996.\*

108. Pietra B, Ivy D, Sondheimer H, Luna M, Schneider K, Hall P, Campbell D, Fullerton D, Kinsella J, Abman SH, Boucek M. Use of postoperative pulmonary vasodilators for orthotopic heart transplant in hypoplastic left heart syndrome: inhaled NO and milrinone. Proceedings of the 3rd Loma Linda International Conference on Pediatric Heart and Lung Transplantation, 1996.\*

109. Hanson KA, Beavo JA, Abman SH, Clarke WC. Chronic intrauterine pulmonary hypertension increases lung cGMP hydrolytic activity and decreases cGMP kinase content in the ovine fetus. Am J Resp Crit Care Med, 1997 meeting.\*

110. Le Cras TD, Abman SH, Johns RA. Decreased expression of endothelial nitric oxide synthase protein in the lung of rat models with main and left branch pulmonary artery stenosis. Am J Resp Crit Care Med, 1997 meeting.\*

111. Le Cras TD, Tyler RD, Horan M, Morris K, McMurtry IF, Johns RA, Abman SH. Chronic hypoxia increases endothelial NO synthase expression despite reduced blood flow due to left pulmonary artery stenosis. FASEB Meeting, 1997.\*

112. White MM, Horan MP, Le Cras TD, Weiser M, Stenmark K, Abman SH, Perryman B, Moore LG. Pregnancy increases and chronic hypoxia decreases endothelial NO synthase protein expression in guinea pig uterine arteries. FASEB Meeting, 1997.\*

113. Kinsella JP, Parker TA, Sheridan BC, Abman SH. Effect of lung recruitment strategies on gas exchange and lung inflammation in severe experimental HMD. Pediatr Res, 41:257A, 1997.\*

114. Ivy DD, Kinsella JP, Parker TA, Abman SH. Endothelin receptor blockade decreases pulmonary vascular resistance in severe experimental HMD. Pediatr Res, 41:21A, 1997.\*

115. Ivy DD, Le Cras TD, Horan MP, Abman SH. Increased lung pre-proendothelin-1 mRNA and decreased endothelin B receptor mRNA expression after chronic pulmonary hypertension in the ovine fetus. Pediatr Res, 41:21A, 1997.\*

116. Best TH, Ivy DD, Kinsella JP, Fox JJ, Abman SH. Pulmonary vascular effects of selective cGMP-specific (Type V) phosphodiesterase inhibitors in the ovine fetus. Pediatr Res, 41:55A, 1997.\*

117. Rairigh RL, Ivy DD, Kinsella JP, Abman SH. Inducible nitric oxide synthase inhibitors increase pulmonary vascular resistance in the late gestation ovine fetus. Pediatr Res, 41:58A, 1997.\*

118. Le Cras TD, Tyler RC, Horan MP, Morris KG, McMurtry IF, Abman SH. Effects of chronic hypoxia and altered hemodynamics on pre-proendothelin-1 mRNA expression in the adult rat lung. Pediatr Res, 41:304A, 1997.\*

119. Parker TA, Kinsella JP, Galan HL, Abman SH. Pulmonary vascular effects of acute estradiol administration in the late gestation ovine fetus. Pediatr Res, 41:50A, 1997.\*

120. Parker TA, Ivy DD, Galan HL, Kinsella JP, Abman SH. Intrauterine treatment with estradiol improves hemodynamics and vascular remodeling in an ovine model of pulmonary hypertension. Pediatr Res, 41:264A, 1997.\*

121. Walsh WF, Kinsella JP, Truog WE, Abman SH. Response to inhaled nitric oxide and high frequency oscillatory ventilation in septic newborns with severe pulmonary hypertension. Pediatr Res, 41:272A, 1997.\*

122. Melton KR, Troug W, Kinsella JP, Abman SH. Do methemoglobin or PC02 predict responses to inhaled nitric oxide. Pediatr Res, 41:260A, 1997.\*

123. Ivy DD, Ziegler JW, Kinsella JP, Wiggins JW, Abman SH. Hemodynamic effects of dipyridamole and inhaled NO in pediatric patients with pulmonary hypertension. 40th Aspen Lung Conference, 1997.\*

124. Ivy DD, Le Cras TD, Horan MP, Abman SH. Chronic intrauterine pulmonary hypertension increases pre-proendothelin-1 and decreases endothelin B receptor mRNA expression in the ovine fetal lung. 40th Aspen Lung Conference, 1997.\*

125. Kinsella JP, Abman SH. Randomized multicenter trial of inhaled NO and high frequency oscillatory ventilation in severe PPHN of the newborn. 40th Aspen Lung Conference, 1997.\*

126. Le Cras TD, Tyler RC, Horan MP, Morris KG, McMurtry IF, Johns RA, Abman SH. Effects of chronic hypoxia and altered hemodynamics on endothelial NO synthase and pre-proendothelin-1 expression in the adult rat lung. 40th Aspen Lung Conference, 1997.\*

127. Parker TA, Galan H, Kinsella JP, Richter G, Horan MP, Abman SH. Chronic estradiol treatment causes a marked and sustained increase in pulmonary blood flow in the late gestation ovine fetus. 40th Aspen Lung Conference, 1997.\*

128. Hanson KA, Rybalkin SD, Beavo JA, Abman SH, Clarke WR. Differential control of pulmonary PDE1 isotypes in an experimental pulmonary hypertensive model. Am Soc Anesthesiol, 1997.\*

129. Abman SH. Controversies in the use of inhaled NO in the hypoxemic newborn. 2nd International Congress on NO in Cardiovascular Regulation, 1997.\*

130. Gothberg S, Parker TA, Abman SH, Kinsella JP. Effects of HFOV and partial liquid ventilation on gas exchange after acutelung injury in premature lambs. Am J Resp CCM, 1998.\*

131. LeCras TD, Richter G, Abman SH, McMurtry IF. Rapid decrease in lung prepro ET-1 mRNA in rats with chronic pulmonary hypertension after brief exposure to normoxia. Am J Resp CCM, 1998.\*

132. Galan HL, Parker TA, Horan M, LeCras TD, Kinsella JP, Abman SH. Comparison of endothelial NO synthase protein content in sheep cotyledon and caruncle. Soc Gyn Invest, 1998.\*

133. LeCras TD, Horan MP, Abman SH. Two mRNA transcripts for inducible (type II) NO synthase in fetal newborn and adult ovine lung. Pediatr Res, 1998.\*

134. Kim DH, LeCras TD, Horan MP, Tuder RM, Abman SH. Impaired developmental expression of lung endothelial NO synthase and abnormal alveolarization in the fawn hooded rat: implications for the risk of developing pulmonary hypertension. Pediatr Res, 1998.\*

135. Gothberg S, Parker TA, Abman SH, Kinsella JP. Rescue treatment with high frequency oscillatory ventilation and partial liquid ventilation after acute lung injury in premature lambs with RDS. Pediatr Res, 1998.\*

136. Ivy DD, LeCras TD, Horan MP, Abman SH. Developmental regulation of endothelin gene expression in the ovine lung. Pediatr Res, 1998.\*

137. Ivy DD, Griebel JL, Kinsella JP, Abman SH. Acute hemodynamic effects of prolonged delivery of low flow nasal NO in childrens with pulmonary hypertension. Pediatr Res, 1998.\*

138. Rairhig RL, Storme L, Parker TA, Abman SH. Selective type II (inducible) NO synthase antagonists attenuate shear stress-induced pulmonary vasodilation in the late gestation ovine fetus. Periatr Res, 1998.\*

139. Rairhig RL, Storme L, LeCras TD, Horan MP, Abman SH. Role of type 1 (neuronal) NO synthase in pulmonary vascular tone in the ovine fetus. Pediatr Res, 1998.\*

140. Storme L, Rairhig RL, Parker TA, Cornfield DN, Abman SH. Potassium channel blockade attenuates shear stress -induced pulmonary vasodilation. Pediatr Res, 1998. \*

141. Dobyns E, Anas NG, Cornfield DN, Fortenberry J, Tasker R, Deshpande J, Liu P, Eells PL, Griebel J, MacKenzie T, Kinsella JP, Abman SH. Multicenter randomized trial of the effects of inhaled NO therapy on gas exchange in children with acute hypoxemic respirator failure. Pediatr Res, 1998.\*

142. Parker TA, Kinsella JP, Galan HL, Richter G, Abman SH. Prolonged estradiol infusion causes a marked and sustained increase in pulmonary blood flow in fetal lambs. Pediatr Res, 1998.\*

143. Parker TA, Horan MP, LeCras TD, Kinsella JP, Abman SH. Developmental changes in lung endothelial NO synthase protein, activity and mRNA in lambs. Pediatr Res, 1998.\*

144. Galan HL, Horan M, LeCras TD, Tyson RW, Regnault TRH, Wilkening RB, Abman SH. Decreased endothelial NO synthase protein content in the cotyledon of the heat-stressed restricted ovine fetus. Pediatr Res, 1998.\*

145. Hanson KA, Abman SH. Differential control of phosphodiesterases during pulmonary fetal development. Pediatr Res, 1998.

146. Kinsella JP, Parker TA, Galan H, Sheridan BC, Abman SH. Independent and combined effects of inhaled NO, liquid perfluorochemical, and HFOV in premature lambs with RDS. Aspen Lung Meeting, 1998.\*

147. Richter GT, Le Cras TD, Gebbs S, Epting C, Jakkula M, Abman SH. Lung vascular endothelial growth factor expression in a rat model of lung hypoplasia and pulmonary hypertension. Clin Res, 1998.\*

148. Galan HL, Le Cras TD, Tyson RW, Regnault TRH, Jakkula M, Anthony RV, Wilkening RB, Abman SH. Heat stress reduces cotyledon endothelial NO synthase protein content in an ovine model of intrauterine growth restriction. Soc Gynecol Invest, 1998.\*

149. Dobyns EL, Eells PL, Griebel J, Abman SH. Elevated endothelin-1 levels in children with severe acute respiratory distress syndrome. Pediatr Res. 1999.

150. Rairigh RL, Grover TR, Kinsella JP, Abman SH. Aminoguanidine, a selective type II (inducible) nitric oxide synthase antagonist, attenuates vasodilation to birth-related stimuli in the ovine lung. Pediatr Res. 1999.

151. Grover TR, Le Cras TD, Ackerman KL, Jobe AH, Abman SH. Repetitive prenatal glucocorticoids increase endothelial NO synthase expression in ovine fetuses delivered at term. Pediatr Res. 1999.\*

152. Grover TR, Rairigh RL, Abman SH, Kinsell JP. Hemodynamic effects of exogenous (inhaled) carbon monoxide on the ovine transitional circulation. Pediatr Res. 1999.\*

153. Ivy DD, McMurtry IF, Yanagisawa M, Gariepy CE, Morris K, Abman SH. Exaggerated pulmonary vasoconstrictor response to acute hypoxia in the endothelin B receptor deficient rat. Pediatr Res. 1999. \*

154. Ivy DD, Parker TA, Abman SH. Prolonged endothelin B receptor blockade causes pulmonary hypertension in the ovine fetus. Pediatr Res. 1999.\*

155. Richter GT, Le Cras TD, Gebb S, Epting C, Jakkula M, Abman SH. Lung vascular endothelial growth factor expression in a rat model of lung hypoplasia and pulmonary hypertension. Pediatr Res. 1999. \*

156. Parker TA, Kinsella JP, Ivy DD, Abman SH. Pulmonary vascular effects of prolonged estrogen receptor blockade on birth-related stimuli in the fetal lamb. Pediatr Res. 1999.\*

157. Epting C, Le Cras TD, Richter GT, Markham N, Abman SH. Maturational changes in lung endothelin-1 expression during the development of pulmonary hypertension in the fawn-hooded rat. Pediatr Res. 1999.\*

158. Le Cras TD, Markham NE, Abman SH. Dexamethasone treatment decreases endothelial NO synthase and increases endothelin-1 expression in the developing rat lung. Pediatr Res. 1999.\*

159. Le Cras TD, Markham NE, Abman SH. Postnatal oxygen therapy attenuates the development of lung hypoplasia and pulmonary hypertension in the fawn-hooded rat. Pediatr Res. 1999.\*

160. Tang J-R, Le Cras TD, Jakkula M, Abman SH. Brief perinatal hypoxia increases the severity of pulmonary hypertension after re-exposure to hypoxia in infant rats. Pediatr Res. 1999.\*

161. Storme L, Rairhig RL, Parker TA, Kinsella JP, Abman SH. Chronic pulmonary hypertension abolishes flow-induced vasodilation and increases the myogenic response in the ovine fetal pulmonary circulation. Pediatr Res. 1999.\*

162. Gothberg S, Parker TA, Abman SH, Kinsella JP. Changes in thoracic volume in term and preterm lambs as measured with impedance plethysmography. Pediatr Res. 1999.\*

163. Jakkula M, Le Cras TD, Abman SH. Effects of fumagillin and thalidomide on alveolarization in the developing rat lung. Pediatr Res. 1999.\*

164. Cornfield DN, Resnik E, Herron J, Abman SH. Calcium-sensitive K+ channel expression is reduced in an ovine model of persistent pulmonary hypertension of the newborn. Pediatr Res. 1999.\*

165. Galan HL, Le Cras TD, Markham NE, Regnault TR, Anthony RV, Wilkening RB, Abman SH. Endothelial nitric oxide synthase protein content in uterine and umbilical vessels in the early gestation heat stress ovine model of intrauterine growth restriction. Pediatr Res. 1999.\*

166. Gebb S, Le Cras TD, Abman SH, Shannon JM. Dexamethasone stimulates epithelial and vascular maturation in cultured fetal rat lungs. FASEB. 1999 \*

167. Dobyns EL, Cornfield DN, Anas NG, Fortenberry JG, Tasker RC, Deshpande J, Liu P, Eells PL, Griebel J, Kinsella JP, Abman SH. Interactive effects of high frequency oscillatory ventilation and inhaled nitric oxide in acute respiratory failure in pediatrics. Crit Care Med, 1999.\*

168. Le Cras TD, Streeter M, Abman SH. Dexamethasone treatment reduces lung expression of PDGF a and ß receptors and the VEGF receptor KDR/flk-1 in newborn rats. FASEB. 1999.\*

169. Storme L, Rairigh RL, Parker TA, Kinsella JP, Abman SH. Calcium-channel blockade increases shear stress-induced pulmonary vasodilation and inhibits the myogenic response in the ovine fetus. Pediatr Res, 2000.\*

170. Rairigh RL, Parker TA, Kinsella JP, Abman SH. Inducible NO synthase activity contributes to pulmonary vasodilation at birth in the ovine fetus. Pediatr Res. 2000. \*

171. Zenge JP, Rairigh RL, Grover TR, Storme L, Parker TA, Kinsella JP, Abman SH. Separate and combined effects of cyclooxygenase and nitric oxide synthase inhibition on shear stress-induced pulmonary vasodilation in the ovine fetus. Pediatr Res. 2000.\*

172. Zenge JP, Grover TR, Abman SH. Nitric oxide contributes to prostacyclin induced pulmonary vasodilation in the ovine fetus. Pediatr Res. 2000.\*

173. Grover TR, Le Cras TD, Abman SH. Chronic intrauterine pulmonary hypertension decreases

 lung vascular endothelial growth factor expression in the ovine fetus. Pediatr Res. 2000.\*

174. Storme L, Rairigh RL, Parker TA, Kinsella JP, Abman SH. Calcium channel blockade inhibits the myogenic resonse in an experimental model of chronic pulmonary hypertension in the ovine fetus. Pediatr Res. 2000.\*

175. Balasubramaniam V, Le Cras TD, Abman SH. Chronic intrauterine pulmonary hypertension increases platelet-derived growth factor a- and ß- receptor protein content in the ovine fetal lung. Pediatr Res, 2000.\*

176. Parker TA, Afshar S, Shaul PW, Abman SH. Effects of estrogen and estrogen receptor blockade on lung cyclooxygenase and prostacylin synthase expression in fetal and neonatal lambs. Pediatr Res. 2000.\*

177. Parker TA, Zenge JP, Abman SH. Chronic estrogen receptor blockade abolishes flow-induced pulmonary vasodilation and unmasks the myogenic response in the ovine fetus. Pediatr Res. 2000.\*

178. Jakkula M, Le Cras TD, Gebb SA, Hirth KP, Tuder RM, Voelkel NF, Abman SH. Inhibition of the vascular endothelial growth factor KDR receptor decreases alveolarization and vascular growth in the developing rat lung. Pediatr Res. 2000.\*

179. Le Cras TD, Balasubramaniam V, Streeter M, Abman SH. Dexamethasone treatment reduces lung expression of PDGF a and ß receptors and the VEGF receptor KDR/flk-1 in newborn rats. Pediatr Res. 1999.\*

180. Le Cras TD, Markham NE, Abman SH. Dexamethasone treatment decreases lung tropo-elastin mRNA expression in the infant rat. Pediatr Res. 2000.\*

181. Gebb SA, Burbano S, Hirth KP, Tuder RM, Abman SH. Inhibition of the VEGF flk-1 receptor down-regulates endothelial nitric oxide synthase expression in the fetal rat lung *in vitro*. Pediatr Res. 2000.\*

182. Abman SH, Kinsella JP. Role of Inhaled NO in the Treatment of Neonatal Pulmonary Hypertension. NIH Workshop on Sickle Cell Disease, September, 2000.\*

183. Kinsella JP, Abman SH. Inhaled NO in Premature Newborns with RDS and BPD. NIH Workshop on Sickle Cell Disease, September 2000.\*

184. Abman SH. Role of inhaled NO in the treatment of premature newborns with severe RDS and chronic lung disease. Toronto Critical Care Symposium, 2000.\*

185. Kinsella JP, Wilkinson K, Le Cras TD, Markham NE, Abman SH. Inhaled NO preserves lung VEGF expression in preterm lambs with severe respiratory distress syndrome. Pediatr Res. 2001\*

186. Grover TR, Zenge J, Le Cras TD, Markham NE, Kinsella JP, Abman SH. Inhibition of VEGF downregulates endothelial NO synthase and impairs lung vascular growth in late gestation fetal lambs. Pediatr Res. 2001. \*

187. Le Cras TD, Jakkula M, Gebb S, Hirth PK, Tuder RM, Voelkel NF, Abman SH. Treatment of newborn rats with a VEGF receptor-2 antagonist reduces alveolarization, impairs vascular growth and causes pulmonary hypertension in adults. Pediatr Res. 2001. \*

188. Le Cras TD, Markham NE, Abman SH. Postnatal alveolarization is reduced in neonatal rats treated with PDGF receptor tyrosine kinase inhibitor AG1296. Pediatr Res. 2001. \*

189. Balasubramaniam V, Grover TR, Kinsella JP, Abman SH. Inhibition of platelet-derived growth factor-B improves vascular remodeling and right ventricular hypertrophy in perinatal pulmonary hypertension. Am J Resp Crit Care Med, 2002.\*

190. Grover TR, Zenge JP, Parker TA, Abman SH. Veascular endothelial growth factor causes pulmonary vasodilation through activation of the PI3-kinase-nitric oxide pathway in the late gestation ovine fetus. Pediatr. Res. 2002.\*

191. Grover TR, Parker TA, Zenge JP, Kinsella JP, Abman SH. Chronic intrauterine pulmonary hypertension decreases alveolarization in the late gestation ovine fetus. Pediatr. Res. 2002.\*

192. Zenge JP, Jones PL, Abman SH.. Exogenous Nitric Oxide (NO) Increases Vascular Endothelial Growth Factor Expression in Isolated Fetal Pulmonary Artery Smooth Muscle Cells. Pediatr Res. 2002.\*

193. Balasubramanium V, Tang J-R, Fagan K, Rodman DM, Abman SH. Mild Hypoxia Impairs Alveolarization in Endothelial Nitric Oxide Synthase Deficient Mice. Pediatr Res. 2002.\*

194. Parker TA, Kinsella JP, Abman SH. DIDS, an inhibitor of 20-HETE, inhibits the myogenic response in the fetal pulmonary circulation. Pediatr Res. 2002.\*

195. Kinsella JP, Parker TA, Davis JM, Abman SH. Recombinant human superoxide dismutase improves gas exchange in premature lambs with RDS. Pediatric Res. 2002.\*

196. Kinsella JP, Ivy DD, Abman SH. Non-invasive Inhaled NO therapy for Late Pulmonary Hypertension in Newborns with Congenital Diaphragmatic Hernia. Pediatr Res. 2002.\*

197. Ivy DD, Doran A, Parker D, Kinsella JP, Abman SH. Acute Hemodynamic Response to Pulsed NO Therapy in Children with Pulmonary Hypertension. Pediatr Res. 2002.\*

198. Abman SH. Pulmonary Circulation in BPD. Lung Injury in the Newborn, Keystone Symposium, 2002.\*

199. Deterding RR, Ivy D, Abman SH, Malcolm J, Coll J, Quinones R, Giller R. Pulmonary hypertension predicts mortality in pediatric allogeneic bone marrow transplantation. Am J Respir Crit Care Med (ATS Meeting) 2003 \*

200. Giller R, Quinones R, Ivy D, Abman S, Malcolm J, Coll J, Hild E, Deterding R. Pulmonary hypertension (PH) complicating allogeneic hematopoietic stem cell transplan (HSCT) in children and adolescents. \*

201. Abman SH. Role of nitric oxide in the regulation of vascular tone and growth in the perinatal pulmonary circulation. Perinatal Society of Australia and New Zealand. 2003.\*

202. Lin J-Y, Markham NE, Balasubramaniam V, Tang J-R, Kinsella JP, Abman SH. Inhaled nitric oxide therapy enhances distal lung growth after exposure to hyperoxia in neonatal rats. Pediatr Res. 2003.\*

203. Tang J-R, Markham NE, Lin Y-J, Kinsella JP, McMurtry IF, Abman SH. Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth after treatment with a VEGF receptor inhibitor in neonatal rats. Pediatr Res. 2003.\*

204. Balasubramaniam V, Majka S, Maxey A, Abman SH. Inhibition of nitric oxide synthase decreases basal and VEGF-induced angiogenesis in fetal pulmonary arterial endothelial cells in vitro. Pediatr Res. 2003.\*

205. Rosenzweig EB, Ivy DD, Widlitz DC, Doran AK, Claussen LR, Yung D, Abman SH. Barst RJ. Effects of long-term bosentan in children with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004.\*

206. Mourani P, Ivy DD, Gao D, Abman SH. Pulmonary vasoreactivity in older children and adolescents with bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2004.\*

207. Balasubramaniam VB, Maxey AM, Markham NE, Abman SH. Inhaled NO reverses hypoxia-induced lung hypoplasia in endothelial NO synthase deficient mice. Am J Respir Crit Care Med. 2004.\*

208. Balasubramaniam VB, Maxey AM, Markham NE, Abman SH. Inhibition of NO synthase during hypoxia decreases fetal pulmonary arterial endothelial cell proliferation and tube formation in vitro. Am J Respir Crit Care Med. 2004.\*

209. Grover TR, Parker TA, Abman SH. Treatment with vascular endothelial growth factor improves pulmonary vascular reactivity and structure in an experimental model of chronic pulmonary hypertension in fetal sheep. Pediatr Res. 2004.\*

210. Parker TA, Roe GA, Grover TR, Hunt-Peacock C, Kinsella JP, Abman SH. Rho kinase activition maintains high pulmonary vascular resistance in late gestation fetal sheep. Pediatr Res. 2004.\*

211. Balasubramaniam VB, Maxey AM, Majka SM, Markham NE, Abman SH. NO synthase inhibition during hypoxia decreases fetal pulmonary artery endothelial cell growth and function in vitro. Pediatr Res. 2004.\*

212. Balasubramaniam VB, Maxey AM, Markham NE, Abman SH. Inhaled NO reverses neonatal hypoxia-induced lung hypoplasia in endothelial NOS deficient mice. Pediatric Res. 2004.\*

214. Grover TR, Parker TA, Abman SH. VEGF improves pulmonary vasoreactivity and structure in an experimental model of chronic pulmonary hypertension in fetal sheep. Aspen Lung Conference. 2004.\*

215. Balasubramaniam V, Maxey A, Abman SH. Inhaled NO reverses hypoxia-induced lung hypoplasia in eNOS deficient mice. Aspen Lung Conference, 2004.\*

216. Kunig A, Balasubramaniam V, Markham N, Montgomery G, Grover T, Abman S. Recombinant human VEGF treatment enhances alveolarization during recovery after hyperoxic lung injury in neonatal rats. International Conference on Lung Development, 2004.\*

217. Deruelle P, Grover TR, Storme L, Abman SH. Bay 41-2272, a soluble guanlyate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus. Pediatric Research. 2005.\*

218. Deruelle P, Grover TR, Hunt-Peacock C, Abman SH. Pulmonary vascular effects of Bay 41-2272, a direct soluble guanlyate cyclase activator, in a model of severe pulmonary hypertension in fetal sheep. Pediatric Research. 2005.\*

219. Parker TA, Roe GB, Groer TR, Abman SH. Rho-kinase inhibition causes pulmonary vasodilation in experimental PPHN. Pediatric Research. 2005.\*

220. Kunig A, Balasubramaniam V, Seedorf G, Markham N, Gien J, Abman SH. Recombinant human VEGF treatment increases edema during early acute lung injury, but enhances alveolarization during recovery after hyperoxia in neonatal rats. Pediatric Research, 2005.\*

221. Kunig A, Balasubramaniam V, Markham N, Montgomery G, Grover T, Abman S. Recombinant human VEGF treatment enhances alveolarization during recovery after hyperoxic lung injury in neonatal rats. Clin Res, 2005 (selected for the *AstraZeneca Cardiovascular Scholar Award*).\*

222. Vaughn RC, Abman SH, Balasubramaniam V, Markham N, Maxey A. Disruption of VEGF signaling causes pulmonary hypertension and decreased lung growth in the newborn but not adult rat. Clin Res, 2005 (selected for the *WAFMR/WSCI Subspecialty Award*).\*

223. Gien J, Seedorf G, Balasubramaniam V, Abman SH. Chronic intrauterine pulmonary hypertension impairs angiogenesis and growth of ovine fetal pulmonary artery endothelial cells in vitro. Pediatr Res, 2006. (PAS national meeting)\*

224. Balasubrmaniam V, Mervis CF, Maxey AM, Markham NE, Abman SH. Hyperoxia decreases endothelial progenitor cells and impairs lung growth in neonatal mice. Pediatr. Res, 2006. (PAS national meeting)\*

225. Deruelle P, Balasubramanuam V, Kunig AM, Seedorf G, Markham NE, Abman SH. Bay 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and improves pulmonary vascular structure during chronic hypoxia in neonatal rats. Pediatr. Res, 2006. (PAS national meeting).\*

226. Grover TR, Aiskainen TM, Abman SH. White CW. Hypoxia inducible factor (HIF)-1 alpha and HIF-2 alpha are decreased in an experimental model of severe RDS in extremely preterm neonatal lambs. Pediatr. Res., 2006. (PAS national meeting).\*

227. Balasubramaniam V, Maxey AM, Markham NE, Abman SH. Increased susceptibility of eNOS -/- mice for impaired alveolar growth after mild neonatal hyperoxia. Pediatr Res. 2006. (PAS national meeting).\*

228. Kinsella JP, Cutter GR, Walsh WF, Gerstmann DR, Bose CL, Hart C, Sekar KC, Auten RL, Bhutani VK, Gerdes JS, George TN, Southgate WM, Carriedo H, Couser RJ, Mammel MC, Hall DC, Pappagallo M, Sardesai S, Strain JD, Baier M, Abman SH. Early Inhaled NO in Premature Newborns with Respiratory Failure. Pediatr Res., 2006. (PAS national meeting).\*

229. Ivy DD, Doran A, Claussen L, Smith K, Mallory G, Abman SH. Acute and chronic effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. Chest. 2006.\*

230. Parker TA, Grover TR, Gien J, Abman SH. Rho-kinase regulates pulmonary vascular tone in the normal and hypertensive fetal lung. American Heart Association Grover Conference, 2006.\*

231. Tang J-R, Seedorf G, Balasubramaniam V, Maxey A, Markham N, Abman SH. Early inhaled nitric oxide treatment decreases apoptosis in the neonatal rat lung after vascular endothelial growth factor receptor inhibition. Pediatr Res, 2007.\*

232. Gien J, Seedorf G, Markham N, Parker TA, Balasubramaniam V, Abman SH. Y-27362, a rho kinase inhibitor, upregulates endothelial nitric oxide synthase expression and increases tube formation by fetal pulmonary artery endothelial cells from normal sheep and a model of persistent pulmonary hypertension of the newborn. Pediatr. Res. 2007.\*

233. Seedorf G, Gien J, Balasubramaniam V, Abman SH. Co-culture of fetal ovine alveolar type II cells with lung mesenchymal cells enhances responsiveness to VEGF. Pediatr Res. 2007.\*

234. Mourani PM, Sontag MK, Ivy DD, Abman SH. Utility of Echocardiograms in the Evaluation of Pulmonary Hypertension in Infants with Chronic Lung Disease. Pediatr Res. 2007.\*

235. Kunig A, Muhlethaler V, BalasubramaniamV, Seedorf G, Abman SH. Nitric Oxide improves lung structure after nitrofen exposure in rat fetal lung explants. Pediatr Res. 2007.\*

236. Beghetti M, Doran AK, Mallory G, Barst RJ, Law Y, Abman SH, Ivy DD. Inhaled iloprost therapy in children with pulmonary arterial hypertension. AECP meeting. 2007.\*

237. Balasubramaniam V, Ryan SL, Seedorf GJ, Markham N, Yoder M, Abman SH. A novel population of bone marrow cells restores lung structure after neonatal hyperoxia in mice. Am J Respir Crit Care Med, 2008.\*

238. Baker CD, Ryan SL, Seedorf GJ, Heumann TR, Ingram DA, Abman SH, Balasubramaniam V. Cord blood endothelial progenitor cells (EPCs) from preterm infants are increased in number and more susceptible to hyperoxia than term EPCs. Am J Respir Crit Care Med, 2008.\*

239. Chester MA, Grover TR, Abman SH. BAY 58-2667, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus. Am J Respir Crit Care Med, 2008.\*

240. Baker CD, Ryan SL, Seedorf GJ, Heumann TR, Ingram DA, Abman SH, Balasubramaniam V. Oxidative Stress Decreases the In Vitro Growth Potential of Umbilical Cord Blood Derived Endothelial Progenitor Cells (EPCs) from Preterm Neonates. Pediatr Res, 2008.\*

241. Muehlethaler V, Seedorf GJ, Balasubramaniam V,Abman SH. Superoxide dismutase improves lung structure after nitrofen exposure in rat fetal lung explants. Pediatr Res, 2008.\*

242. Mourani PM, Sontag M, Lui G, Ivy DD, Abman SH. Sildenafil therapy for pulmonary hypertension in infants with chronic lung disease. Pediatr Res., 2008.\*

243. Abman SH. Impaired NO-cGMP signaling in neonatal pulmonary hypertension: novel mechanisms and treatments,” Proceeding of the 5th International Conference on Nitric Oxide, Bergenz, Austria, Nitric Oxide, 2008.\*

244. Abman SH. Recent advances in the pathogenesis and treatment of PPHN. Reason 2008.\*

1. Gunville CF, Stratton KA, Ranade DJ, Sontag MK, Abman SH, Mourani PM. The scope and impact of early and late preterm infants admitted to the PICU with respiratory illness. Am J Respir Crit Care Med, 2009.\*
2. Balasubramaniam V, Roth EV, Seedorf G, Ryan S, Abman SH. A bone marrow progenitor cell enhances mouse alveolar type II cell growth in vitro. Am J Respir Crit Care Med, 2009.\*
3. Kinsella JP, Cutter GR, Walsh WF, Gerstmann DR, Bose Cl, Hart C, Sekar KC, Auten RL, Gerdes JS, George TN, Southgate WM, Carriedo H, Couser RJ, Mammel MC, Hall DC, Pappagallo M, Sardesai S, Abman SH . Outcomes of Premature Infants Enrolled in the Early Inhaled Nitric Oxide for the Prevention of Chronic Lung Disease Trial. Pediatric Academic Societies, 2009.
4. Tourneux P, Markham N, Seedorf G, Balasubramaniam V, Abman SH. Effects of Inhaled Nitric Oxide on Lung Structure in Experimental Bronchopulmonary Dysplasia Induced by Bleomycin Treatment of Neonatal Rats. Pediatric Academic Societies, 2009.
5. Seedorf G, Balasubramaniam V, Markham N, Abman SH. Mesenchymal–derived Hepatocyte Growth Factor Mediates the Effects of Vascular Endothelial Growth Factor on Fetal Alveolar Type II Cells during Co-Culture in vitro, Pediatric Academic Societies, 2009.\*
6. Chester MA, Seedorf G, Gien J, Abman SH. BAY 58-2667, a soluble guanylate cyclase activator, augments cGMP production in fetal pulmonary artery smooth muscle cells from normal sheep and in experimental PPHN. Pediatric Academic Societies, 2009.\*
7. Rozance PJ, Seedorf G, Gien J, Abman SH. Pulmonary artery endothelial cell dysfunction and impaired insulin responsiveness in fetal sheep with intrauterine growth restriction. Pediatric Academic Societies, 2009.\*
8. Delaney C, Grover TR, Abman SH. Serotonin causes potent vasoconstriction in the pulmonary circulation of the late gestation ovine fetus. Pediatric Academic Societies, 2009.\*
9. Gien J, Seedorf GJ, Markham N, Tseng N, Abman SH.Endothelin-1-Rho-kinase Interactions Impair Angiogenesis in Fetal Pulmonary Artery Endothelial Cells (PAECs) after Chronic Intrauterine Pulmonary Hypertension, Pediatric Academic Societies, 2009.\*
10. Gien J, Tseng N, Abman SH. Chronic Intrauterine Pulmonary Hypertension Increases Rho-kinase Activity and Proliferation of Ovine Fetal Pulmonary Artery Smooth Muscle Cells *in vitro.* Pediatric Academic Societies, 2009.\*
11. Rock R,Meuhlethaler V, Kunig A, Balasubramaniam V, Abman SH.VEGF Improves Lung Structure in Fetal Lung Explants and After Neonatal Hyperoxia in Mice Genetically Deficient for Endothelial Nitric Oxide Synthase (eNOS). Pediatric Academic Societies, 2009. \*

.

1. Tang JR, Seedorf GJ, Meuhlethaler V, Walker DL, Markham N, Balasubramaniam V, Abman SH. Postnatal Hyperoxia Enhances Alveolarization in Infant Rats Exposed to Antenatal Endotoxin. Pediatric Academic Societies, 2009.\*
2. Balasubramaniam V, Roth EV, Ryan SL, Seedorf GJ, Abman SH. A novel population of bone marrow cells enhances mouse alveolar type II cell growth in vitro. Pediatric Academic Societies, 2009.\*
3. Fujinaga H, Baker CD, Ryan SL, Seedorf GJ, Balasubramaniam V, Abman SH. Exogenous VEGF increases the in vitro growth potential of umbilical cord blood derived endothelial progenitor cells from preterm neonates in mild hyperoxia. Pediatric Academic Societies, 2009.\*
4. Abman SH. Impaired NO-cGMP signaling in the pathogenesis of neonatal pulmonary hypertension and therapeutic implications. 4th International Conference on cGMP Generators, Effectors and Therapeutic Implications. Regensburg, Germany, 2009.\*
5. Sagel SD, Monchill L, Parker D, Emmet P, Wagner B, Abman S. Safety and antimicrobial effects of inaled nitric oxide in cystic fibrosis: a pilot study. North American CF Conference, 2009.\*
6. Rose B, Jung J, Faroud T, Ingram D, Murray J, Dagle J, Abman S, Mourani P, Poindexter B. Bronchopulmonary dysplasia and polymorphisms of pulmonary vascular genes. Midwest Society for Pediatric Research, 2009.\*
7. Abman SH, Cornfield DN. Crafting Successful Clinician-Scientists in Child Health Research. Pediatric Academic Societies, 2010.\*
8. Roth EV, Seedorf GS, Ryan SL, Abman SH, Balasubramaniam V. Bone marrow derived progenitor cells enhance mouse alveolar type II cell growth and differentiation in vitro. American Thoracic Society International Conference, 2010.\*
9. Baker CD, Mourani PM, Sontag MK, Balasubramaniam V, Roth EM, Ryan SL, Ingram DA, Abman SH. Early decreased peripheral blood progenitor cell levels in preterm newborns are associated with development of moderate to severe BPD. American Thoracic Society International Conference, 2010.\*
10. Mourani PM, Sontag MK, Kerby GS, Fashaw L, Abman SH. Persistent impairment of lung function during infancy correlates with the severity of bronchopulmonary dysplasia at diagnosis. American Thoracic Society International Conference, 2010.\*
11. Wright RH, Tang JR, van Rheen Z, Abman SH, Nozik-Grayck E. Loss or gain of SOD3 affects development of pulmonary hypertension and bleomycin-induced bronchopulmonary dysplasia. Pediatric Academic Societies International Conference, 2010.\*
12. Rock R, Seedorf G, Walker D, Balasubramaniam V, Abman SH. Vascular endothelial growth factor (VEGF) improves lung structure and increases hepatocyte growth factor (HGF) after neonatal hyperoxia in eNOS -/- mice. Pediatric Academic Societies International Conference, 2010.\*
13. Roth EV, Seedorf GS, Ryan SL, Abman SH, Balasubramaniam V. Bone marrow derived progenitor cells enhance mouse alveolar type II cell growth and differentiation in vitro. Pediatric Academic Societies International Conference, 2010.\*
14. Baker CD, Wisniewski BL, Graham DK, Molk DF, Ryan SL, Abman SH, Balasubramaniam V. Blockade of receptor tyrosine kinase, Mer, impairs growth of umbilical cord blood-derived endothelial colony forming cells (ECFCs).Pediatric Academic Societies International Conference, 2010.\*
15. Delaney CA, Gates R, Grover TR, Abman SH. Selective serotonin reuptake inhibitors cause vasoconstriction in the pulmonary circulation of the late-gestation PPHN ovine fetus. Pediatric Academic Societies International Conference, 2010.\*
16. Seedorf G, Balasubramaniam V, Baker C, Ryan S, Abman SH. Effects of conditioned media from endothelial colony forming cells on fetal pulmonary growth and tube formation. Pediatric Academic Societies International Conference, 2010.\*
17. Chumra K, Seedorf G, Markham N, Tseng N, Abman SH, Gien J. Endothelin-1 – rho kinase interactions decrease AKT signaling and impairs angiogenesis in oving fetal pulmonary artery endothelial cells after chronic intrauterine pulmonary hypertension. Pediatric Academic Societies International Conference, 2010.\*
18. Rozance PJ, Seedorf G, Brown A, Gien J, Tang, J-R, Abman SH. Pulmonary artery endothelial cell dysfunction and impaired insulin responsiveness in fetal sheep with intrauterine growth restriction. Western Society for Pediatric Research, 2010.\*
19. Lich E, Seedorf GJ, Markham R, Balasubramaniam V, Abman SH. Cinaciguat, a soluble guanylate cyclase activator, augments growth, tube formation, and cGMP production in fetal pulmonary artery endothelial cells (PAEC) in vitro. Pediatric Academic Societies International Conference, 2011.\* (**Received Outstanding Student Award from the PAS).**
20. Rozance PJ, Seedorf GJ, Brown A, Gien J, Tang, J-R, Abman SH. Pulmonary artery endothelial cell dysfunction and impaired insulin responsiveness in fetal sheep with intrauterine growth restriction. Pediatric Academic Societies International Conference, 2011.\*
21. Delaney CA, Gates R, Isenberg N, Gien J, Abman SH. Role of serotonin receptors in pulmonary vasoregulation in the ovine fetus. Pediatric Academic Societies International Conference, 2011.\*
22. Tang JR, Karumanchi SA, Seedorf GJ, Markham N, Abman SH. Intra-amniotic soluble vascular endothelial growth factor receptor-1 impairs alveolarization and causes pulmonary hypertension in infant rats. Pediatric Academic Societies International Conference, 2011.\*
23. Tang JR, Hartman-Filson M, Douglas IS, Seedorf GJ, Balasubramaniam V, Abman SH. Nuclear factor-kB inhibition preserves growth and tube formation in fetal pulmonary artery endothelial cells treated with endotoxin in vitro. Pediatric Academic Societies International Conference, 2011.\*
24. Baker C, Balasubramaniam V, Black CP, Ryan SL, Mourani R, Abman SH. Decreased umbilical cord blood-derived endothelial colony-forming cells in moderate and severe bronchopulmonary dysplasia. Pediatric Academic Societies International Conference, 2011.\*
25. Mourani PM, Kinsella JP, Clermont G, Kong L, Cutter GR, Linde-Zwible WT, Abman SH, Angus DC, Watson RS. Intensive care unit readmissions after premature birth for respiratory failure. Pediatric Academic Societies International Conference, 2011.\*
26. Mourani PM, Harris K, Sontag M, Abman SH. The airway microbiome in BPD. Pediatric Academic Societies International Conference, 2011.\*
27. Duran J, Fashaw L, Abman SH, Mourani PM, Sontag M. Maternal smoking is associated with the development of moderate and severe BPD. Pediatric Academic Societies International Conference, 2011.\*
28. Balasubramaniam V, Ryan S, Baker C, Nuanez B, Abman SH. Hyperoxia decreases Notch signaling in preterm but not term cord blood endothelial progenitor cells. Pediatric Academic Societies International Conference, 2011.\*
29. Wright R, Tang JR, Field C, Kluck D, Birari R, Van Rheen Z, Abman SH, Nozik-Graych E. Loss of SOD3 impairs alveolar and vascular development in saline and bleomycin treated neonatal mice. Pediatric Academic Societies International Conference, 2011.\*
30. Wright CJ, Tang JR,Seedorf GJ, Abman SH. Nuclear Factor-κB inhibition preserves growth and tube formation in fetal pulmonary artery endothelial cells treated with endotoxin *in vitro*. Pediatric Academic Societies International Conference, 2012. \*
31. Hurt KJ, Roe G, Abman SH. Hydrogen Sulfide Causes Pulmonary Vasodilation in Normal Fetal Sheep and in an Experimental Model of Persistent Pulmonary Hypertension of the Newborn (PPHN). Pediatric Academic Societies International Conference, 2012. \*
32. Seedorf G, Vu T, Gien J, Abman SH. Vitamin A is Pro-Angigogenic and Contributes to Vascular Endothelial Growth Factor - Mediated Effects on Fetal Pulmonary Artery Endothelial Cells. Pediatric Academic Societies International Conference, 2012. \*
33. Crnich R, Hurt KJ, Breen K, Abman SH. Ontogeny of Hydrogen Sulfide Synthesizing Enzyme Expression in the Developing Lung and the Effects of Chronic Intrauterine Pulmonary Hypertension. Pediatric Academic Societies International Conference, 2012. \*
34. Seedorf G, Lich E, Crnich R, Gien J, Markham N, Balasubramaniam V, Abman SH. Augmenting the NO - cyclic GMP Pathway Preserves Lung Growth and Vascular Development and Prevents Right Ventricular Hypertrophy after Bleomycin Induced Lung Injury.Pediatric Academic Societies International Conference, 2012. \*
35. Wolf D, Tseng N, Roe G, Seedorf G, Abman SH, Gien J. Chronic intrauterine pulmonary hypertension decreases peroxisome proliferator-activated receptor gamma (PPARγ) expression in ovine fetal pulmonary endothelial cells and impairs angiogenesis in vitro. Pediatric Academic Societies International Conference, 2012.\*
36. Mourani PM, Sontag MK, Harris JK, Miller JI, Abman SH. Airway bacterial diversity is directly associated with inflammatory markers in mechanically ventilated preterm infants. Pediatric Academic Societies International Conference, 2012.\*
37. Mourani PM, Sontag MK, Younoszai A, Miller JI, Poindexter BB, Abman SH. Prospective study of pulmonary hypertension in preterm infants. Pediatric Academic Societies International Conference, 2012. \*
38. Younoszai AK, Miller JI, Sontag MK, Poindexter BB, Abman SH, Mourani PM. A multicenter prospective study of developmental differences in ventricular diastolic function in premature infants. American Echocardiography Society, 2012.\*
39. Acker S, Seedorf GJ, Gien J, Partrick D, Abman SH. Impaired angiogenesis and decreased highly proliferative endothelial cells in an ovine model of congenital diaphragmatic hernia. American Pediatric Surgery Association, 2013.
40. Mandell E, Seedorf GJ, Tang JR, Gien J, Abman SH. Vitamin D attenuates lung injury and improves survival in infant rats after antenatal endotoxin exposure. Western Society for Pediatric Rsearch, 2013. (**Received David Smith Award for Outstanding Fellowship Research, WPSR**)•
41. Michaelis KA, Luna J, Han K, Liu T, Tang JR, Balasubramaniam V, Abman SH, Wright C. The unique role of the NFkB inhibitory protein IKBB in mediating the response to inflammation in the developing lung. Western Society for Pediatric Research. 2013. \*
42. Acker S, Seedorf GJ, Gien J, Partrick D, Abman SH. Impaired lung angiogenesis and decreased highly proliferative endothelial cells in an ovine model of congenital diaphragmatic hernia. Pediatric Academic Societies Meeting, 2013.\*
43. Mandell E, Seedorf GJ, Wright C, Gien J, Abman SH. Vitamin D attenuates lung injury and improves survival in infant rats after antenatal endotoxin exposure. Pediatric Academic Societies Meeting 2013.\* (***Selected for PAS Research Travel Award***).
44. Gien J, Seedorf GJ, Tseng N, Wolf D, Abman SH. Effects of Endothelin ReceptorBlockade on Endothelial Cell Function, Lung Structure and Pulmonary Hypertension after Bleomycin Exposure in Rat Pups. Pediatric Academic Societies Meeting 2013.\*
45. Gadhia MM, Cutter GR, Abman SH, Kinsella JP. Effects of early inhaled NO therapy and vitamin A supplementation on the risk for bronchopulmonary dysplasia in premature newborns with respiratory failure. Pediatric Academic Societies Meeting 2013.\*
46. Gien J, Tseng N, Roe G, Seedorf GJ, Abman SH. Peroxisome proliferator-activated receptor gamma – rho kinase interactions contribute to smooth muscle cell proliferation in experimental persistent pulmonary hypertension of the newborn. Pediatric Academic Societies Meeting 2013.\*
47. Baker CD, Mourani PM, Black CP, Poindexter B, Miller JI, Balasubramaniam V, Ingram DA, Abman SH. Peripheral blood angiogenic and non-angiogenic circulating progenitor cells are decreased in preterm infants with clinical chorioamnionitis. Pediatric Academic Societies Meeting 2013.\*
48. Delaney C, Gien J, Roe G, Kailey J, Abman SH. Serotonin contributes to high pulmonary vascular tone in an ovine model of persistent pulmonary hypertension of the newborn. Pediatric Academic Societies Meeting, 2013.\*
49. Acker S, Seedorf GJ, Gien J, Grayck E, Partrick DJ, Abman SH. Impaired Endothelial Cell Nitric Oxide Signaling in an Ovine Model of Congenital Diaphragmatic Hernia. American College of Surgeons Clinical Congress, 2013. \*
50. Mandell E, Seedorf GJ, Gien J, Abman SH. Vitamin D attenuates lung injury and improves survival in infant rats after antenatal endotoxin exposure. American Academy of Pediatrics District VIII Meeting 2013.\* (***Selected for AAP Felllows Research Award; \*\* Recipient of the Young Investigator Award from the American Academy of Pediatrics***).
51. Galambos C, Minic A, Seedorf G, Abman SH. Increased lung endostatin expression impairs perinatal lung development in Down Syndrome. Society for Pediatric Pathology Institute, 2013.\* (**Selected for Society for Pediatric Pathology Award for outstanding research).**
52. Acker SN, Seedorf G, Abman SH, Partrick DA, Gien J. Altered pulmonary artery endothelial-smooth muscle cell interactions in experimental congenital diaphragmatic hernia. Academic Surgical Congress, 2013.\*
53. Wright RH, Tang JR, Delaney C, Woods C, Abman SH, Nozik-Grayck E. Lack of the extracellular superoxide dismutase (SOD3) worsens alveolar development and pulmonary hypertension in a neonatal mouse model of bleomycin-induced bronchopulmonary dysplasia. Soc Crit Care Med, 2013.\*
54. Acker SN, Seedorf G, Abman SH, Nozik-Grayck E, Partrick DA, Gien J. Reactive Oxygen Species Disrupts Pulmonary Artery Endothelial – Smooth Muscle Cell Interactions, Contributing to Smooth Muscle Cell Hyperplasia in Experimental Congenital Diaphragmatic Hernia. American Pediatric Surgery Association meeting, 2014.\*
55. Wright RH, Tang JR, Delaney C, Woods C, Villegas L, Johnson R, Abman SH, Savani R, Nozik-Grayck E. Lack of EC-SOD worsens alveolar development and pulmonary hypertension in a neonatal mouse model of bleomycin-induced bronchopulmonary dysplasia. American Thoracic Society, 2014.\*
56. Dodson RB, Mandell E, Seedorf G, Crombleholme T, Abman SH. Intrauterine endotoxin causes persistent increases in pulmonary artery stiffness and remodeling in infant rats. American Thoracic Society Meeting, 2014.\*
57. Mourani PM, Sontag MK, Younaszai A, Miller JI, Kinsella JP, Poindexter BB, EV Liptsen, Ingram DA, Abman SH. Echocardiographic signs of pulmonary vascular disease at 7 days is associated with increased risk for bronchopulmonary dysplasia and late PH. Pediatric Academic Societies Meeting, Vancouver, Canada, 2014.\*
58. Carlton E, Sontag M, Younoszai A, Miller J, Abman SH, Mournia PM. Inter-reader reliability of echocardiogram indicators of pulmonary hyperension in preterm infants at risk for bronchopulmonary dysplasia. Pediatric Academic Societies Meeting, Vancouver, Canada, 2014.\*
59. Dodson RB, Morgan M, Seedorf S, Tan W, Abman SH. Hemodynamic stress alters fetal pulmonary artery endothelial cell gene expression in vitro. Pediatric Academic Societies Meeting, Vancouver, Canada, 2014.\*
60. Dodson RB, Rozance P, Seedorf G, Abman SH. Impaired pulmonary and systemic arterial vasoreactivity in a model of intrauterine growth restricion in fetal sheep. Pediatric Academic Societies Meeting, Vancouver, Cana, 2014.\*
61. Dodson RB, Morgan M, Seedorf G, Abman SH. Chronic intrauterine pulmonary hypertension induces main pulmonary artery stiffening due to altered collagen deposition and elastin fiber dixtribution in fetal sheep. Pediatric Academic Societies Meeting, Vancouver, Canada, 2014.\*
62. Gien J, Kinsella JP, Grenolds A, Abman SH, Baker CB. Improved survival with multidisciplinary care team for infants with tracheostomy–dependent severe bronchopulmonary dysplasia. Pediatric Academic Societies Meeting, Vancouver, Canada, 2014.\*
63. Acker SN, Mandell EW, Sims-Lucas S, Abman SH, Galambos C. Histologic identification of intrapulmonary shunt vessels in congenital diaphragmatic hernia. Pediatric Academic Societies Meeting, Vancouver, Canada, 2014.\*
64. Gien J, Brock L, Kuhn K, Tseng N, Abman SH. Autocrine endothelin-1 production regulates fetal pulmonary artery smooth muscle cell (PASMC) growth and increases hyper-proliferation of PASMC from fetal sheep with experimental PPHN. Pediatric Academic Societies Meeting, Vancouver, Canada, 2014.\*
65. Acker SN, Seedorf G, Abman SH, Nozik-Grayck E, Partrick D, Gien J. Altered pulmonary artery endothelial-smooth muscle cell interactions in experimental congenital diaphragmatic hernia: role of endothelin and superoxide dismutase signaling. Pediatric Academic Societies Meeting, Vancouver, Canada, 2014.\*
66. Kinsella JP, Cutter GR, Steinhorn RH, Nelin LD, Walsh WF, Finer NN, Abman SH. Non-invasive inhaled nitric oxide for the prevention of bronchopulmonary dysplasia in preerm newborns. Pediatric Academic Societies Meeting, Vancouver, Canada, 2014.\*
67. Seedorf G, Vu T, Gien J, Abman SH. Vascular endothelial growth factor - vitamin A interactions promote angiogenesis and preserve lung structure in experimental bronchopulmonary dysplasia. Pediatric Academic Societies Meeting, Vancouver, Canada, 2014.\*
68. Galambos C, Minic AD, Nguyen D, Seedorf G, Abman SH. Increased lung endostatin impairs perinatal lung development in Down Sydrome. Pediatric Academic Societies Meeting, Vancouver, Canada, 2014.\*
69. Kerby GS, Sontag MK, Miller JI, Abman SH, Mourani PM. Lung function impairment during infancy is associated with the severity of brochopulmonary dysplasia at diagnosis. Pediatric Academic Societies Meeting, Vancouver, Canada, 2014.\*
70. Mandell E, Seedorf GJ, Gien J, Cramer S, Abman SH. Maturational Changes in Lung Vitamin D Receptor and Converting Enzyme Expression in the Developing Rat Fetus and Newborn. Pediatric Academic Societies Meeting, Vancouver, Canada, 2014.\*
71. Galambos C, Dodson B, Minic AD, Seedorf G, Abman SH. Evidence for impaired vascular growth in prenatal Down syndrome. Society for Pediatric Pathology, 2014.\*
72. Guaman MC, Collaco JM, for the BPD Collaborative.Prevalence, Clinical Characteristics and Care Patterns of Infants with Severe BPD Pediatric Academic Societies Meeting, Vancouver, Canada, 2014.
73. Acker SH, Seedorf G, Abman SH, Nozik-Grayck E, Partrick D, Gien J. Abnormal pulmonary artery endothelial – smooth muscle cell interactions in experimental congenital diaphragmatic hernia. American College of Surgeons. 2014.\*
74. Galambos C, Sims-Lucas S, Ali N, Gien J, Dishop MK, Abman SH. Intrapulmonary Shunt Pathways in Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins. Society for Pediatric Pathology, 2014.\*
75. Mandell E, Seedorf GJ, Gien J, Cramer S, Abman SH. Maturational Changes in Lung Vitamin D Receptor and Converting Enzyme Expression in the Developing Rat Fetus and Newborn. Neonatal Cardiopulmonary Young Investigator Symposium, Chicago IL, 2014 (\***Awarded Outstanding Research Award**).
76. Liptzin D, Hoch H, Abman SH. “She coughed up blood”- an unusual etiology of infantile hemoptysis. Am Thoracic Society Internatioal Conference, 2015. \*
77. Wymore E, Sontag M, Cutter G, Abman SH, Kinsella JP. Cytokine production in preterm infants with early respiratory failure. Pediatric Academic Societies Meeting, San Diego, CA, 2015.
78. Wagner B, Mourani P, Sontag M, Miller J, Poindexter B, Ingram D, Abman S, MD1*.* Early Changes in Circulating Angiogenic Biomarkers are Associated with the Subsequent Diagnosis of Bronchopulmonary Dysplasia in Preterm Infants, Pediatric Academic Societies Meeting, San Diego, CA, 2015.
79. Mandell M, Seedorf G, Ryan S, Gien J, Cramer SD, Abman S. Effects of Antenatal Endotoxin on Lung Vitamin D Receptor and 25-hydroxyvitamin D 1-alpha hydroxylase Expression in the Developing Rat. Pediatric Academic Societies Meeting, San Diego, CA, 2015.
80. Ali N, Abman SH, Galambos C. Bronchopulmonary Anastomotic Pathways (BAP) in Neonates with Meconium Aspiration Syndrome (MAS). Pediatric Academic Societies Meeting, San Diego, CA, 2015.
81. Dodson RB, Mandell E, Seedorf G, Powers K, Hunter KS, Abman SH. Vitamin D Treatment Alleviates Intrauterine Endotoxin-Induced Impairment of Right Ventricular Performance and Proximal Pulmonary Artery Stiffness in Infant Rats Pediatric Academic Societies Meeting, San Diego, CA, 2015.
82. Seedorf G, Metoxen A, Gien J, Abman SH. Hepatocyte Growth Factor Promotes Angiogenesis and Preserves Lung Structure In Experimental BPD. Pediatric Academic Societies Meeting, San Diego, CA, 2015.
83. Mourani PM, Sontag MK, Harris JK, Miller JI, Ingram DA, Poindexter BB, Wagner BD, Abman SH. Airway bacterial diversity is associated with inflammatory markers in mechanically-ventilated preterm infants. Pediatric Academic Societies Meeting, San Diego, CA, 2015.
84. Dodson B et al. Intrauterine growth restriction creates persistent increased vascular stiffness and remodling in postnatal rats. Pediatric Academic Societies Meeting, San Diego, CA, 2015.
85. Powers KN, Alvira C, Gien J, Rozance P, Seedorf G, Astling D, Jones K, Crombleholme T, Abman SH, Dodson RB. Altered Extracellular Matrix-Receptor Interaction and NF-kappa B Signaling Pathways in Fetal Pulmonary Artery Endothelial Cells in an Ovine Model of Intrauterine Growth Restriction (IUGR). North American Vascular Biology Organization, 2015.
86. Dodson RB, Powers K, Seedorf G, Hunter KS, Abman SH, Mandell E. Vitamin D Alleviates Intrauterine Endotoxin-Induced Impairment of Right Ventricular Performance and Improves Pulmonary Vascular Function in Infant Rats. North American Vascular Biology Organization, 2015.
87. Peisl A\*, Seedorf G, Wallace B, Keefe D, Abman SH. Treatment with an Anti-sFlt-1 Monoclonal Antibody Improves Lung Structure and Prevents Pulmonary Hypertension in an Experimental Model of Bronchopulmonary Dysplasia due to Preeclampsia in Infant Rats***.*** Western Society for Pediatric Research, 2016. (\****Recipient of 2016 Abbott Nutrition Research Award***).
88. Cookson MW, Ryan S, Seedorf GJ, Dodson RB, Abman SH, Mandell E. Antenatal Vitamin D Preserves Placental Weight and Vessel Density and Fetal Growth After Intra-amniotic Endotoxin Exposure. Western Society for Pediatric Research, 2016.
89. Schaffer M, Hunter KS, Ivy DD, Abman SH, Barker AJ, Truong A. Aortic wall shear stress and left ventricualr systolic performance are reduced in pediatric patients with pulmonary arterial hypertension. American Thoracic Society, 2016.
90. Bush D, Abman SH, Galambos C. Pulmonary vasculature in infants with Down syndrome is underdeveloped. American Thoracic Society, 2016. (***\* Selected for Pediatric Assembly Young Investigator Award at the ATS).***
91. Seedorf G, Wallace B, Peisl A, Keefe D, Abman SH, Fetal or Postnatal treatment with an anti-sFlt-1 monoclonal antibody improves lung structure and prevents pulmonary hypertension in an experimental model of bronchopulmonary dysplasia due to chorioamnionitis. Pediatric Academic Societies, 2016.
92. Wallace B, Seedorf G, Peisl A, Keefe, Abman SH. Maternal ttreatment with an anti-sFlt-1 monoclonal antibody improves lung growth and prevents pulmonary hypertension in an experimental model of bronchopulmonary dysplasia due to preeclampsia. Pediatric Academic Societies, 2016.
93. Mourani P, Younoszai A, Whitfield L, Wagner B, Abman SH. Echocardiogram signs of early pulmonary vascular disease in preterm infants are associated with respiratory outcomes during early childhood. Pediatric Academic Societies, 2016.
94. Dodson RB, Alvira C, Powers KN, Gien J, Rozance PJ, Seedorf G, Astling D, Jones K, Crombleholme TM, Abman SH. Altered extracellular matrix-receptor interaction and NF-kappa B signaling pathways in fetal pulmonary artery endothelial cells in a sheep model of intrauterine growth restriction. Pediatric Academic Societies, 2016.
95. Cookson MW, Ryan S, Seedorf GJ, Dodson RB, Abman SH, Mandell E. Antenatal Vitamin D Preserves Placental Weight and Vessel Density and Fetal Growth After Intra-amniotic Endotoxin Exposure. Pediatric Academic Societies, 2016.
96. Mandell E, Whitfield L, Wagner B, Mourani P, Abman SH*.* Early Postnatal Vitamin D Levels in Preterm Infant: Associations with Prenatal Factors and Neonatal Outcomes. Pediatric Academic Societies, 2016.
97. Gien J, Kuhn K, Greenwald E, Seedorf G, Abman SH. Mesenchymal stem cells and conditioned media improve pulmonary artery endothelial cell function in experimental congenital diaphragmatic hernia. Pediatric Academic Societies, 2016.
98. Peisl A, Seedorf G, Wallace B, Keefe D, Abman SH. Anti-sFlt-1 Monoclonal Antibody Therapy of Fetal and Neonatal Rat Pups Preserves Lung Structure an Experimental Model of Bronchopulmonary Dysplasia due to Preeclampsia. Pediatric Academic Societies, 2016.
99. Nowlin T, Seedorf G, Wallace B, Peisl A, Keefe D, Abman SH. Insulin-like growth factor-1/binding peptide 3 (IGF-1/BP3) improves alveolar growth and prevents pulmonary hypertension (PH) in a rodent model of preeclampsia-induced bronchopulmonary dysplasia (BPD). European Pediatric Academic Societies, 2016.
100. Seedorf G, Nowlin T, Wallace B, Peisl A, Keefe D, Abman SH. Postnatal treatment with insulin-like growth factor-1/binding peptide 3 (IGF-1/BP3) improves lung structure and prevents pulmonary hypertension in experimental bronchopulmonary dysplasia due to chorioamnionitis in rats. European Pediatric Academic Societies, 2016.
101. Wallace B\*, Seedorf G, Peisl A, Keefe D, Abman SH. Maternal treatment with an anti-sFlt-1 monoclonal antibody improves lung growth and prevents pulmonary hypertension in an experimenatal model of bronchopumonary dysplasia due to preeclampsia. Neonatal Cardiopulmonary Young Investigators Forum. Chicago, 2016. **\* Award recipient for outstanding research.**
102. Ehrmann DE, Mourani PM, Abman SH, Morrow LA, Wagner BD, Di Maria MV. Right ventricular mechanics in bronchopulmonary dysplasia. American Society of Echocardiographers. 2016.
103. Dodson RB, Tan W, Powers KN, Gien J, Seedorf G, Abman SH, Crombleholme TM. Hemodynamic stress alters fetal pulmonary artery endothelial cell gene expression *in vitro:* a potential role in intrauterine growth restriction. North American Vascular Biology Organization (NAVBO), 2016.
104. Wallace B, Seedorf G, Peisl A, Abman SH. Anti-sFlt-1 antibody treatment prevents respiratory distress in a BPD rat model. Academic Surgical Congress, 2016
105. Keefe D, Nowlin T, Seedorf G, Wallace B, Peisl A, Bosco J, Abman SH. Recombinant (rh)IGF-1/rhIGFBP-3 improves alveolar growth and lung structure and pevents pulmonary hypertension in rodent models of BPD. International Congress of the Growth Hormone Research Society and Insulin-Growth Factor Research Society, 2016.
106. Bush D, Minic A, Seedorf G, Abman SH, Galamabos C. Decreased alveolarizaton in a genetic mouse model of Down Syndrome due to increased expression of Regulator of Calcineurin 1. American Thoracic Society, 2017. (***\* Selected for Best of the Pediatric Assembly at the ATS).***
107. Kim C, Seedorf G, Nowlin T, Keefe D, Albertine K, Dahl MJ, Abman S. Maturational changes in pulmonary artery endothelial cell function in vitro and responsiveness to insulin growth factor-1/binding protein 3 in the developing sheep lung. Pediatric Academic Societies, 2017.
108. Ivy DD, Lawrence JP, Stockbridge N, Bossar S, Taylor A, Ariagno R, Abman S, Murphy D, Soreth J, Crescenzi T, Sun H. Potential role for actigraphy in the ambulatory assessment of children with pulmonary hypertension. Pediatric Academic Societies, 2017.
109. Mandell E, Ryan S, Seedorf GJ, Abman SH. Fetal vitamin D deficiency impairs lung structure and increases susceptibility to hyperoxia injury in the developing rat. Pediatric Academic Societies, 2017.
110. Dodson RB, Seedorf G, Powers K, Gien J, Abman SH. Loss of highly-proliferative pulmonary artery endothelial cells after chronic intrauterine pulmonary hypertension in the sheep fetus. Pediatric Academic Societies, 2017.
111. Abman S, Mullen M, Ivy D, Hanna B, Hopper R, Austin E, Rosenzweig EB, Krishnan U, Feinstein J, Fineman J, Keller R, Adatia I, Raj U, Natter M, Luckey H, Batson D, Mandl K. Characterization of pediatric pulmonary hypertensive disorders through a large multicenter registry. Pediatric Academic Societies, 2017.
112. Seedorf G, Nowlin T, Wallace B, Peisl A, Bosco J, Keefe D, Abman SH. Insulin-Like Growth Factor-1/IGF Binding Protein-3 (IGF-1/IGFBP-3) improves lung structure and prevents pulmonary hypertension in antenatal models of bronchopulmonary dysplasia. Pediatric Academic Societies, 2017.
113. Wallace B, Seedorf G, Peisl A, Nowlin T, Bosco J, Keefe D, Abman SH. Antenatal and postnatal anti-sFlt-1 antibody treatments preserve lung structure in experimental bronchopulmonary dysplasia. Pediatric Academic Societies, 2017.
114. Mandl K et al. Automated surveillance of disease and drug effects in pediatric pulmonary hypertension. Pediatric Academic Societies, 2017.
115. Bush D, Minic A, Seedorf G, Abman S, Galambos C. RCAN-1 overexpression causes lung hypoplasia and pulmonary hypertension in a mouse model of Down syndrome. 10th Annual Neonatal and Pediatric Pulmonary Vascular Disease Conference, 2017.
116. Ehrmann DE, Mourani PM, Abman SH, Morrow LA, Wagner BD, Di Maria MV. Right ventricular mechanics in bronchopulmonary dysplasia. CHOP Cardiology Meeting. 2017.
117. Galambos C, Bush D, Abman SH, Caplan M. Histologic features of impaired lung development identify a subset of infants with sudden unexplained infant death. Soc Pediatr Pathol, 2017.
118. Williams K, Huang L, Abman S, Galambos C. Early unexplained deaths of Norwich Terrier puppies are associated with abnormal lung development and pulmonary vascular disease. Soc Pediatr Pathol, 2017.
119. Huang L, Galambos C, Abman S, Williams KJ. Developmental lung disease leading to early death in Norwich Terrier puppies. American College of Veterinary Pathologists, 2017.
120. Hirsh K, Seedorf G, Nowlin T, Kim C, Abman SH. Stabilization of Hypoxia Inducible Factor Improves Lung Structure and Function and Prevents Pulmonary Hypertension in an Antenatal Model of Bronchopulmonary Dysplasia. Western Society for Pediatric Research, 2017.
121. Hirsh K, Seedorf G, Nowlin T, Kim C, Abman SH. Stabilization of Hypoxia Inducible Factor Improves Lung Structure and Function and Prevents Pulmonary Hypertension in an Antenatal Model of Bronchopulmonary Dysplasia. 32nd Annual Student Research Forum, 2017. ***\* awarded “Best Student Research Forum Poster”***
122. Effinger D, Seedorf G, Nowlins T, Law AJ, Abman S, Paterson C. Investigating the effects of insulin growth factor signaling on the delveoping brain in response to prenatal VEGF inhibition. Society for Neuroscience, Washington DC, 2017.
123. Hirsh K, Seedorf G, Nowlin T, Kim C, Abman SH. Stabilization of Hypoxia Inducible Factor Improves Lung Structure and Function and Prevents Pulmonary Hypertension in an Antenatal Model of Bronchopulmonary Dysplasia. *Pediatric Academic Societies, 2018. \**
124. Mandell E, Ryan S, Seedorf GJ, Abman SH, Fleet JC. Maternal Vitamin D Deficiency Decreases Angiogenic Signaling Pathways in Newborn Rat Lungs. *Pediatric Academic Societies, 2018. \**
125. Kim C, Seedorf G, Nowlin T, Abman SH, Shepherd D. Heterogeneity of Vascular Endothelial Growth Factor and Endothelial Nitric Oxide Synthase Protein Expression in Pulmonary Artery Endothelial Cells Using Single Cell Immunofluorescence in Response to Insulin-Like Growth Factor-1. *Pediatric Academic Societies, 2018. \**
126. Seedorf G, Nowlin T, Kim C, Abman SH. Inhaled and Subcutaneous Treprostinil Improves Lung Structure and Prevents Pulmonary Hypertension in Hyperoxia-Induced Bronchopulmonary Dysplasia in Rats. *Pediatric Academic Societies, 2018*. \*
127. Seedorf G, Nowlin T, Kim C, Galambos C, Abman SH, Shepherd D. Non-destructive Three-Dimentional (3D) Imaging and Quantification of the Distal Lung by Cleared Tissue Digital Scanned Light-Sheet Microscope (C-DSLM) in Experimental Models of Bronchopulmonary Dysplasia and Human Tissue. *Pediatric Academic Societies, 2018. \**
128. Sun H, Lawrence JP, Stockbridge N, Bossart S, Taylor A, Ariagno R, Abman S, Murphy D, Soreth J, Kleppinger C, Ivy DD. Combined Physical Activity and Heart Rate Variability as Measured by Actigraphy as a Potential Assessment Endpoint in Children with Pulmonary Hypertension. *Pediatric Academic Societies, 2018.\**
129. Danhaive O, Mullen MP, Calambos C, Kielt MJ, Agrawal P, Shieh J, Bansal M, Stucin-Gantar I, Haass C, Griese M, Ivy D, Abman SH, Austin ED. TBX4 Rare Variants Presenting with Neonatal Hypoxic Respiratory Failure and Persistent Pulmonary Hypertension of the Newborn (PPHN). *Pediatric Academic Societies, 2018. \**
130. Galambos C, Bush D, Abman SH, Caplan M. Histologic Features of Impaired Lung Development Identify a Subset of Infants with Sudden Unexplained Infant Death. *Pediatric Academic Societies, 2018. \**
131. Frank B, Grenolds A, Schafer M, Ivy DD, Abman SH, Darst J. Acute vasoreactivity testing during cardiac catheterization of neonates with bronchopulmonary dysplasia-associated pulmonary hypertension. *Pediatric Academic Societies, 2018*. \*
132. McKinney RL, Keszler M, Truog W, Norberg M, Sindelar R, Wallström L, Schulman B, Gien J, Abman SH on behalf of the Bronchopulmonary Dysplasia Collaborative. Multicenter experience with neurally adjusted ventilatory assist in infants with evolving or established bronchopulmonary dysplasia. *Pediatric Academic Societies, 2018*. \*
133. Bush D, Galambos C, Ivy DD, Abman S, Wolter-Warmerdam K, Hickey F. Clinical Characteristics and Risk Factors for Developing Pulmonary Hypertension in Children with Down Syndrome. *Pediatric Academic Societies, 2018*.\*
134. Abman SH. Managing Pulmonary Hypertension in Infants and Children Beyond the NICU. *35th Annual Repiratory Conference Advances in Therapeutics and Technology: Care of Critically Ill Neonates, Children, and Adults,* 2018.\*
135. Frank B, Ivy DD, Abman SH, Howley L. A case of pulmonary hypertension secondary to scurvy in a developmentally typical child. 11th Annual Neonatal and Pediatric Pulmonary Vascular Disease Conference, 2018.\*
136. Schafer M, Ivy D, Abman S, Browne L, Fonseca B, DiMaria MV, Barker A, Mitchell M, Truong U. Abnormal Aortic Flow in Children with Pulmonary Arterial Hypertension is Associated with Non-uniform Wall Shear Stress Distribution. AHA International Conference, 2018.\*
137. Zimmerman D, J Douwes JM, Schafer M, Ivy DD, Abman S, Barker AJ, Naresh N, Kheyfets V, Truong U. Non-invasive assessment of acute vasoreactivity testing in children with pulmonary arterial hypertension using comprehensive phase-contrast MRI: preliminary report. SCMR, 2018.
138. Di Maria MV, Bush D, Morgan G, Abman SH, Galambos C. Prominent intrapulmonary bronchopulmonary anastomoses in children with single ventricle heart disease.
139. Gonzalez T, Ryan S, Seedorf GJ, Fleet JC, Abman SH, Mandell EW. Maternal vitamin D deficiency decreases distal lung vascular development and pulmonary endothelial cell growth and function. Western Society for Pediatric Research, 2019.
140. Taylor-Couser JL, Hunt KC, St. Clair C, Everett D, Fenster B, Nick JA, Saavedra MT, Abman SH.
Sildenafil improves cardiac function, exercise tolerance, QOL in people with moderate to severe CF lung disease. North American Cystic Fibrosis Conference, 2018.
141. Smith BJ, Mattson C, Seedorf G, Ryan S, Gonzalez T, Wallbank A, Abman SH, Mandell EW. Antenatal endotoxin impairs lung mechanical function and increases sensitivity to ventilator-induced lung injury in newborn rat pups. American Thoracic Society, 2019.
142. Di MariaMV, Bush D, MorganG, Abman SH, Galambos C. Prominent Intrapulmonary Bronchopulmonary Anastomoses in Children with Single Ventricle Heart Disease. American Thoracic Society, 2019.
143. Bush D, Wolter-Warmerdam K, Wagner BD, Galambos C, Ivy DD, Abman SH, McMorrow D, Hickey F. Angiogenic Profile Identifies Pulmonary Hypertension in Children with Down Syndrome. American Thoracic Society, 2019.
144. Seedorf G, Kim C, Mandell E, Shepherd D, Abman S. Insulin-like growth factor-1 promotes angiogenesis, prevents pulmonary hypertension and preserves lung growth in experimental models of BPD. Pulmonary Vascular Research Institute International Conference, Barcelona SPAIN
145. Seedorf G, Gonzalez T, Alvira C, Mandell E, Abman SH. Experimental chorioamnionitis impairs endothelial cell growth, function and responsiveness to pro-angiogenic stimuli in vitro. Pedatric Academic Societies Conference, 2019.
146. Taglauer E, Seedorf G, Abman S, Kourembanas S. Pathogenetic mechanisms underlying placental pathology in an experimental model of late preeclampsia in rats. Pedatric Academic Societies Conference, 2019.
147. Gonzalez T, Ryan S, Seedorf GJ, Fleet JC, Abman SH, Mandell EW. Maternal Vitamin D Deficiency Decreases Distal Lung Vascular Development and Pulmonary Endothelial Cell Growth and Function in Infant Rats. Pedatric Academic Societies Conference, 2019.
148. Smith B, Mattson C, Seedorf G, Ryan S, Gonzalez T, Wallbank A, Abman SH, Mandell EW Antenatal Endotoxin Impairs Lung Mechanical Function and Increases Sensitivity to Ventilator-Induced Lung Injury in Newborn Rat Pups. Pedatric Academic Societies Conference, 2019.
149. Gard C, Wagner BD, Williamson K, Mandell EW, Kerby G, Abman SH, Mourani PM.Infant Pulmonary Function is Associated with the Severity of Bronchopulmonary Dysplasia (BPD) and Late Respiratory Disease. Pediatric Academic Societies Conference, 2019
150. Miller P, Bothwell S, Spell P, Rosales O, Rusk S, Austin R, Mandell E, Wagner BD, Abman SH, Mourani PM. Chorioamnionitis and Pre-eclampsia are Associated with Distinct Circulating Protein Profiles in Preterm Infants. Pediatric Academic Societies Conference, 2019
151. Levin JC, Hayden LH, Keszler M, Troug WE, Abman SH, Nelin LD; for the BPD Collaborative. Enteral Feeding Patterns in a National Cohort of Infants with Severe Bronchopulmonary Dysplasia. Pediatric Academic Societies Conference, 2019.
152. Guaman MC, Pishevaresfahani N, Abman SH, Keszler M, Truog WE, Nelin LD, for the BPD Collaborative. Characteristis of Preterm Infants with Severe Bronchopulmonary Dysplasia Based on the Level of Respiratory Support at 36 weeks Post Menstrual Age. Pediatric Academic Societies Conference, 2019.
153. Zimmerman D, J Dowes JM, Schafer M, Ivy DD, Abman SH, Barker AJ, Naresh N, Kheyfets V, Truong U. Non-Invasive Wave Intensity Analysis by Phase-Contrast MRI Correlates with Mean Pulmonary Artery Pressure Before and After Nitric Oxide Testing in Children with Pulmonary Arterial Hypertension. Society for Cardiac MR, 2019.
154. Pierro M, Villamor-Martinez E, Alvarez-Fuente M, Abman SH, Villamor E. Gestational hypertensive disorders and intrauterine growth restriction as risk factors for bronchopulmoanry dysplasia: a meta-analysis and meta-regression. European Society for Pediatric Research, 2019.
155. Effinger D, Seedorf G, Law AJ, Abman SH, Paterson C. Antenatal sFlt-1 exposure causes sustained abnormalities of brain structure and function in juvenile rats. Society for Neuroscience, 2019.
156. Seedorf G, Hirsch K, Callahan C, White CW, Abman SH. Stabilization of Hypoxia Inducible Factor Improves Lung Structure and Function and Prevents Pulmonary Hypertension in an Antenatal Model of Bronchopulmonary Dysplasia. Grover Conference on the Pulmonary Circulation, 2019.
157. AbeleA, Wilson N, Abikoye A, Brooks, A, Seedorf G, Kourembanas S, Abman SH.. Antenatal exosome treatment preserves lung structure and vascular growth in an experimental model of bronchopulmonary dysplasia due to chorioamnionitis. Western Society for Pediatric Research, 2020.
158. Cookson M, Gonzalez T, Seedorf GJ, Smith B, Abman SH, Mandell EW. Antenatal Vitamin D Attenuates Lung Injury in a Preeclampsia Model of Bronchopulmonary Dysplasia. Western Society for Pediatric Research, 2020.
159. Gonzalez T, Seedorf GJ, Fleet JC, Abman SH, Mandell EW. Vitamin D Stimulates Fetal Pulmonary Artery Endothelial Cell Growth Through Enhanced PPARγ Signaling. Western Society for Pediatric Research, 2020.
160. Seedorf G, Hirsch K, Callahan C, White CW, Abman SH. Stabilization of Hypoxia Inducible Factor Improves Lung Structure and Function and Prevents Pulmonary Hypertension in an Antenatal Model of Bronchopulmonary Dysplasia. Neonatal and Pediatric Pulmonary Vascular Diseases, 2020.
161. Galambos C, Wartchow E, Weinman JP, Abman SH. Evidence that pulmonary interstitial glygogenosis cells have mesenchymal stem cell properties. Pediatric Academic Societies Meeting 2020.
162. Taglauer ES, Abele AN, Seedorf G, Willis GR, Mitsialis SA, Abman SH, Kourembanas S.Intra-amniotic mesenchymal stromal cell extracellular vesicle therapy improves placental pathology and preserves infant lung growth in experimental chorioamnionitis. Pediatric Academic Societies Meeting 2020. (Meeting cancelled due to Coronavirus Pandemic)
163. Guaman MC, Abman SH, Panitch H, Davis A, Nelin LD, for the BPD Collaborative. Invasive ventilation at 36 weeks PMA is associated with greatest mortality and morbidity in preterm infants with severe BPD. Pediatric Academic Societies Meeting 2020. (Meeting cancelled due to Coronavirus Pandemic)
164. Seedorf G, Hirsch K, Callahan C, White CW, Abman SH. Stabilization of Hypoxia Inducible Factor Improves Lung Structure and Function and Prevents Pulmonary Hypertension in an Antenatal Model of Bronchopulmonary Dysplasia. Pediatric Academic Societies, 2020.(Meeting cancelled due to Coronavirus Pandemic but presented as part of PAS Virtual Meeting)
165. CooksonM, Gonzalez T, Seedorf GJ, Smith B, Abman SH, Mandell EW. Antenatal Vitamin D Attenuates Lung Injury in a Preeclampsia Model of Bronchopulmonary Dysplasia. Pediatric Academic Societies, 2020**.** (\* Selected for Medical Student Research Award; Meeting cancelled due to Coronovirus Pandemic but presented as part of PAS Virtual Meeting)
166. Gonzalez T, Seedorf GJ, Fleet JC, Abman SH, Mandell EW. Vitamin D Stimulates Fetal Pulmonary Artery Endothelial Cell Growth Through Enhanced PPARγ Signaling. Pediatric Academic Societies, 2020**.** (Meeting cancelled due to Coronavirus Pandemic)
167. Mandell E, Ryan S, Seedorf GJ, Gonzalez T, Bye E, Abman SH, Fleet JC. Vitamin D decreases inflammatory and increases angiogenic signaling pathways in newborn rat lungs after antenatal endotoxin exposure. Pediatric Academic Societies, 2020**.** (Meeting cancelled due to Coronovirus Pandemic)
168. Austin ED, Elia E, Mullen MP, Sleeper LA, Avitabile K, Bates A, Bernier M, Keller R, Kinsella J, Krishnan U, McGrath-Morrow S, Raj JU, Romer L, Mandl KD and Abman SH, on behalf of the PPHNet Investigators. Bronchopulmonary dysplasia-associated pulmonary hypertension diagnosed beyond infancy associates more strongly with adverse perinatal conditions than cases diagnosed during infancy. American Thoracic Society Conference, 2020. (Meeting cancelled due to Coronovirus Pandemic).
169. McGinn E, Bye E, Gonzalez T, Seedorf GJ, Smith B, Abman SH, Mandell EW. Physiologic Vitamin D, 1,25-OHD, Postnatal Supplementation in Newborn Rats. Western Society for Pediatric Research, 2021.
170. Bye E, Gonzalez T, Seedorf GJ, McGinn E, Smith BJ, Fleet JC, Abman SH, Mandell EW. Impaired Infant Lung Growth and Function in Mice with Genetic Deletion of Endothelial Cell -Specific Vitamin D Receptor Expression. Western Society for Pediatric Research, 2021.
171. Thayapran K, Seedorf GJ, Abman SH. Treprostinil, a Prostacyclin Analog, Enhances Neonatal Lung Endothelial Cell Growth and Angiogenesis in vitro. Western Society for Pediatric Research, 2021.

.